WO2021231797A1

WO2021231797A1 - Treatment or prevention of pro-inflammatory diseases or conditions using induced regulatory t (itreg) cells

Info

Publication number: WO2021231797A1
Application number: PCT/US2021/032342
Authority: WO
Inventors: Daniel Harding FOWLER
Original assignee: Rapa Therapeutics, Llc
Priority date: 2020-05-13
Filing date: 2021-05-13
Publication date: 2021-11-18
Also published as: US20230270781A1; EP4150060A1; CA3177588A1; EP4150060A4

Abstract

The present disclosure provides methods for treating pro-inflammatory diseases and conditions, optionally using pento statin and cyclophosphamide pre-treatment, by administration of T_REG and/or T_REG/Th2 hybrid cells from de-differentiated T cells. The source of T cells can be autologous (from the affected subject) or allogenic (off-the-shelf bank of therapeutic cells; generated from healthy unrelated volunteers). The present disclosure further provides methods for producing T_REG and T_REG/Th2 hybrid cells from de-differentiated T cells, said T_REG and T_REG/Th2 hybrid cells, populations thereof and compositions thereof. Methods for producing dedifferentiated T cells, said de-differentiated T cells, populations thereof and compositions thereof are also provided.

Description

Treatment Or Prevention of Pro-Inflammatory Diseases or Conditions Using Induced

Regulatory T (ITREG) Cells

CROSS-REFERENCE TO RELATED APPLICATIONS

[1] The present application claims priority to U.S. Provisional Application No. 63/024,429, filed May 13, 2020, the entirety of which is incorporated herein by reference.

BACKGROUND

[2] Adoptive T cell therapy is an emerging intervention for the effective treatment of cancer and infectious disease, auto-immunity, and neuro-degenerative disease. It is increasingly clear that the transfer of T cells with a more primitive differentiation state, which translates into a higher proliferative potential and other key attributes, is associated with improved in vivo effects after adoptive transfer. However, most forms of adoptive T cell therapy require an ex vivo manufacturing step, which typically results in further cellular differentiation; this is parfticularly problematic, as T cells from the adult human are already primarily in an advanced state of differentiation (termed effector memory cells) and often exist in a senescent state that is under the control of checkpoint inhibitory molecules. Approaches can be taken to alleviate this limitation, including the isolation (purification) of more naive T cell subsets at the time of culture initiation; however, this approach is restricted in part by the small number of naive T cells present in the adult human peripheral blood. Accordingly, a great need exists for isolated T cells in primitive differentiation states.

[3] It is well known that even highly differentiated cells possess an inherent capacity for de differentiation towards a more primitive state. Indeed, in the most extreme examples, differentiated cells can be manipulated to attain an induced pluripotent stem cell (iPSC) state, whereby such iPS cells share key characteristics with embryonic stem cells and can then be further modulated towards re-differentiation to divergent tissue fates; cellular therapy using such iPSC methodologies has numerous potential clinical applications. Generation of iPS cells from differentiated somatic cells was initially demonstrated by the transfer of key transcription factors via viral or non-viral mediated approaches, including Sox2, Oct3/4, KLF4, and c-myc or Sox2, Oct3/4, Nanog, and Lin28. [4] However, the ability to convert somatic cells to iPS cells is inefficient and dependent in part upon the degree of somatic cell differentiation. As one example, the ability to convert mature murine immune T cells into iPS cells is 300-fold less efficient relative to conversion of murine hematopoietic stem cells into iPS cells. Nonetheless, using gene transfer methods, it was demonstrated that mature human peripheral blood T cells maintain a capacity for conversion to an iPS cell state. Over the past decade, investigators have also characterized transcription factors associated with the earliest stages of T cell differentiation. However, the re-differentiation of T cells from various types of stem cell precursors is a relatively inefficient process that typically takes one-to-two months.

[5] Although the biology of de-differentiation is becoming increasingly characterized, a great deal remains unknown in terms of the specific transcription factors and transcription factor kinetics associated with de-differentiation. It is also important to recognize that gene transfer methods of achieving de-differentiation are laborious and associated with complications such as teratoma generation that must be addressed through additional genetic interventions such as cell fate suicide gene programming. As a potential alternative, various pharmacologic interventions can be utilized to achieve some degree of de-differentiation. As one example, calcineurin- inhibition during cell culture by use of the immune suppressive agent cyclosporine resulted in molecular alterations that replaced the need for gene delivery of Sox2 transcription factor for the promotion of murine iPS cells. In addition, rapamycin, which is an immune suppression drug that inhibits the mammalian target of rapamycin (mTOR), can result in a de-differentiation effect on end-stage effector T cells through starvation-induced up-regulation of the transcription factor KLF2, which in turn increases the T central-memory molec ules CD62L and CCR7. In addition, rapamycin and resultant inhibition of mTOR signaling is critical for the maintenance of cellular quiescence in naive T cells having a reduced state of differentiation. It is important to note that the mTOR pathway is comprised of both an mTORCl complex (which contains the Raptor sub unit) and the mTORC2 complex (which contains the Rictor sub-unit). Inhibition of both mTORCl and mTORC2 has been associated with an increase in memory T cell promotion and maintenance. Of note, rapamycin can only directly inhibit mTORCl; however, with prolonged rapamycin-mediated inhibition of mTORCl, down-stream inhibition of mTORC2 can occur. Reduction in T cell growth factor signaling via mTOR inhibition or other pathway inhibition is also known to up-regulate another key molecule associated with T cells of more primitive differentiation status, namely, IL-7 receptor alpha (CD 127). In further studies, inhibition of the T cell mTOR pathway through the pharmacologic agent rapamycin or the Wnt-P-catenin signaling activator TWS11 promoted the de-differentiation of human naive T cells towards a less-differentiated, T stem cell memory population that was previously identified and characterized in murine and human T cells. In further experimental model research, pharmacologic inhibition of the AKT signaling pathway or combined inhibition of the PI3 kinase and vasoactive intestinal peptide signaling pathways resulted in the generation of T cells with a reduced differentiation status and increased T cell function upon adoptive transfer.

[6] It has been demonstrated that blockade of mTOR through ex vivo culture of human T cells in rapamycin reduces T cell expression of molecules associated with effector differentiation, such as cytokine secretion molecules and cytolytic effector molecules.

[7] In addition, the 1, 25-hydroxylated form of Vitamin D (“Vitamin D” as used herein) can inhibit human T cell effector function. The inhibitory effect of Vitamin D on human T cell proliferation can be synergistic with immune suppressive drug exposure using agents such as cyclosporine A or rapamycin. However, previous research indicated that the inhibitory effect of Vitamin D on T cell effectors was relatively specific for Thl-type molecules rather than Th2- type molecules. Furthermore, Vitamin D was shown to promote the immune suppressive regulatory T (TREG) cell population.

[8] In a somewhat contradictory finding, it was determined that human CD8⁺ T cells express high levels of the Vitamin D receptor, and individuals with the highest values tended to have high levels of T cell effector function and immune senescence.

[9] In more recent research, using a murine model of Mycobacterium tuberculosis infection, it was demonstrated that Vitamin D was critical for macrophage elimination of intracellular pathogens through a mechanism that involved IFN-g production and autophagy. In addition, in human non-small cell cancer cell lines, Vitamin D signaling can promote a cytotoxic form of autophagy that contributes to an anti-tumor effect when combined with radiation. Finally, Vitamin D receptor signaling promotes autophagy in normal human mammary tissue; loss of such Vitamin D receptor signaling was associated with an increased risk of developing breast cancer. In spite of this evidence linking Vitamin D to autophagy in innate immunity (macrophage context), there exists a paucity of data relating to Vitamin D effects on autophagy in T cells during adaptive immunity, and in this context, whether the potential effects of Vitamin D and rapamycin on T cell autophagy are redundant.

[10] These somewhat conflicting results pertaining to the potential role of Vitamin D in T cell biology likely relates to the recently discovered, wide-spread effects of Vitamin D on the entire genome, both at the mRNA level and at the microRNA level. As such, the effects of Vitamin D on immunity need to be evaluated in a context-dependent framework.

[11] Regulatory T (TREG) cells are essential for the maintenance of immune tolerance. A reduction in the quantity or quality of TREG cells is a fundamental cause of a multitude of primary auto-immune diseases, including type I diabetes mellitus (T1DM), multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus, to name just a few. In addition, T_REG-deficiency has been associated with acceleration in the natural history of primary neurodegenerative diseases. Finally, T_REG-deficiency is associated with severe complications in the solid organ and hematopoietic cell transplantation setting, most notably, an increased rate of graft rejection and graft-versus-host disease (GVHD). Given this critical role of TREG cells in the maintenance of immune homeostasis, many experimental approaches have been developed to promote TREG cells for the treatment of disease. One such promising approach is the adoptive transfer of TREG cells, which exist in two main sub-types: (1) natural (n) TREG cells, which are derived from the thymus (“nT_REG” or “natural TREG”)_» which involutes with age, thereby reducing the number of UTREG cells available for adoptive transfer; and (2) inducible (i) TREG cells, which are converted in the periphery from the more plentiful pool of effector T cells. Because nT_REG cells are limiting in number, attempts to use nT_REG cells for adoptive T cell therapy have relied upon ex vivo manufacturing methods for isolation and subsequent expansion of nT_REG cells. Clinical trials of nT_REG cells for adoptive cell therapy are in the early stages of implementation, primarily in phase I/phasc II clinical trials for the prevention of GVHD and for the treatment of T1DM. In contrast, other challenges exist for the possibility of using ITREG cells (ex vivo produced TREG cells including TREG and TREG/T1I2 cells of the present disclosure) in adoptive cell therapy, namely: (1) although peripheral effector T cells are relatively plentiful, they primarily exist in a state of effector memory maturation with limited replicative and therapeutic potential; and (2) such peripheral effector T cells have a high degree of pre-existing effector differentiation towards T cell subsets that contribute to disease pathogenesis, namely, the Thl- and Thl7-type subsets. As such, if ITREG cell therapy is to become highly feasible, it will be necessary to develop an ex vivo manufacturing method that both: (1) causes a de-differentiation of effector T cells towards a less- differentiated memory phenotype that has an increased proliferative potential and demonstrable improvement in TREG cell therapeutic potential; and (2) extinguishes pathogenic Thl- and Thl7- type pathways while promoting T cell differentiation towards the TREG phenotype.

[12] The manufacture of ITREG cells is initiated by collection of lymphocyte-containing peripheral blood mononuclear cells from the subject to be treated (in the case of autologous therapy) or from a normal donor (in the case of allogeneic therapy). Typically, this collection is performed in the steady-state, that is, without any growth factor administration; however, in the allogeneic context, collection is sometimes performed in the context of administration of molecules such as granulocyte colony stimulating factor (G-CSF) or plerixifor (as described in DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G- CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720-5726). In this disclosure, we describe that anti-TNF-oc therapeutic agents can be administered prior to collection of lymphocytes for ITREG manufacturing for the purpose of enriching culture input T cells for the TREG phenotype. That is, we demonstrate that the anti-TNF-oc agent etanercept, which is a recombinant receptor that preferentially inhibits serum, cell-free TNF-oc with relative preservation of the cell surface, membrane-bound form of TNF-oc, induces a global change in the T cell receptor (TCR) repertoire when measured by RNA sequencing. Because membrane-bound TNF-oc provides a positive signal to TREG cells through the TNFR2 receptor, our method offers a robust intervention to enrich for TREG cells prior to ITREG cell manufacturing. Other therapeutics that preferentially inhibit serum, cell-free TNF-oc can also be used for this intervention, including but not limited to the anti-TNF-oc monoclonal antibody, adalimumab. [13] Induced (i) TREG cells are not derived from the thymus as in the UTREG cell population; rather, the ITREGS are a population that is converted from otherwise pathogenic post-thymic T cell subsets such as Thl cells. Although both UTREGS and ITREGS play important and non-redundant roles in the dampening of inflammatory responses, development of an ITREG therapy is relatively advantageous in terms of regulatory T cell potency and ease of manufacturing.

[14] The coronavims disease 2019 (COVID-19) is caused by a novel coronavirus (SARS- CoV-2) that results in acute respiratory disease and inflammation in a multitude of organs, including but not limited to: heart, kidney, and brain. As of March 1, 2020, more than 87,000 cases of COVID-19 infections were confirmed globally, primarily in China, with nearly 3,000 deaths at that time (3.4% lethality rate). Unfortunately, these numbers have been rising exponentially, with disease spread to Italy, France, the United States, and indeed across the world as a global pandemic. Many questions remain unanswered relating to various aspects of COVID-19, including virus diagnosis, treatment, vaccine development, and lung disease pathogenesis. Although COVID-19 is a self-limited disease in more than 80% of infected individuals, the severe pneumonia and systemic inflammation that occurs in approximately 15% of cases is primarily responsible for the substantial mortality rate. Respiratory compromise in COVID-19 is characterized by: onset at a median of 8 days from disease onset; abnormal findings on chest CT scan; acute respiratory distress syndrome; acute cardiac injury; and secondary infection. In another recent study involving 138 patients hospitalized for COVID-19, 26% of patients required ICU admission.

[15] COVID-19 disease has been characterized as having three separate stages with classical clinical presentations, underlying pathophysiologic mechanisms, and potential therapies. In Stage 1, patients present with mild constitutional symptoms and may benefit from treatment with anti-viral interventions such as remdesivir, hydroxychloroquine, and convalescent plasma transfusions. A pro-inflammatory host immune response to viral infections takes on an increasingly prominent role in Stage 2, and particularly in Stage 3 disease; nonetheless, it is also likely important to maintain anti-viral therapies in these advanced stages. In Stage 2, the Pulmonary Phase, hypoxia and abnormal chest imaging occur; relatively moderate immune suppressive therapies such as corticosteroids, IL-6 inhibitors, or other anti-inflammatory agents can be considered in Stage 2 to prevent progression to Stage 3, which is the Hyper- Inflammation Phase that is characterized by both inflammation and end-organ, alveolar tissue injury. Stage 3 requires Intensive Care Unit therapy because it is associated with respiratory failure and the subsequent need for mechanical ventilation, ARDS, shock, and cardiac failure.

[16] Stage 3 COVID-19 disease is associated with a high mortality, which ranges from 30 to 70%, primarily depending on patient co-morbidities and rapidity of ICU care initiation. At Hackensack University Medical Center (Hackensack, NJ), the estimated one-month mortality in patients with severe, post-intubation Stage 3 COVID-19 disease at this institution is estimated to be 50%. Thus, it is a critical public health mandate to develop new methods to reduce severe pulmonary inflammation in the setting of severe, Stage 3 COVID-19. Unfortunately, previous clinical trial attempts to reverse ARDS in the setting of pneumonia have yet to identify any specific effective pharmacotherapy other than supportive care. There is a need for the evaluation of novel treatment strategies for therapy of Stage 3 COVID-19 disease, including new cellular agents such as allogeneic RAPA-501 cells that may address both the inflammatory and tissue destruction mechanisms of disease.

[17] The treatment of pro-inflammatory diseases and conditions such as COVID-19 disease and a myriad of additional diagnoses is typically required on an emergent basis because continued inflammation and tissue damage can result in substantial morbidity and mortality within days. As such, because of the substantial amount of time (weeks) required for ex vivo manufacturing, autologous ITREG cell therapy may have a very limited application for the treatment of such diseases and conditions. Therefore, there exists a great need to develop allogeneic, off-the-shelf ITREG cell therapy that can be administered on an emergent basis using cryopreserved, banked ITREG cells. In other cases, treatment or prevention of pro-inflammatory diseases or conditions can occur on a sub-acute or chronic basis: in such cases, autologous ITREG cell therapy can be envisioned.

SUMMARY

[18] The present disclosure is directed to methods for de-differentiation of T cells and differentiation of such cells to TREG or TREG/T1L2 cells. [19] In some embodiments, the initial de-differentiation method can include initiating the culture with an input cell populations harvested in the steady-state (without drug administration).

[20] In some embodiments, the method comprises initiating the de-differentiation culture with an input cell populations harvested from a subject (in the autologous context) or a normal donor (in the allogeneic context) who has been or is being treated with an anti-TNF-oc therapeutic agent that is preferentially selective for inhibition of the serum, cell-free form of TNF-oc with relative preservation of membrane-bound TNF-oc. Such therapeutic agents include but are not limited to the recombinant receptor etanercept, which can be administered at the conventional dose of 25 or 50 mg per week by subcutaneous injection, or the monoclonal antibody adalimumab, which can be administered at the conventional dose of 40 mg per week or 40 mg every other week by intravenous injection. In all of these cases, the dosing of the anti-TNF-oc therapeutic can be adjusted according to the desired biomarker change, which can include but is not limited to alteration of the TCR repertoire by RNA sequencing analysis and a shift towards type 2 TNF receptors (TNFR2) and a shift away from type 1 TNF receptors (TNFR1), as measured by flow cytometry.

[21] In some embodiments, the method comprises inoculating a culture input population of cells comprising T cells from a subject at a cell density in a culture medium comprising vitamin D, temsirolimus and an IL-2 signaling inhibitor; adding anti-CD3/anti-CD28 coated magnetic beads to said T cells and culture medium at a bead:T cell ratio of 1:1 or less to stimulate said T cells, or, in the most extreme example, no addition of anti-CD3/anti-CD28 co-stimulation; incubating said culture input population of cells and culture medium for a period of time to yield de-differentiated T cells. It is also possible to perform this de-differentiation procedure in the absence of any bead co-stimulation.

[22] In any of the foregoing embodiments, the method may further comprise harvesting said de-differentiated T cells.

[23] In any of the foregoing embodiments, the method may further comprise, after harvesting said de-differentiated T cells: packaging at least a portion of said de-differentiated T cells in a package; and freezing said package containing said portion of said de-differentiated T cells. [24] In any of the foregoing embodiments, the method may further comprise before inoculating said culture input population of cells into said culture medium: harvesting said culture input population of cells from said subject.

[25] In any of the foregoing embodiments, the method may further comprise measuring an expression level of RAPTOR or RICTOR in said culture input population of cells wherein said period of time lasts until the expression level of RAPTOR or RICTOR, respectively, in said culture input population of cells is reduced by at least 50% and more preferably 90% relative to a control population of T cells, and wherein said control population of T cells are manufactured under the same conditions as the culture input population of cells without temsirolimus, IL-2 signaling inhibitor and Vitamin D.

[26] In any of the foregoing embodiments, the method may further comprise measuring an expression level of RAPTOR or RICTOR and a housekeeping protein in said culture input population of cells, wherein said period of time lasts until the expression level of RAPTOR or RICTOR, normalized by the housekeeping protein, in the manufactured T cells is at least 50% and more preferably 90% lower than the expression level of RAPTOR or RICTOR, respectively, normalized by the housekeeping protein, in the control population of T cells manufactured under the same conditions as the culture input population of cells without temsirolimus, IL-2 signaling inhibitor and Vitamin D.

[27] The present disclosure is also directed to a de-differentiated T cell produced by the methods of any of the foregoing embodiments.

[28] The present disclosure is also directed to a composition comprising a population of de differentiated cells, wherein at least a portion of said population of said de-differentiated cells express at least 50% and more preferably 90% less of RAPTOR or RICTOR as compared to a control population of T cells manufactured under the same conditions as the culture input population of cells without temsirolimus, IL-2 signaling inhibitor and Vitamin D.

[29] In any of the foregoing embodiments, the method may further comprise measuring at least a portion of said population of said de-differentiated cells whereby they express at least a 10% and more preferably a 50% change in RNA expression of the following molecules relative to a control population of T cells, namely: reduction in T cell effector molecules including but not limited to granzyme B, IL-10, and IFN-g; increase in transcription factors associated with cells of reduced differentiation status, including but not limited to Nanog, KLF4, and KLF10; increase in expression of molecules preferentially expressed on narve T cell subsets, including but not limited to CD 127, the IL-7 receptor alpha chain; reduction in transcription factors associated with Thl-type differentiation, including but not limited to T-BET and STAT1; and relative preservation of transcription factors that promote cell survival, including but not limited to HIF- 1 alpha.

[30] In any of the foregoing embodiments, the method may further comprise measuring at least a portion of said population of said de-differentiated cells whereby they express at least a 10% and more preferably a 50% change in expression of molecules indicative of cells that have undergone autophagy. As one, example, the said de-differentated cells have increased expression of p62 by western blot analysis relative to control T cells. Other standard methods that measure autophagy may also be used, such as those described in Yoshii SR, Mizushima N. Monitoring and Measuring Autophagy. International Journal of Molecular Sciences. 2017; 18(9): 1865.

[31] The present disclosure is also directed to a de-differentiated T cell produced by the methods of any of the foregoing embodiments.

[32] The present disclosure is also directed to a composition comprising a population of de differentiated cells, wherein at least a portion of said population of said de-differentiated cells express at least a 10% and more preferably a 50% change in RNA expression of the following molecules relative to a control population of T cells, namely: reduction in T cell effector molecules including but not limited to granzyme B, IL-10, and IFN-g; increase in transcription factors associated with cells of reduced differentiation status, including but not limited to Nanog, KLF4, and KLF10; increase in expression of molecules preferentially expressed on narve T cell subsets, including but not limited to CD 127, the IL-7 receptor alpha chain; reduction in transcription factors associated with Thl-type differentiation, including but not limited to T-BET and STAT1; and relative preservation of transcription factors that promote cell survival, including but not limited to HIF-1 alpha. [33] The present disclosure is also directed to a composition comprising a population of de differentiated cells, as defined by said de-differentiated cells expressing at least a 10% and more preferably a 50% change in expression of molecules indicative of cells that have undergone autophagy. As one, example, the said de-differentated cells have increased expression of p62 by western blot analysis relative to control T cells. Other methods that measure autophagy can also be applied, such as those described in Yoshii SR, Mizushima N. Monitoring and Measuring Autophagy. International Journal of Molecular Sciences. 2017; 18(9): 1865.

[34] The present disclosure is also directed to a composition comprising a population of de differentiated cells, wherein at least a portion of said population of said de-differentiated cells express less than 50% of both RAPTOR and RICTOR as compared to a control population of T cells.

[35] The present disclosure is directed to methods for differentiating de-differentiated T cells to TREG or TREG/T1I2 cells.

[36] In some embodiments, the method comprises culturing de-differentiated T cells of the present disclosure, or that are otherwise de-differentiated, in a culture medium comprising IL-2, IL-4 and TGF-b; adding anti-CD3/anti-CD28 coated magnetic beads at a ratio of 3:1 (bead:T cell ratio); and incubating said de-differentiated T cells for a period of time to yield TREG/T1I2 cells.

[37] In some embodiments, the method comprises culturing de-differentiated T cells having reduced expression of at least 50% less of RAPTOR or RICTOR relative to a control population of T cells manufactured under the same conditions as the culture input population of cells without temsirolimus, IL-2 signaling inhibitor and Vitamin D, in a culture medium comprising IL-2, IL-4 and TGF-b; adding anti-CD3/anti-CD28 coated magnetic beads at a ratio of 3:1 (bead:T cell ratio); and incubating said de-differentiated T cells for a period of time to yield TREG/T1I2 cells.

[38] In some embodiments, the method comprises culturing de-differentiated T cells having reduced expression of at least 90% less of RAPTOR or RICTOR relative to a control population of T cells manufactured under the same conditions as the culture input population of cells without temsirolimus, IL-2 signaling inhibitor and Vitamin D, in a culture medium comprising IL-2 and TGF-b; adding anti-CD3/anti-CD28 coated magnetic beads at a ratio of 3:1 (bead:T cell ratio); and incubating said de-differentiated T cells for a period of time to yield TREG cells.

[39] In any of the foregoing embodiments, the culture medium can further comprise pemetrexed.

[40] The present disclosure is also directed to a TREG or TREG/T1L2 cell produced by any of the foregoing methods.

[41] The present disclosure is also directed to methods for treating or preventing a pro- inflammatory disease or condition in a subject in need thereof. The therapeutic cell product can be manufactured from the subject in need (autologous) or from a healthy, unrelated normal volunteer (allogeneic).

[42] In some embodiments, the method comprises subjecting said subject to one injection of the ITREG cell product in the steady- state (without conditioning chemotherapy). Multiple infusions of ITREG cells can be envisioned, depending on the durability of the beneficial clinical response. In some embodiments, it may be beneficial to treat the subject with conditioning chemotherapy prior to the ITREG cell infusion. In such cases, a primary treatment cycles would be comprised of: administering to said subject pentostatin; and/or administering to said subject cyclophosphamide; and subjecting said subject to one or more immune therapy treatment cycles comprising: administering to said subject a composition comprising a therapeutically effective amount of manufactured TREG cells. Multiple infusions of ITREG cells after such conditioning chemotherapy can be envisioned, depending on the durability of the beneficial clinical response.

[43] In some embodiments, a method comprises a first treatment cycle, a second treatment cycle, optionally, one or more additional treatment cycles, and one or more immune therapy treatment cycles, said first treatment cycle comprising: administering pentostatin to said subject, and/or administering cyclophosphamide to said subject; said second treatment cycle comprising: administering pentostatin to said subject, and/or administering cyclophosphamide to said subject; each of said one or more additional treatment cycles comprising: administering pentostatin to said subject, and/or administering cyclophosphamide to said subject each of said one or more immune therapy treatment cycles comprising: administering pentostatin to said subject, and/or administering cyclophosphamide to said subject, and administering manufactured TREG cells to said subject.

[44] In some embodiments, a method comprises one or more treatment cycles comprising: administering to said subject a therapeutically effective amount of manufactured TREG cells.

[45] In some embodiments, a method can comprise administering to said subject a therapeutically effective amount of manufactured TREG cells.

BRIEF DESCRIPTION OF THE DRAWINGS

[46] FIGURE 1A depicts normalized GAPDH mRNA expression for the control cells and cells treated under various conditions.

[47] FIGURE IB depicts normalized granzyme B mRNA expression for the control cells and cells treated under various conditions.

[48] FIGURE 1C depicts normalized IL-10 mRNA expression for the control cells and cells treated under various conditions.

[49] FIGURE ID depicts normalized IFN-g mRNA expression for the control cells and cells treated under various conditions.

[50] FIGURES 1A-1D illustrate that the combination of Vitamin D and temsirolimus reduces effector molecule expression in human CD4+ and CD8+ T cells.

[51] FIGURE 2A depicts normalized NANOG mRNA expression for the control cells and cells treated under various conditions.

[52] FIGURE 2B depicts normalized KLF4 mRNA expression for the control cells and cells treated under various conditions.

[53] FIGURE 2C depicts normalized KLF10 mRNA expression for the control cells and cells treated under various conditions. [54] FIGURE 2D depicts normalized IL-7 receptor mRNA expression for the control cells and cells treated under various conditions.

[55] FIGURES 2A-2D illustrate that the combination of Vitamin D and temsirolimus increases expression of stem cell-associated transcription factors and the primitive T cell molecule IL-7 receptor-alpha in human CD4+ and CD8+ T cells.

[56] FIGURE 3A depicts normalized T-BET mRNA expression for the control cells and cells treated under various conditions.

[57] FIGURE 3B depicts normalized STAT1 mRNA expression for the control cells and cells treated under various conditions.

[58] FIGURE 3C depicts normalized HIF-1-a mRNA expression for the control cells and cells treated under various conditions.

[59] FIGURES 3A-3C illustrate that the combination of Vitamin D and temsirolimus reduces expression of transcription factors associated with effector Thl/Tcl cells without reducing expression of a transcription factor associated with T cell survival, HIF-1-a.

[60] FIGURE 4 depicts p62 expression normalized by actin expression for cells treated under various conditions and illustrates that the combination of Vitamin D, temsirolimus, and anti-IL-2 receptor blockade induces expression of the autophagy-related molecule, p62.

[61] FIGURE 5 depicts Raptor expression normalized by actin expression for cells treated under various conditions and illustrates that the combination of Vitamin D, temsirolimus, and anti-IL-2 receptor blockade reduces expression of the mTORCl -related molecule, Raptor.

[62] FIGURE 6 depicts a Western blot of GAPDH, p70S6K, SGK1, Raptor and Rictor expression for cells treated under various conditions and illustrates that the combination of Vitamin D, temsirolimus, and anti-IL-2 receptor blockade reduces expression of the mTORCl- related molecule, Raptor, and the mTORC2-related molecule, Rictor. [63] FIGURE 7 depicts BIM expression normalized by actin expression for cells treated under various conditions and illustrates that the combination of Vitamin D, temsirolimus, and anti-IL-2 receptor blockade reduces expression of the pro-apoptosis molecule, BIM. FIGURE 8 illustrates the effect of culture components during the de-differentiation interval on subsequent T cell yield (at day 13 of culture).

[64] FIGURE 8 illustrates the effect of culture components during the de-differentiation interval on subsequent T cell yield (at day 13 of culture).

[65] FIGURE 9A depicts the percent of CD4 cells that are CD45RA+ for cells treated under various conditions.

[66] FIGURE 9B depicts the percent of CD4 cells that are CD62L+ and CCR7+ for cells treated under various conditions.

[67] FIGURE 9C depicts the percent of CD4 cells that are CD62L+, CCR7+, and CD 127+ for cells treated under various conditions.

[68] FIGURES 9A-9C illustrate the effect of culture components during the de-differentiation interval on CD4+ T cell expression of memory markers (at day 13 of culture).

[69] FIGURE 10A depicts the percent of CD8 cells that are CD62L+ and CCR7+ for cells treated under various conditions.

[70] FIGURE 10B depicts the percent of CD8 cells that are CD62L+, CCR7+, and CD 127+ for cells treated under various conditions.

[71] FIGURES 10A-10B illustrate the effect of culture components during the de differentiation interval on CD8+ T cell expression of memory markers.

[72] FIGURES 1 lA-1 ID depict the inflammatory Thl/Thl7 cytokine analysis of cultured de differentiated T cells in polarization-neutral media.

[73] FIGURE 11A depicts the IFN-g secretion for cells treated under various conditions. [74] FIGURE 1 IB depicts the GM-CSF secretion for cells treated under various conditions.

[75] FIGURE 11C depicts the TNF-a secretion for cells treated under various conditions.

[76] FIGURE 1 ID depicts the IL-17 secretion for cells treated under various conditions.

[77] FIGURES 12A-12D depict the IL-2 and Th2-type cytokine analysis of cultured de differentiated T cells in polarization-neutral media.

[78] FIGURE 12A depicts the IL-2 secretion for cells treated under various conditions.

[79] FIGURE 12B depicts the IL-4 secretion for cells treated under various conditions.

[80] FIGURE 12C depicts the IL-5 secretion for cells treated under various conditions.

[81] FIGURE 12D depicts the IL-13 secretion for cells treated under various conditions.

[82] FIGURE 13 depicts favorable expansion of de-differentiated T cells in hybrid Th2/TREG polarization condition relative to Thl polarization condition.

[83] FIGURE 14A depicts the percentage of CD4+CD45RA+ cells out of total CD4+ cells for cells treated under various conditions.

[84] FIGURE 14B depicts the percentage of CD4+CD62L+CCR7+ cells out of total CD4+ cells for cells treated under various conditions.

[85] FIGURE 14C depicts the percentage of CD4+CD62L+CCR7+CD127+ cells out of total CD4+ cells for cells treated under various conditions.

[86] FIGURES 14-A14C illustrate that the culture of de-differentiated T cells in hybrid Th2/TReg polarization condition results in the generation of naive and triple-positive T central memory CD4+ T cells.

[87] FIGURE 15A depicts the percentage of CD8+CD62L+CCR7+ cells out of total CD8 cells for cells treated under various conditions. [88] FIGURE 15A depicts the percentage of CD8+CD62L+CCR7+CD127+ cells out of total CD8 cells for cells treated under various conditions.

[89] FIGURES 15A-15B illustrates that culture of de-differentiated T cells in hybrid Th2/TReg polarization condition results in the generation of triple-positive T central memory CD8+ T cells.

[90] FIGURE 16A depicts IL-2 secretion for cells treated under various conditions.

[91] FIGURE 16B depicts IL-4 secretion for cells treated under various conditions.

[92] FIGURE 16C depicts IL-5 secretion for cells treated under various conditions.

[93] FIGURES 16A-16C illustrate that the culture of de-differentiated T cells in hybrid Th2/TReg polarization condition results in the generation of T cells with a primitive Th2 cell cytokine phenotype: IL-2, IL-4, and IL-5 secretion.

[94] FIGURE 17A depicts IL-10 secretion for cells treated under various conditions.

[95] FIGURE 17B depicts IL-13 secretion for cells treated under various conditions.

[96] FIGURE 17C depicts IL-17 secretion for cells treated under various conditions.

[97] FIGURES 17A-17C illustrate that the culture of de-differentiated T cells in hybrid Th2/TReg polarization condition results in the generation of T cells with a primitive Th2 cell cytokine phenotype: IL-10, IL-13, and IL-17 secretion.

[98] FIGURE 18A depicts IFN-g secretion for cells treated under various conditions.

[99] FIGURE 18B depicts TNF-a secretion for cells treated under various conditions.

[100] FIGURE 18C depicts GM-CSF secretion for cells treated under various conditions.

[101] FIGURES 18A-18C illustrates that the culture of de-differentiated T cells in hybrid Th2/TREG polarization condition results in the generation of T cells with a primitive Th2 cell cytokine phenotype: IFN-gamma, TNF-alpha, and GM-CSF secretion. [102] FIGURE 19A depicts the percent of CD4+ T cells in culture by day and culture inhibitor.

[103] FIGURE 19B depicts the percent of CD4+FOXP3+ T cells in culture by day and culture inhibitor.

[104] FIGURE 19C depicts the percent of CD4+Tbet+ T cells in culture by day and culture inhibitor.

[105] FIGURE 19D depicts the percent of CD4+GATA3+ T cells in culture by day and culture inhibitor.

[106] FIGURES 19A-19D illustrate that extended culture of de-differentiated T cells in the hybrid Th2/TREG polarization condition containing pemetrexed results in the generation of CD4+ T cells expressing FOXP3 and GATA3 transcription factors.

[107] FIGURE 20A depicts the percent of CD8+ T cells in culture by day and culture inhibitor.

[108] FIGURE 20B depicts the percent of CD8+FOXP3+ T cells in culture by day and culture inhibitor.

[109] FIGURE 20C depicts the percent of CD8+Tbet+ T cells in culture by day and culture inhibitor.

[110] FIGURE 20D depicts the percent of CD8+GATA3+ T cells in culture by day and culture inhibitor.

[111] FIGURES 20A-20D illustrate that extended culture of de-differentiated T cells in the hybrid Th2/TREG polarization condition containing pemetrexed results in the generation of CD8+ T cells expressing FOXP3 and GATA3 transcription factors.

[112] FIGURE 21 A depicts IL-4 secretion for cells in culture by day and culture inhibitor.

[113] FIGURE 2 IB depicts IL-5 secretion for cells in culture by day and culture inhibitor.

[114] FIGURE 21C depicts IL-13 secretion for cells in culture by day and culture inhibitor. [115] FIGURES 21A-21C illustrate that extended culture of de-differentiated T cells in the hybrid Th2/TREG polarization condition results in the generation of T cells expressing with a predominant Th2 cytokine phenotype: IL-4, IL-5, and IL-13 secretion.

[116] FIGURE 22 A depicts IL-2 secretion for cells in culture by day and culture inhibitor.

[117] FIGURE 22B depicts IFN-g secretion for cells in culture by day and culture inhibitor.

[118] FIGURE 22C depicts GM-CSF secretion for cells in culture by day and culture inhibitor.

[119] FIGURES 22A-22C illustrate that extended culture of de-differentiated T cells in the hybrid Th2/TREG polarization condition results in the generation of T cells expressing with a predominant Th2 cytokine phenotype: IL-2, IFN-gamma, and GM-CSF secretion.

[120] FIGURES 23 A and 23B illustrate that the anti-TNF-oc therapy etanercept therapy results in marked alteration of the TCR repertoire when measured by RNA sequencing, thereby representing a new approach for subject treatment prior to lymphocyte collection by apheresis.

[121] FIGURE 24 illustrates that extended culture of de-differentiated T cells in the hybrid Th2/TREG polarization condition results in the generation of T cells expressing increased levels of the following molecules relative to control Thl/Tcl cells: CD25, CD27, 2B4, BTLA, and CTLA.

[122] FIGURE 25 illustrates that extended culture of de-differentiated T cells in the hybrid Th2/TREG polarization condition results in the generation of T cells expressing increased levels of the following molecules relative to control Thl/Tcl cells: TIGIT, TIM3, ICOS, LAIR1, and 0X40.

[123] FIGURE 26A depicts FOXP3 expression in CD4+ and CD8+ T cells at culture initiation and after culture as measured by flow cytometry.

[124] FIGURE 26B depicts GATA3 expression in CD4+ and CD8+ T cells at culture initiation and after culture as measured by flow cytometry. [125] FIGURE 27A depicts CD73 expression in CD4+ and CD8+ T cells at culture initiation and after culture as measured by flow cytometry.

[126] FIGURE 27B depicts CD 103 expression in CD4+ and CD8+ T cells at culture initiation and after culture as measured by flow cytometry.

[127] FIGURE 28A depicts CD150 frequency as measured by flow cytometry in CD4+ and CD8+ T cells at culture initiation, after culture and for control T cells not exposed the mTOR inhibitors, as measured by flow cytometry.

[128] FIGURE 28B depicts CD27 versus CD95 expression for CD4+ T cells at culture initiation and after culture as measured by flow cytometry.

[129] FIGURE 29 depicts the IL-4, IL-2, IFN-g, TNF-a, IL- 17 and GM-CSF for differently cultured cells and control cells.

[130] FIGURE 30A depicts the cytokine content for a transwell assay of Thl/Tcl cells with or without RAPA-501 cells.

[131] FIGURE 30B depicts the flow cytometry results for assays of CD4 and PD1 in Example 24.

[132] FIGURE 31A depicts IL-6, IP- 10, and IFN-g secretion for human microglial cells with or without exposure to RAPA-501 cells.

[133] FIGURE 3 IB depicts IL-6, IP-10, and IFN-g secretion for human microglial cells with or without exposure to RAPA-501 cells.

[134] FIGURE 32 schematically depicts the PC Regimen and the overall therapeutic approach.

[135] FIGURE 33 schematically depicts lymphocyte collection by apheresis pre- and post-PC regimen.

[136] FIGURE 34 schematically depicts the PC regimen prior to each of the repetitive doses of ITREG cells. [137] FIGURE 35 schematically depicts monitoring of patients treated with IT_REG cells.

[138] FIGURES 36A-36B illustrate that the anti-TNF-oc therapy etanercept therapy results in marked alteration of the TCR repertoire when measured by RNA sequencing, thereby representing a new approach for subject treatment prior to lymphocyte collection by apheresis.

[139] FIGURE 37 illustrates that extended culture of de-differentiated T cells in the hybrid T1L2/T_REG polarization condition results in the generation of T cells expressing increased levels of the following molecules relative to control Thl/Tcl cells: CD25, CD27, 2B4, BTLA, and CTLA.

[140] FIGURE 38 illustrates that extended culture of de-differentiated T cells in the hybrid T1L2/T_REG polarization condition results in the generation of T cells expressing increased levels of the following molecules relative to control Thl/Tcl cells: TIGIT, TIM3, ICOS, LAIR1, and 0X40.

[141] FIGURE 39 depicts an alternative protocol design.

[142] FIGURE 40A depicts RAPA-501 GATA3 and FOXP3 as measured by flow cytometry for CD4⁺ cells.

[143] FIGURE 40B depicts RAPA-501 GATA3 and FOXP3 as measured by flow cytometry for CD8⁺ cells.

[144] FIGURE 41 depicts an exemplary workflow of a de-differentation method of the present disclosure.

[145] FIGURE 42 depicts a putative mechanism of action for the hybrid T_REG/T1L2 cells of the present disclosure.

[146] FIGURE 43 depicts disease progression by stages and potential therapies for COVID-19.

DETAILED DESCRIPTION

[147] The present disclosure provides a method for T cell de-differentiation and resulting cells, a method for manufacturing of human hybrid regulatory T/Th2 cells (hybrid T_REG/T1L2 cells) from de-differentiated T cells, and a method for treating or preventing a pro-inflammatory disease or condition using induced regulatory T (ITREG) cells. The ITREG cells can be from the subject to be treated or in whom the disease or condition is to be prevented, however, allogenic (“off-the-shelf’) ITREG cells from other subjects may be used.

Definitions

[148] As used herein, the singular forms “a”, “an” and “the” include plural referents unless the context clearly dictates otherwise.

[149] The use of the term “or” in the claims and the present disclosure is used to mean “and/or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive.

[150] Use of the term “about”, when used with a numerical value, is intended to include +/- 10%. For example, if a number of amino acids is identified as about 200, this would include 180 to 220 (plus or minus 10%).

[151] The terms “patient,” “individual,” and “subject” are used interchange- ably herein, and refer to a mammalian subject to be treated, with human patients being preferred. In some cases, the methods of the invention find use in experimental animals, in veterinary application, and in the development of animal models for disease, including, but not limited to, rodents including mice, rats, and hamsters, and primates.

[152] “Sample” is used herein in its broadest sense. A sample comprising cells, polynucleotides, polypeptides, peptides, antibodies and the like may comprise a bodily fluid; a soluble fraction of a cell preparation, or media in which cells were grown; a chromosome, an organelle, or membrane isolated or extracted from a cell; genomic DNA, RNA, or cDNA, polypeptides, or peptides in solution or bound to a substrate; a cell; a tissue; a tissue print; a fingerprint, skin or hair; and the like.

[153] “Treatment” is an intervention performed with the intention of preventing the development or altering the pathology or symptoms of a disorder. Accordingly, “treatment” can refer to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those already with the disorder as well as those in which the disorder is to be prevented. In tumor (e.g., cancer) treatment, a therapeutic agent may directly decrease the pathology of tumor cells, or render the tumor cells more susceptible to treatment by other therapeutic agents, e.g., radiation and/or chemotherapy.

[154] “Treatment cycle” as used herein can generally refer to any of the primary treatment cycles, a first treatment cycle, a second treatment cycle or one or more additional treatment cycles.

[155] “Immune cells” as used herein, is meant to include any cells of the immune system that may be assayed, including, but not limited to, B lymphocytes, also called B cells, T lymphocytes, also called T cells, natural killer (NK) cells, natural killer T (NKT) cells, lymphokine-activated killer (LAK) cells, monocytes, macrophages, neutrophils, granulocytes, mast cells, platelets, Langerhans cells, stem cells, dendritic cells, peripheral blood mononuclear cells, tumor- infiltrating (TIL) cells, gene modified immune cells including hybridomas, drug modified immune cells, and derivatives, precursors or progenitors of the above cell types.

[156] “T cells” or “T lymphocytes” are a subset of lymphocytes originating in the thymus and having heterodimeric receptors associated with proteins of the CD3 complex (e.g., a rearranged T cell receptor, the heterodimeric protein on the T cell surfaces responsible for antigen/MHC specificity of the cells). T cell responses may be detected by assays for their effects on other cells (e.g., target cell killing, activation of other immune cells, such as B-cells) or for the cytokines they produce.

[157] As used herein, the term “de-differentiated T cell” refers to a T cell that has been de differentiated by any of the methods of the present disclosure. In certain aspects, the de differentiated T cell has reduced expression of RAPTOR or RICTOR relative to a control population of T cells manufactured under the same conditions without temsirolimus, IL-2 signaling inhibitor and Vitamin D. The “de-differentiated T cell” does not include T cells as collected from a patient, i.e. naturally occurring T cells.

[158] As used herein, the term “anti-CD3/anti-CD28” should be understood to refer to anti- CD3/anti-CD28 antibodies. For example, “anti-CD3/anti-CD28 magnetic beads” should be understood to refer to magnetic beads having anti-CD3/anti-CD28 antibody moieties associated therewith. In instances where it is disclosed that no anti-CD3/anti-CD28 co-stimulation is provided, even by a specific form such as anti-CD3/anti-CD28 magnetic beads, it should be understood that this can also exclude co-stimulation with other forms of anti-CD3/anti-CD28.

[159] It should also be understood that, in the present disclosure, where co-stimulation by anti- CD3/anti-CD28 antibodies is performed, this co-stimulation can be provided in any form of anti- CD3/anti-CD28 antibodies. By way of example, but not limitation, where co- stimulation is indicated as being performed by using anti-CD3/anti-CD28 beads, anti-CD3/anti-CD28 nanoparticles or microparticles can be used. Alternative methods of providing T cell co stimulation can be envisioned, including but not limited to alternative methods of delivering co stimulation via novel hydrogel technology (Jesuraj NJ et al; Blood, 2016; 128(22):3368: A Novel Phase-Change Hydrogel Substrate for T Cell Activation Promotes Increased Expansion of CD8+ Cells Expressing Central Memory and Naive Phenotype Markers), alternative monoclonal antibodies (Han X et al; International Review in Cellular and Molecular Biology, 2019; 342: 1- 25: Stimulating T cells against cancer with agonist immuno stimulatory monoclonal antibodies) or pharmacologic agents that yield co-stimulatory signals such as staphylococcus enterotoxin B (SEB) or lenalidomide ( [1] Popugailo A et al; Frontiers in Immunology; 2019; 10: 942: Staphylococcal and Streptococcal Superantigens Trigger B7/CD28 Costimulatory Receptor Engagement to Hyperinduce Inflammatory Cytokines; and [2] LeBlanc R et al; Blood, 2004; 103(5): 1787-90: Immunomodulatory drug costimulates T cells via the B7-CD28 pathway). One of skill in the art can readily determine the amount of such reagents to use based on their effect. By way of example, in the methods of the present disclosure SEB can be used at about 1 pg/mL to about 100 pg/mL, such as at about 10 pg/mL or lenalidomide can be used at about 0.01 pmol/L to about 2.0 pmol/L. In instances where it is disclosed that no anti-CD3/anti-CD28 co stimulation is provided, even by a specific form such as anti-CD3/anti-CD28 magnetic beads, it should be understood that this can also exclude co-stimulation with other forms of anti- CD3/antiCD28.

[160] As used herein, the term “manufactured TREG cells,” “human hybrid TREG/T1I2 cells,” “iTREG” and “TREG/T1I2 cells,” unless otherwise noted, refer to cells that have been differentiated by methods of the present disclosure or having the properties of those cells. The “manufactured TREG cells,” “human hybrid TREG/T1I2 cells,” “iTREG” and “TREG/T1I2 cells” of the present disclosure do not include T cells as collected from a patient, i.e. naturally occurring T cells. It should be understood that RAPA-501 cells are included as manufactured TREG cells.”

[161] As used herein “control Thl/Tcl cells,” unless otherwise noted, refers to cells that have not been treated with vitamin D, temsirolimus or the IL-2 signaling inhibitor and, rather, have been co-stimulated with anti-CD3/anti-CD28 magnetic coated beads at a ratio of 3:1 (beads:T cell) in media supplemented with 20 IU/mL IL-2 and 20,000 IU/mL of IFN-a and otherwise cultured the same as the cells to which they are being compared. It should also be understood that where a control population of cells (or control T cell) is referred to as having been treated without culture additives, including temsirolimus, vitamin D and the IL-2 signaling inhibitor, or in the context of de-differentiated cells, this population (or T cell) has been further co-stimulated with anti-CD3/anti-CD28 magnetic coated beads at a ratio of 3:1 (beads :T cell) in media supplemented with 20 IU/mL IL-2 and 20,000 IU/ml of IFN-a and otherwise cultured the same as the cells to which they are being compared, i.e. they are “control Thl/Tcl cells.”

[162] As used herein, the term “therapeutically effective dose” or “therapeutically effective amount” is meant an amount of an agent of the present invention effective to yield the desired therapeutic response. By way of example but not limitation, a dose effective to delay the growth of or to cause the cancer to shrink or prevent metastasis can be a “therapeutically effective dose.” The specific therapeutically effective dose will vary with such factors as the particular condition being treated, the physical condition of the patient, the type of mammal or animal being treated, the duration of the treatment, the nature of concurrent therapy (if any), and the specific formulations employed and the structure of the compounds or its derivatives.

[163] The present disclosure provides new methodology for the ex vivo generation of T cells of a reduced differentiation state that is based upon the conversion of differentiated effector memory T cells into less differentiated central-memory type T cells using a novel pharmacologic combination and defined T cell co-stimulatory conditions.

[164] As shown in FIGURE 41, a de-differentiated T cell of the present disclosure can have a quiescent phenotype with low or no expression of checkpoint inhibitor receptors (such as PD1, CTLA4, TIM3, and LAG3), memory markers (such as CD45RO) and fate molecules (such as TBET, RORy, FOXP3 and GATA3). The re-differentiated T cell can have a hybrid fate characterized GAT A3 and FOXP3 expression, as well as stem cell memory characterized by CD45RA and CD 150 expression and no checkpoint protein expression.

[165] As shown in FIGURE 42, a putative mechanism of action of the hybrid TREG/T1I2 cells of the present disclosure whereby the hybrid TREG/T1I2 cell can be activated by inflammation via the CD39 or CD73 receptors and by TNF-a, which can enable the cell to regulate pathogenic T cells to prevent killing.

Method for T cell de-differentiation and resulting cells

[166] We present a new methodology for the ex vivo generation of T cells of a reduced differentiation state that is based upon the conversion of differentiated effector memory T cells into less differentiated central-memory type T cells using a novel pharmacologic combination and defined T cell co- stimulatory conditions.

[167] In an embodiment, the method comprises inoculating a culture input population of cells comprising T cells from a subject at a cell density in a culture medium comprising vitamin D, temsirolimus and an IL-2 signaling inhibitor; adding anti-CD3/anti-CD28 coated magnetic beads to said T cells and culture medium at a bead:T cell ratio of 1:1 or less to stimulate said T cells or without adding any co- stimulation beads; incubating said culture input population of cells and culture medium for a period of time to yield de-differentiated T cells. In some embodiments, the subject has been treated with an anti-TNF-a therapy prior to collection of the culture input population of cells. In some embodiments, the anti-TNF-a therapy is etanercept or adalimumab. In some embodiments, no co-stimulation with anti-CD3/anti-CD28 is performed.

[168] In any of the foregoing embodiments, said culture medium can not contain IL-2 and no IL-2 can be added to said culture medium.

[169] In any of the foregoing embodiments, said cell density can be about 1.5 x 10⁶ T cells per mL to 18 x 10⁶ T cells per mL. By way of example but not limitation, 6 x 10⁶ T cells per mL to 18 x 10⁶ T cells per mL, 12 x 10⁶ T cells per mL to 18 x 10⁶ T cells per mL, 1.5 x 10⁶ T cells per mL to 12 x 10⁶ T cells per mL, 1.5 x 10⁶ T cells per mL to 6 x 10⁶ T cells per mL, 6 x 10⁶ T cells per mL to 12 x 10⁶ T cells per mL, or 1.5 x 10⁶ T cells per mL, 3 x 10⁶ T cells per mL, 6 x 10⁶ T cells per mL, 9 x 10⁶ T cells per mL, 12 x 10⁶ T cells per mL, 15 x 10⁶ T cells per mL, or 18 x 10⁶ T cells per mL. In some embodiments, by way of example but not limitation, it is anticipated that it may be preferable to initiate cell culture at higher densities such at 9 x 10⁶ T cells per mL or 18 x 10⁶ T cells per mL.

[170] In any of the foregoing embodiments, said temsirolimus can be present at a concentration of about 0.3 mM to about 10 pM. By way of example but not limitation, said temsirolimus can be present in said culture medium at a concentration of about 0.3 pM to about 1 pM, 0.3 pM to about 0.75 pM, 0.3 pM to about 0.5 pM, 0.5 pM to about 1 pM, 0.75 pM to about 1 pM, 0.5 pM to about 0.75 pM, 0.3 pM to about 10 pM, 0.3 pM to about 5 pM, 0.3 pM to about 3.3 pM, 1 pM to about 3.3 pM, 5 pM to about 10 pM, 3.3 pM to about 10 pM, 3.3 pM to about 5 pM, or, by way of example but not limitation, at a concentration of about 0.3 pM, 0.4 pM, 0.5 pM, 0.6 pM, 0.7 pM, 0.8 pM, 0.9 pM, or 1 pM, 2 pM, 3 pM, 3.3 pM, 4 pM, 5 pM, 6 pM, 7 pM, 8 pM, 9 pM, or 10 pM.

[171] In any of the foregoing embodiments, said IL-2 signaling inhibitor can be an anti-IL-2 receptor antibody or fragment thereof. By way of example but not limitation, said IL-2 signaling inhibitor can be basiliximab or daclizumab. By way of example but not limitation, said IL-2 signaling inhibitor is present in said culture medium at a concentration of 5 to 50 pg/mL, 5 to 40 pg/mL, 5 to 30 pg/mL, 5 to 20 pg/mL, 5 to 10 pg/mL, 10 to 50 pg/mL, 20 to 50 pg/mL, 30 to 50 pg/mL, 40 to 50 pg/mL, 30 to 40 pg/mL, 20 to 40 pg/mL, 10 to 40 pg/mL, 5 to 40 pg/mL, 5 to 30 pg/mL, 5 to 20 pg/mL, 5 to 10 pg/mL, 10 to 20 pg/mL, 10 to 30 pg/mL, 20 to 30 pg/mL, or, by way of example but not limitation, at a concentration of about 5 pg/mL, 10 pg/mL, 15 pg/mL, 20 pg/mL, 25 pg/mL, 30 pg/mL, 35 pg/mL, 40 pg/mL, 45 pg/mL, or 50 pg/mL.

[172] In any of the foregoing embodiments, by way of example but not limitation, said period of time can be about 1.5 days to about 5 days, 1.5 days to about 3.5 days, 1.5 days to about 2.5 days, 2.5 days to about 3.5 days, 2.5 days to about 5 days, 3.5 days to about 5 days, or, about 1.5 days, 2 days, 2.5 days, 3 days, 3.5 days, 4 days, 4.5 days, or 5 days. In some embodiments, the level of mTORCl and mTORC2 reduction may be used as a guide to determine optimal culture interval. In some embodiments other molecular signatures of the de-differentiated cells can be used to determine optimal culture interval, including but not limited to: RNA expression of T cell effector molecules (i.e., decreased IFN-g); RNA expression of transcription factors (i.e., increased KLF4); evidence of an autophagy signature (i.e., increased p62); and up-regulation of markers present on naive T cell subsets (i.e., increased CD127).

[173] In any of the foregoing embodiments, by way of example but not limitation, said bead:T cell ratio can be 1:3 or no co- stimulation can be performed. By way of example but not limitation, said bead:T cell ratio can be between 1:1 and 1:12, 1:1 and 1:3, 1:3 to 1:12. By way of further example but not limitation, said bead:T cell ratio can be 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11 or 1:12. Finally, in the most extreme example, no anti-CD3/anti-CD28 co stimulation can be utilized, i.e. in some embodiments, no anti-CD3/anti-CD28 co- stimulation is performed during the initial de-differentiation process.

[174] In any of the foregoing embodiments, co-stimulation of the culture input population of cells can be achieved using anti-CD3/anti-CD28 containing nanoparticles which can be used at a reduced concentration than recommended. By way of example, but not limitation, such nanoparticles can be used at about 0.01X to about 0.1X, about 0.025X to about 0.1X, about 0.05X to about 0.1X, about 0.075X to about 0.1X, about 0.01X to about 0.075X, about 0.01X to about 0.05X, about 0.01X to about 0.025X, about 0.025X to about 0.075X, about 0.025X to about 0.05X, about 0.05X to about 0.075X, or about 0.01X, about 0.025X, about 0.05X, about 0.075X, or about 0.01X the recommended dose. By way of example but not limitation, a reagent such as Miltenyi® T Cell TransActTM could be used at a reduced dose compared to the recommended dose of 10 pL per 1 x 10⁶ T cells such as, by way of example but not limitation,

1.1 pL (a nine-fold decrease) or about 0.1 IX. Finally, in the most extreme example, no anti- CD3/anti-CD28 co-stimulation can be utilized, i.e. in some embodiments, no anti-CD3/anti- CD28 co-stimulation is performed during the initial de-differentiation process.

[175] Alternatively, if anti-CD3/anti-CD28 co- stimulation is to be used for producing manufactured T cells, the source of co- stimulation can be provided by dissolvable anti-CD3/anti- CD28 microparticles. By way of example, but not limitation, the dissolvable anti-CD3/anti- CD28 microparticles can be used at 20% of the strength recommended by the manufacturer (e.g. Cloudz®; Bio-Techne). By way of further example, the dissolvable anti-CD3-anti-CD28 microparticles can be used at 5%, 10%, 15%, 20%, 25% or 30% of the manufacturer’s recommended strength.

[176] In any of the foregoing embodiments, the anti-CD3/anti-CD28 stimulation, if performed, can be performed using anti-CD3/anti-CD28 in an amount sufficient to achieve the desired de differentiated cell properties.

[177] In any of the foregoing embodiments, said culture medium can further comprise 5% human serum. By way of example but not limitation said culture medium can comprise at least 1%, 2% 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%,

19% or 20% human serum and any range comprising values therebetween.

[178] In any of the foregoing embodiments, said culture medium can comprise X-Vivo 20 medium. Any appropriate culture medium for culturing T cells can be used.

[179] In any of the foregoing embodiments, by way of example but not limitation, said vitamin D can be present in said culture medium at about 0.03 nM to about 1 nM, 0.03 nM to about 0.5 nM, 0.03 nM to about 0.1 nM, 0.03 nM to about 0.05 nM, 0.05 nM to about 0.1 nM, 0.05 nM to about 0.5 nM, 0.05 nM to about 1 nM, 0.1 nM to about 1 nM, 0.1 nM to about 0.5 nM, or 0.5 nM to about 1 nM, or by way of example but not limitation, said vitamin D is present at a concentration of about 0.03 nM, 0.05 nM, 0.1 nM, 0.5 nM, or 1 nM.

[180] In any of the foregoing embodiments, the method can further comprise measuring an expression level of RAPTOR or RICTOR and a housekeeping protein in said culture input population of cells, wherein said period of time lasts until the expression level of RAPTOR or RICTOR, respectively, in the manufactured T cells is at least 50% reduced relative to a control population of T cells, wherein said control population of T cells are manufactured under the same conditions as the culture input population of cells without temsirolimus, IL-2 signaling inhibitor and Vitamin D. In some embodiments, the period of time lasts until the expression level of RAPTOR or RICTOR, respectively, in the manufactured T cells is reduced by 50% or more relative to the control population of T cells manufactured under the same conditions as the culture input population of cells without temsirolimus, IL-2 signaling inhibitor and Vitamin D. By way of example, but not limitation, the period of time can last until the expression level of RAPTOR or RICTOR, respectively, is reduced by at least 50%, 60%, 70%, 80%, 90%, 95%, 99% or more relative to the control population of T cells manufactured under the same conditions as the culture input population of cells without temsirolimus, IL-2 signaling inhibitor and Vitamin D.

[181] In any of the foregoing embodiments, said housekeeping protein can be actin. In some embodiments, the housekeeping protein can be GAPDH. In any of the foregoing embodiments, the step of measuring the expression level can be performed by Western blot analysis.

[182] In any of the foregoing embodiments, the period of time can last until the expression level of RAPTOR or RICTOR in said culture input population of cells is reduced by at least 50% relative to a control population of T cells manufactured under the same conditions as the culture input population of cells without temsirolimus, IL-2 signaling inhibitor and Vitamin D. In some embodiments, the reduction in the expression level of RAPTOR or RICTOR can be at least 50%, 60%, 70%, 80%, 90%, 95%, 99% or more relative to the control population of T cells.

[183] In any of the foregoing embodiments, the period of time of the initial de-differentiation culture can last until the RNA expression pattern is at least 10% and more optimally 50% different relative to control T cells cultured under the same conditions without temsirolimus, vitamin D and the IL-2 signaling inhibitor, namely: reduction in T cell effector molecules including but not limited to granzyme B, IL-10, and IFN-g; increase in transcription factors associated with cells of reduced differentiation status, including but not limited to Nanog, KLF4, and KLF10; increase in expression of molecules preferentially expressed on naive T cell subsets, including but not limited to CD 127, the IL-7 receptor alpha chain; reduction in transcription factors associated with Thl-type differentiation, including but not limited to T-BET and STAT1; and relative preservation of transcription factors that promote cell survival, including but not limited to HIF-1 alpha.

[184] In any of the foregoing embodiments, the period of time of the initial de-differentiation culture can last until the RNA expression pattern is at least 10% and more optimally 50% different relative to control T cells cultured under the same conditions without temsirolimus, vitamin D and the IL-2 signaling inhibitor, namely: whereby there is least a 10% and more preferably a 50% change in expression of molecules indicative of cells that have undergone autophagy. As one, example, the said de-differentated cells have increased expression of p62 by western blot analysis relative to control T cells; other methods of measuring autophagy can also be utilized, by way of example but not limitation, those described in Yoshii SR, Mizushima N. Monitoring and Measuring Autophagy. International Journal of Molecular Sciences.

2017; 18(9): 1865.

[185] In any of the foregoing embodiments, the culture medium may not contain human serum, temsirolimus, Vitamin D, the IL-2 signaling inhibitor or any combination thereof can be absent from the culture medium at the time of culture initiation. In such embodiments, human serum, temsirolimus, Vitamin D or the IL-2 signaling inhibitor can be added to the culture medium at about the same time as inoculation of the culture input population of cells or at a subsequent time.

[186] By way of example and not limitation, an intravenous formulation of 1,25-vitamin D (“Calcitriol”) can be used. This formulation is preferable because it is fully soluble in culture media and has the 1, 25 hydroxylation that is naturally produced in the kidneys and therefore must be present when adding vitamin D to culture. Trade name for calcitriol includes Rocaltrol, Calcijex, and Decostriol). It is also envisioned that other vitamin D receptor (VDR) ligands may be substituted for calcitriol, including but not limited to lithocholic acid, as described in Maestro et al; Vitamin D receptor 2016: novel ligands and structural insights; Expert Opinion on Therapeutic Patents; Volume 26, 2016, issue 11.

[187] In some embodiments, a de-differentiated T cell that can be obtained by any of the methods of the present disclosure is provided. In some embodiments, a composition comprising a population of de-differentiated T cells is provided. In some embodiments, at least a portion of the de-differentiated T cells express less than 50% of RAPTOR or RICTOR relative to a control population of T cells manufactured under the same conditions as the culture input population of cells without temsirolimus, IL-2 signaling inhibitor and Vitamin D. In some embodiments, a de differentiated T cell expresses less than 50% RAPTOR or RICTOR relative to a control population of T cells manufactured under the same conditions as the culture input population of cells without temsirolimus, IL-2 signaling inhibitor and Vitamin D. By way of example, but not limitation, said de-differentiated T cell or population of de-differentiated T cells can express 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, 1% or less RAPTOR or RICTOR relative to a control T cell or population of T cells, respectively, manufactured under the same conditions as the culture input population of cells without temsirolimus, IL-2 signaling inhibitor and Vitamin D.

[188] In some embodiments a de-differentiated T cell population or de-differentiated T cell can be characterized by a reduction in RNA expression for cytolytic molecules relative to a control T cell population incubated under the same conditions without temsirolimus, vitamin D and the IL- 2 signaling inhibitor, including, but not limited granzyme B and/or for cytokine molecules including, but not limited to IFN-g. Such a reduction can be, by way of example but not limitation, at least 10%, at least 20%, at least 30%, at least 40%, at least 50% or more.

[189] In some embodiments a de-differentiated T cell population or de-differentiated T cell can be characterized by an increase in RNA expression for transcription factors associated with iPSCs relative to a control T cell population incubated under the same conditions without temsirolimus, vitamin D and the IL-2 signaling inhibitor, including, but not limited to Nanog, KLF4, and KLF10 and/or for molecules associated with naive T cells including, but not limited to the IL-7 receptor, CD127. Such an increase can be, by way of example but not limitation, at least 10%, at least 20%, at least 30%, at least 40%, at least 50% or more.

[190] In some embodiments a de-differentiated T cell population or de-differentiated T cell can be characterized by a reduction in RNA expression for transcription factors associated with Thl effector T cells relative to a control T cell population incubated under the same conditions without temsirolimus, vitamin D and the IL-2 signaling inhibitor, including, but not limited T- Bet and STAT1 with a concomitant maintenance about equivalent HIF-1-a expression. Such a reduction can be, by way of example but not limitation, at least 10%, at least 20%, at least 30%, at least 40%, at least 50% or more. By way of example, but not limitation, the HIF-1-a expression can be within about 20%, 15%, 10% or 5% or the control T cell population.

[191] In some embodiments a de-differentiated T cell population or de-differentiated T cell can be characterized by an increase in protein expression of p62 relative to a control population of T cells incubated under the same conditions without temsirolimus, vitamin D and the IL-2 signaling inhibitor. Such an increase can be, by way of example but not limitation, at least 10%, at least 20%, at least 30%, at least 40%, at least 50% or more.

Method for manufacturing of human hybrid regulatory T/Th2 cells (hybrid T_REc/Th2 cells) and T_REcfrom de-differentiated T cells

[192] In the present disclosure, we provide an ex vivo manufacturing process that results in the generation of iTREG cells enhanced for an early state of differentiation combined with depletion of Thl- and Thl7-type polarization. This method requires a two-step process, the first step consisting of T cell de-differentiation, the second step iTREG cell manufacturing. Manufacture of human iTREG cells from this de-differentiated T cell substrate can be performed using a novel combination of cytokines (standard iTREG use of IL-2 and TGF-b cytokines plus additional use of the cytokine classically-associated with Th2 differentiation, IL-4) and, optionally, a novel pharmaceutical agent, pemetrexed as described herein. In some embodiments, the iTREG cells can be generated without pemetrexed. Because such cells have expression of both TREG and Th2 molecules, cells generated by this method are termed ‘human hybrid TREG/Th2 cells’.

[193] In some embodiments, the method comprises culturing de-differentiated T cells of the present disclosure in a culture medium comprising IL-2, IL-4 and TGF-b; adding anti-CD3/anti- CD28 coated magnetic beads, such as at a ratio of 3:1 (bead:T cell ratio); and incubating said de differentiated T cells for a period of time to yield TREG/Th2 cells. In some embodiments, the method comprises culturing a population of de-differentiated T cells of the present disclosure.

The ratio of anti-CD3/anti-CD28 beads can be varied so long as the co-stimulation is sufficient to differentiate the cells.

[194] In some embodiments, the method comprises culturing de-differentiated T cells having reduced expression of RAPTOR or RICTOR relative to a control population of T cells manufactured under the same conditions without temsirolimus, IL-2 signaling inhibitor and Vitamin D, in a culture medium comprising IL-2, IL-4 and TGF-b; adding anti-CD3/anti-CD28 coated magnetic beads, such as at a ratio of 3:1 (bead:T cell ratio); and incubating said de differentiated T cells for a period of time to yield TREG/Th2 cells. In some embodiments, the method comprises culturing a population of de-differentiated T cells of the present disclosure. The ratio of anti-CD3/anti-CD28 beads can be varied so long as the co-stimulation is sufficient to differentiate the cells. In some embodiments, the expression of RAPTOR or RICTOR is normalized by a housekeeping protein, such as, by way of example, but not limitation, actin or GAPDH.

[195] In any of the foregoing embodiments, IL-2 can be present in said culture medium at a concentration of about 100 IU/ml to 10,000 IU/ml, 100 IU/ml to 1,000 IU/ml, 1,000 IU/ml to 10,000 IU/ml, or, about 100 IU/ml, 1,000 IU/ml, or 10,000 IU/ml.

[196] In any of the foregoing embodiments the culture medium can further comprise IL-4. In any of the foregoing embodiments, IL-4 can be present in said culture medium at a concentration of about 100 IU/mL to 1000 IU/M1, 100 IU/mL to 1000 IU/mL, 100 IU/mL to 250 IU/mL, 100 IU/mL to 500 IU/mL, 250 IU/mL to 1000 IU/mL, 500 IU/mL to 1000 IU/mL, 250 IU/mL to 500 IU/mL, or, 100 IU/mL, 200 IU/mL, 300 IU/mL, 400 IU/mL, 500 IU/mL, 600 IU/mL, 700 IU/mL, 800 IU/mL, 900 IU/mL, or 1000 IU/mL. In some embodiments, by way of example but not limitation, lower concentrations such as 100 IU/mL can be used if there is a desire to achieve reduced Th2 polarization.

[197] In any of the foregoing embodiments, TGF-b can be present in said culture medium at a concentration of about 10 ng/mL. By way of example, but not limitation, the concentration of TGF-b can be about 5 ng/mL, 6 ng/mL, 7 ng/mL, 8 ng/mL, 9 ng/mL or 10 ng/mL.

[198] In any of the foregoing embodiments for differentiation, said bead:T cell ratio can be 3:1. In some embodiments, an equivalent amount, having the same effect, of alternative forms of anti-CD3/anti-CD28 can be used. In some embodiments, the amount of co- stimulation is sufficient to saturate the cells. In any of the foregoing embodiments, the amount of co stimulation can be sufficient to increase the expression of GAT A3 and FOXP3 in the human hybrid TREG/Th2 cells.

[199] In any of the foregoing embodiments the culture medium can further comprise pemetrexed. By way of example but not limitation, pemetrexed can be present in said culture medium at a concentration from about 1 nM to 100 nM, 5 nM to 100 nM, 10 nM to 100 nM, 25 nM to 100 nM, 50 nM to 100 nM, 75 nM to 100 nM, 50 nM to 75 nM, 25 nM to 75 nM, 10 nM to 50 nM, 10 nM to 25 nM, or at such values as 5 nM, 10 nM, 25 nM, 50 nM, 75 nM, or 100 nM. In some embodiments, the culture medium does not comprise pemetrexed and pemetrexed is not added to the culture medium.

[200] In any of the foregoing embodiments said period of time for incubating said de differentiated T cells can be, by way of example but not limitation, between 3 days to 40 days, 2 days to 20 days, 3 days to 10 days, 3 days to 6 days, 6 days to 10 days, 10 days to 40 days, 10 days to 20 days, 10 days to 15 days, 15 days to 40 days, 20 days to 40 days, 30 days to 40 days, 20 days to 30 days, or 15 days to 30 days, or 15 days to 20 days. In some embodiments, by way of example but not limitation, shorter intervals of culture such as 3 days to 10 days can be considered if hybrid Th2/TREG cells of very limited differentiation status.

[201] The present disclosure is also directed to methods and a TREG cell produced by any of the foregoing methods without the use of IL-4.

[202] In some embodiments, a TREG or TREG/Th2 cell produced by the methods of the present disclosure can have increased expression by flow cytometry of at least one of CD25, CD27, 2B4, BTLA, CTLA4, TIGIT, TIM3, ICOS, LAIRl, and 0X40 relative to control Thl/Tcl cells. In some embodiments, this increase can be, by way of example but not limitation, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or more.

[203] In some embodiments, a TREG or TREG/Th2 cell produced by the methods of the present disclosure can have decreased secretion of inflammatory cytokines relative to control Thl/Tcl cells. By way of example, but not limitation, such cyotkines can include IFN-g and TNF-a. In some embodiments, this decrease can be, by way of example but not limitation, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or more.

[204] In some embodiments, a TREG or TREG/Th2 cell produced by the methods of the present disclosure can have reduced TBET and increase FOXP3 expression relative to control Thl/Tcl cells and/or increased IL-4 secretion and increased expression of GAT A3 relative to control Thl/Tcl cells. In some embodiments, this decrease orincrease can be, by way of example but not limitation, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or more. [205] In some embodiments, a population of TREG or TREG/Th2 cells can have at least 5% of CD4+ or CD8+ cells that express GAT A3. By way of example, but not limitation, a population of TREG or TREG/Th2 cells can have at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 45%, at least 50%, or at least 60% of CD4+ or CD8+ T cells that express GAT A3. In some embodiments, whether the cells express GATA3 is determined by flow cytometry. . In some embodiments, population of TREG or TREG/T1L2 cells can exhibit an increased frequency of CD4⁺ or CD8⁺ T cells expressing GATA3 relative to a control T cell population characteristic of the T cells from which the population of TREG or TREG/T1L2 cells was produced . In some embodiments, the increased frequency can be an increase of 50% or more. By way of example, but not limitation, the increase can be by 50%, 100%, 200%, 300%, 500%, 1000%, 2000%, 3000% or more.

[206] In some embodiments, a population of TREG or TREG/Th2 cells can have at least 5% of CD4+ or CD8+ cells that express FoxP3. By way of example, but not limitation, a population of TREG or TREG/Th2 cells can have at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, or at least 45% of CD4+ or CD8+ T cells that express FoxP3. In some embodiments, whether the cells express FoxP3 is determined by flow cytometry. In some embodiments, population of TREG or TREG/T1L2 cells can exhibit an increased frequency of CD4⁺ or CD8⁺ T cells expressing FOXP3 relative to a control T cell population characteristic of the T cells from which the population of TREG or TREG/T1L2 cells was produced . In some embodiments, the increased frequency can be an increase of 50% or more. By way of example, but not limitation, the increase can be by 50%, 100%, 200%, 300%, 500%, 1000%, 2000%, 3000% or more.

[207] In some embodiments, a population of TREG or TREG/Th2 cells can have at least 10% of CD4+ or CD8+ cells that express CD73. By way of example, but not limitation, a population of TREG or TREG/Th2 cells can have at least 10%, at least 15%, at least 20%, or at least 25% of CD4+ T cells that express CD73. By way of further example, but not limitation, a population of TREG or TREG/Th2 cells can have at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, or at least 80% of CD8+ T cells that express CD73. In some embodiments, whether the cells express CD73 is determined by flow cytometry. In some embodiments, population of TREG or T_REG/Th2 cells can exhibit an increased frequency of CD4⁺ or CD8⁺ T cells expressing CD73 relative to a control T cell population characteristic of the T cells from which the population of TREG or TREG/T1L2 cells was produced . In some embodiments, the increased frequency can be an increase of 50% or more. By way of example, but not limitation, the increase can be by 50%, 100%, 200%, 300%, 500%, 1000%, 2000%, 3000% or more.

[208] In some embodiments, a population of TREG or TREG/Th2 cells can have at least 10% of CD4+ or CD8+ cells that express CD 103. By way of example, but not limitation, a population of TREG or TREG/Th2 cells can have at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% of CD4+ or CD8+ T cells that express CD 103. In some embodiments, whether the cells express CD 103 is determined by flow cytometry. In some embodiments, population of TREG or TREG/T1L2 cells can exhibit an increased frequency of CD4⁺ or CD8⁺ T cells expressing CD 103 relative to a control T cell population characteristic of the T cells from which the population of TREG or TREG/T1L2 cells was produced . In some embodiments, the increased frequency can be an increase of 50% or more. By way of example, but not limitation, the increase can be by 50%, 100%, 200%, 300%, 500%, 1000%, 2000%, 3000% or more.

[209] In some embodiments, a population of TREG or TREG/T1L2 cells can have at least 5% of CD4⁺ or CD8⁺ cells that express both FOXP3 and GAT A3 as measured by flow cytometry. By way of example, but not limitation, the population of TREG or TREG/T1L2 cells can have at least 5%, 10%, 20%, 30%, 40%, or 50% of CD4⁺ or CD8⁺ cells that express both FOXP3 and GAT A3.

[210] In some embodiments, a population of TREG or TREG/Th2 cells can have at least 20% of CD4+ or CD8+ T cells that express CD150. By way of example, but not limitation, a population of TREG or TREG/Th2 cells can have at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45% or at least 50% of CD4+ or CD8+ T cells that express CD 150. In some embodiments, a population of TREG or TREG/Th2 cells can an increased frequency of cells that express CD 150 relative to a control population of T cells incubated without exposure to mTOR inhibitors. In some embodiments, whether the cells express CD150 is determined by flow cytometry. In some embodiments, population of TREG or TREG/T1L2 cells can exhibit an increased frequency of CD4⁺ or CD8⁺ T cells expressing CD 150 relative to a control T cell population characteristic of the T cells from which the population of TREG or TREG/T1L2 cells was produced . In some embodiments, the increased frequency can be an increase of 50% or more. By way of example, but not limitation, the increase can be by 50%, 100%, 200%, 300%, 500%, 1000%, 2000%, 3000% or more.

[211] In some embodiments, a population of TREG or TREG/Th2 cells can express at least 5 pg/mL/1 x 10⁶ cells/day of IL-4 after co-stimulation with anti-CD3/anti-CD28 beads at a bead:T cell ratio of 3 : 1. By way of example, but not limitation, a population of TREG or TREG/Th2 cells can express at least 5, at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, or at least 100 pg/mL/1 x 10⁶ cells/day IL-4.

[212] In some embodiments, a population of TREG or TREG/Th2 cells can express at least 100 pg/mL/1 x 10⁶ cells/day of IL-2 after co-stimulation with anti-CD3/anti-CD28 beads at a bead:T cell ratio of 3:1.

[213] In some embodiments, a population of TREG or TREG/Th2 cells can express less than 100 pg/mL/1 x 10⁶ cells/day of IFN-g or GM-CSF after co-stimulation with anti-CD3/anti-CD28 beads at a bead:T cell ratio of 3:1.

[214] In some embodiments, a population of TREG or TREG/Th2 cells can express less than 10 pg/mL/1 x 10⁶ cells/day of TNF-a or IL-17 after co- stimulation with anti-CD3/anti-CD28 beads at a bead:T cell ratio of 3:1.

[215] In some embodiments, a TREG or TREG/Th2 cell can express both GATA3 and FOXP3. In some embodiment, a TREG or TREG/Th2 cell can express GATA3, FOXP3, CD103 and CD73. In some embodiments, a population of TREG or TREG/Th2 cells can be characterized by at least 5% of the T cells expressing GATA3, at least 5% of the T cells expressing FOXP3, at least 5% of the T cells expressing CD103 and at least 5% of the T cells expressing CD73, as measured by flow cytometry. [216] In any of the foregoing embodiments, the TREG or TREG/Th2 cell or population thereof can have at least one or any combination of the foregoing recited properties to the extent the properties are not incompatible.

Methods for treating or preventing a pro-inflammatory disease or condition

[217] The present disclosure provides methods of treating or preventing a pro-inflammatory disease or condition. Because manufactured TREG cells can reduce inflammation, they can provide a therapeutic or preventive treatment for diseases and conditions associated with inflammation.

[218] The mechanism of fatal pneumonia in experimental murine coronavims infection is mediated by innate inflammasome activation, a resultant robust infiltration of inflammatory monocytes and macrophages, and a subsequent increase in multiple pro-inflammatory cytokines and chemokines. Importantly, the CD4+ and CD8+ adaptive T cell response to experimental coronavims infection can be either curative or disease propagating. Viral-induced pulmonary inflammation has also been evaluated in non-human primate models, which have confirmed that dysregulated immune activation during viral pneumonia involves T cell subset imbalance, a downstream monocyte-derived inflammatory cascade, and resultant epithelial cell injury.

[219] In humans, severity of viral-induced lower respiratory tract infection correlates with increased numbers of effector memory CD8+ T cells in the airway. As recently reviewed, human coronavims infection represents an ongoing battle between vims and host, with the nature of the response dictating disease cure or alternatively, aggravated lung disease. Evidence exists that the adaptive immune system contributes to pulmonary inflammation during SARS-associated Coronavims (SARS-CoV) disease: that is, bronchoalveolar fluid from such subjects had increased T cell numbers and increased Thl-associated molecules IL-12, IFN-g and IP- 10. This downstream adaptive T cell-mediated inflammatory response is driven in part by the SARS-Co- V protein viroporin 3 a; specifically, viroporin molecules activate the NLRP3 inflammasome that links innate-to-adaptive inflammatory responses. Furthermore, both SARS-CoV and SARS- CoV-2 express an open-reading-frame ORF3a molecule, which also activate the NLRP3 inflammasome. [220] The nature of immunity during resolution of symptomatic COVID-19 infection has recently been reported, namely: emergence of antibody-secreting cells and CD4+ T follicular helper cells; increase in perforin- and granzyme-expressing CD8+ T cells; and relative lack of an increase in pro-inflammatory cytokines and chemokines. In marked contrast, patients with severe COVID-19 disease had greatly increased plasma levels of cytokines (including IL-2 and TNF-oc) and chemokines (including IP- 10 and MIP-1-a). Collectively, these results indicate that pro- inflammatory cytokine and chemokine responses that occur in severe COVID-19 is detrimental and that effective anti-inflammatory approaches may ultimately prove to be therapeutic. However, as previously detailed, the more advanced Stage 3 COVID-19 disease is characterized by an ARDS component, and as such, novel approaches to treat the COVID-19 viral pneumonia should optimally incorporate both an anti-inflammatory element and a tissue protection/tissue repair element.

[221] Given the literature and the current public health crisis, investigators are developing clinical protocols to assess various interventions that might prevent or treat COVID-19, including severe COVID-19 cases that involve pneumonia requiring intensive care efforts. Diverse anti-inflammatory approaches are currently being pursued for COVID-19 therapy, including targeted therapies (IL-6 neutralization; tocilizumab [ClinicalTrials.gov NCT04306705] and sarilumab [NCT04306705]) or allogeneic cellular therapies (mesenchymal stem cells, MSC; NCT04302519, NCT04252118; NCT04288102). However, it should be emphasized that the great majority of clinical trials are directed towards the treatment of Stage 1 and Stage 2 disease, and as such, there is a paucity of trials addressing the Stage 3 COVID-19 patient population. It is in this context that allogeneic RAPA-501 cell therapy should be considered for therapy of severe Stage 3 COVID-19 disease. That is, relative to the targeted anti-cytokine approach, RAPA-501 therapy offers the possibility of reducing a wide array of cytokines and chemokines associated with disease pathogenesis. In addition, RAPA-501 therapy holds particular promise for Stage 3 COVID-19 disease, which is associated with tissue damage and ARDS. It is important to note that MSC, which are another candidate cell population with anti-inflammatory and tissue protective effects, have been previously evaluated for ARDS, with some promising results published in phase I and phase II clinical trials. However, MSC therapies have been in the clinic for more than a decade with only anecdotal signs of success and no US FDA regulatory approvals. Therefore, there exists a great public health need to evaluate alternative forms of cellular therapy for patients with the advanced stage of COVID-19 disease. Towards this end, RAPA-501 therapy offers treatment with a novel T cell population that offers several phenotypic advantages, including: a hybrid TREG/T1I2 immune suppressive phenotype; expression of T stem cell markers that associate with durable in vivo effects; the capacity for innate inflammasome inhibition via CD39/CD73 expression; the reduction in a wide array of cytokines and chemokines emanating from inflammatory T cells and inflammatory myeloid-derived cells; and, an ability to work in a contact- and TCR-independent manner, thereby facilitating allogeneic off- the-shelf therapy.

[222] In general, classical autoimmune disease, neurodegenerative disease, and viral-induced inflammatory disease are driven by predominance of Thl/Thl7-type responses with a relative insufficiency of the counter-regulatory immune suppressive Th2 and TREG subsets.

[223] Ex vivo manufacturing can be utilized to generate induced TREG cells from the post- thymic pool of peripheral T cells. In the current protocol, the manufacturing method will focus upon mTOR inhibition, which is an established intervention that promotes the induction of TREG cells. In combination with mTOR inhibition, the culture system that we will utilize incorporates cytokines that promote both a Th2 phenotype and a TREG phenotype, namely, IL-4, TGF-b, and IL-2. Finally, the protocol will include a TREG/T1I2 cell product comprised of both CD4+ and CD8+ T cell subsets, as these counter-regulatory T cell subsets express differential T cell receptor (TCR) repertoires and a diversity of effector mechanisms that can potentially enhance an anti-inflammatory effect. For RAPA-501 ITREG manufacture, peripheral blood mononuclear cells are collected from a steady-state apheresis and subjected to the following two-step culture intervention: in step 1, a severe starvation step results in T cell de-differentiation, which is realized through both selective media utilization and the addition of FDA-approved pharmaceutical agents that potently inhibit mTOR signaling; and in step 2, re-differentiation of T cells occurs using co-stimulation agents and Th2- and T_REG-type polarizing cytokines. After 6- days in culture, the resultant TREG/T1I2 population is cryopreserved in single-use aliquots at protocol-driven therapeutic doses. [224] T cells of type II cytokine phenotype are characterized in part by their expression of the transcription factor GAT A3 whereas regulatory T cell populations are identified in part by their expression of FOXP3 transcription factor. At RAPA-501 culture initiation, a very low frequency of T cells express either GATA3 or FOXP3. In marked contrast, the RAPA-501 cell product manufactured in the TREG/T1I2 culture conditions express a high frequency of T cells that are either single-positive for GATA3 (fourth column), single-positive for FOXP3 (second column), or double-positive for both GATA3 and FOXP3 (not shown). Importantly, this transcription factor profile is expressed in both manufactured CD4+ and CD8+ T cells. It is important to note that both CD4+ and CD8+ T cell populations with TREG function have been defined, including a CD8+ TREG population that potently suppresses GVHD; it is potentially advantageous to have both subsets represented in a therapeutic product because CD4+ and CD8+ TREG cells utilize differential effector mechanisms.

[225] Regulatory T cell populations can suppress pathogenic effector T cell populations by several defined mechanisms, including through expression of CD39 and CD73 ectonucleotidase molecules, which act to hydrolyse pro-inflammatory ATP towards the immune suppressive adenosine substrate. Indeed, TREG cells that express CD39 possess increased suppressive function and have been associated with resolution of inflammatory bowel disease. Furthermore, suppressive function of human TREG cells is mediated in part by CD73. T cells manufactured in the RAPA-501 TREG/T1I2 culture condition have an increase in expression of the T_REG-associated effector molecule, CD73. CD39 is also highly expressed on the T_REG/Th2-manufactured T cells (not shown). In addition to the CD39/CD73 ectonucleotidases, TREG cell function has also been correlated with expression of CD 103, which is an integrin that dictates epithelial lymphocyte localization. Indeed, CD 103 and IL-2 receptor signaling cooperate to maintain immune tolerance in the gut mucosa; furthermore, CD 103-expressing TREG cells are critical for amelioration of experimental chronic GVHD. T cells manufactured in the RAPA-501 TREG/T1I2 culture condition have increased expression of the TREG effector molecule CD 103.

[226] In experimental models, the efficacy of adoptive T cell therapy is dependent upon successful engraftment and in vivo T cell persistence. Importantly, the T cell differentiation state helps dictate in vivo persistence, with less differentiated cells having increased persistence. In initial studies performed by the Fowler Lab at the National Institutes of Health (NIH), murine rapamycin-resistant T cells, which expressed a T central memory (TCM) phenotype, had increased in vivo engraftment potential relative to control T cells. In addition, human rapamycin-resistant T cells also had increased engraftment in a human-into-murine model of xenogeneic graft-versus- host disease. Other investigators have determined that T cells with reduced differentiation relative to the T effector memory (TEM) population have increased in vivo persistence and mediate increased in vivo effects, including the TCM subset, the naive T cell subset, and more recently, the T stem cell memory (TSCM) subset. This relationship between T cell differentiation status and in vivo T cell function is operational relative to TREG cells, as: (1) TREG cells of TCM phenotype were more effective at reducing experimental GVHD relative to TREG cells of TEM phenotype; and (2) TREG cells that expressed the stem cell marker CD 150 were highly effective for the prevention of stem cell graft rejection. RAPA-501 cells manufactured in the TREG/Th2 culture condition are enriched for cells having a reduced differentiation state consistent with a T stem cell subset, including expression of the CD 150 marker.

[227] It is also important to assess the cytokine secretion profile of the manufactured RAPA- 501 cells. First, it is critical that the cell product is capable of IL-4 secretion, which is the driver cytokine for subsequent Th2 differentiation. Second, it is desirable that an adoptively transferred T cell population is capable of secreting IL-2, as this capacity indicates a progenitor function that permits T cells to expand more readily in vivo without the need for exogenous IL-2. Finally, it is important that the RAPA-501 cell population has reduced secretion of the Thl- or Thl7-type cytokines IFN-g, TNF-oc, IL-17, and GM-CSF. Indeed, the manufactured RAPA-501 cell product secretes IL-4 and IL-2 with minimal secretion of Thl- or Thl7-type cytokines.

[228] The RAPA-501 cell product also mediates a suppressive effect upon inflammatory cell populations. One method to evaluate potential mechanisms of suppression is the transwell assay, whereby effector T cells and RAPA-501 cells are separated by a filter that prevents cell-to-cell contact but allows cell communication by small soluble mediators such as cytokines. In this type of experiment, RAPA-501 cells modulate effector T cells in a contact- independent manner (experiments performed in a transwell vessel). First, RAPA-501 cell acted in a TCR-independent manner to suppress the cytokine secretion capacity of effector T cells. Because no co-stimulation beads are added to the transwell chamber containing RAPA-501 cells, it can be concluded that RAPA-501 cells do not require co- stimulation to modulate inflammatory cytokine levels, including IL-2, IFN-g, GM-CSF, and TNF-oc. The ability of TREG cells to consume IL-2 is a commonly described phenomenon, although previous studies identified the requirement of cell-to- cell contact for IL-2 consumption. As such, RAPA-501 cells are somewhat uniquely capable of modulating the level of multiple inflammatory cytokines in a contact-independent manner. Therefore, RAPA-501 cells represent a suitable candidate for neutralization of multiple inflammatory mediators associated with various diseases, including viral-induced lung inflammation. In light of this capacity of the RAPA-501 cell product to suppress T cell-mediated inflammation in a TCR-independent manner, RAPA-501 therapy is highly suitable for allogeneic, off-the-shelf treatment applications.

[229] We also evaluated the RAPA-501 cell product for stability of T cell phenotype. That is, it has been determined that a limiting factor of TREG cell therapy may be differentiation plasticity (Feng et ah, 2015), for example, whereby TREG cells can be influenced by inflammatory cytokines to lose their TREG characteristics and adopt a Thl-type inflammatory state, which may then promote disease pathogenesis. To address this possibility, we studied RAPA-501 cell capacity to modulate T cell differentiation transcription factors after an extended culture interval that involved T cell co- stimulation, the absence of mTOR inhibitors, and the presence of the polarizing inflammatory cytokines IFN-oc and IL-6. The results of such experiments identified that the RAPA-501 cell product had remarkable differentiation stability (continued expression of FOXP3 and GAT A3 in CD4+ and CD8+ subsets; lack of up-regulation of TBET).

[230] The autologous RAPA-501 cell product will be evaluated in patients with a severe neuroinflammatory disease, amyotrophic lateral sclerosis [ALS] (Appel, Zhao, Beers, & Henkel, 2011; W. Zhao, Beers, & Appel, 2013). On this protocol, initial patients (n=3) will receive a dose of RAPA-501 cells that is similar to doses evaluated on prior TREG trials (Bluestone, Buckner, et ah, 2015; Thonhoff et ah, 2018), namely, a flat dose of 40 x 10⁶ cells per infusion. Provided that dose level 1 is safe, subsequent participants will receive a RAPA-501 cell dose of 160 x 10⁶ cells per infusion; this cell dose for Cohort 2 is also within the range of that administered on the previously mentioned TREG cell clinical trials. In addition, these proposed RAPA-501 cell doses are within the range of that administered for the most commonly utilized allogeneic, off-the-shelf cell therapy (mesenchymal stromal cells [MSC]) (Galipeau & Sensebe, 2018). Because initial safety information for this trial in patients will not be available at the time of initiation of the COVID-19 trial (described in the example below), the COVID-19 trial will also utilize a similar dosing scheme during the phase I component of the trial (40 x 10⁶ cells per infusion [Cohort 1], with advancement to the 160 x 10⁶ cell dose [Cohort 2] provided that safely is established). For the COVID-19 study, provided that safety is achieved in the phase I component of the study, both Cohort 1 (Low-Dose) and Cohort 2 (High-Dose) of allogeneic RAPA-501 cell therapy will be expanded in a phase II manner to evaluate potential efficacy in patients with severe Stage 3 COVID-19 disease.

[231] It is expected, without being bound to theory, that the PC regimen will deplete and suppress the Thl/Tcl-type adaptive immune subsets. Indeed, it has recently been proposed that NLRP3 inhibition represents a novel approach to the therapy of a wide variety of neurodegenerative diseases. Nucleoside reverse transcriptase inhibitors (NRTI) are anti-viral agents approved for therapy of HIV disease that may also play a role in the therapy of pro-inflammatory diseases and conditions. The NRTI molecule lamivudine (3TC) has also been described to inhibit the P2X7 receptor that drives NLRP3 activation.

[232] Therefore, it is expected, without being bound to theory, that a sequential strategy whereby one first depletes and suppresses the Thl/Tcl response (via the PC regimen) and then secondarily controls the driving-force inflammasome activation will represent a new approach to treat or prevent pro-inflammatory diseases and conditions. Use of lamivudine in the methods may also be beneficial in terms of our next step, which is to further incorporate ITREG cell therapy into the platform. That is, each of the three therapeutic modalities (pentostatin/cyclophosphamide; lamivudine; and ITREG cells) operates at least in part by shunting the trafficking of ATP away from the P2X7-driven, NLRP3 -mediated inflammasome and towards the immunosuppressive molecule, adenosine. First, pentostatin increases adenosine by inhibiting adenosine deaminase, thereby preventing the conversion of adenosine to inosine; second, lamivudine is a known inhibitor of P2X7, thereby directly inhibiting the inflammasome; and third, ITREG cells provide CD39- and CD73-mediated ecto-nucleotidase activity that processes ATP towards adenosine. [233] There are several reasons to explain why such a combination approach may be necessary. First, if the underlying inflammasome activation is not addressed through maintenance therapy, then any immunologic and therapeutic gains accomplished during host conditioning therapy and TREG cell therapy will likely be eroded by the primary underlying pro-inflammatory process. Second, stand-alone infusion of even an optimized TREG cell population into a host with uncontrolled Thl -driven inflammation represents a daunting immunologic challenge for many reasons: the pre-existent Thl -type cells can manifest differentiation plasticity upon the adoptively transferred TREG cells, thereby converting a protective TREG population into a pathogenic subset that can contribute to disease pathogenesis. And third, the efficacy of adoptively transferred T cell populations is intricately linked to the degree of immunologic T cell space, which can be defined in large part by the presence of T cell growth factors such as IL-7 and IL-15; the creation of such immunologic space is created by host preparative regimens, including the pentostatin plus cyclophosphamide (PC) regimen, which have been utilized for decades in allogeneic hematopoietic stem cell transplantation, and now in the field of using adoptive T cell transfer for cancer therapy. Of note, prior clinical trials involving TREG cell therapy of neurodegenerative or autoimmune (pro-inflammatory) diseases have not incorporated host preparative regimens such as the PC regimen.

[234] In some embodiments, the method comprises subjecting said subject to one or more primary treatment cycles, each of said one or more primary treatment cycles comprising: administering to said subject pentostatin; and/or administering to said subject cyclophosphamide; and subjecting said subject to one or more immune therapy treatment cycles comprising: administering to said subject a composition comprising a therapeutically effective amount of manufactured TREG cells. One of skill in the art can determine the therapeutically effective amount by methods known in the art and as disclosed herein.

[235] In the foregoing embodiments, each of said one or more immune therapy treatment cycles can further comprise administering to said subject a nucleoside reverse transcriptase inhibitor. Said nucleoside reverse transcriptase inhibitor can be an inhibitor of the NLRP3 inflammasome; or said nucleoside reverse transcriptase inhibitor can be lamivudine. Each of said one or more immune therapy treatment cycles can further comprise: administering to said subject pentostatin; and/or administering to said subject cyclophosphamide. Said step of administering to said subject pentostatin during each of said one or more immune therapy treatment cycles can be performed on days 1 and 4 of each of said one or more immune therapy treatment cycles. Said step of administering to said subject pentostatin during each of said one or more immune therapy treatment cycles can be performed on days 1, 2, 3, 4 and 5 of each of said one or more immune therapy treatment cycles. Said method can comprise two or more immune therapy treatment cycles and each of said two or more immune therapy treatment cycles are separated, by way of example and not limitation, by 0 to 4 weeks, 0 to 3 weeks, 0 to 2 weeks, 0 to 1 weeks, and any value between such as, by way of example but not limitation, 0 weeks, 1 week, 2 weeks, 3 weeks, or 4 weeks. Each of said one or more immune therapy treatment cycles can be 18 weeks long. Each of said one or more immune therapy treatment cycles can further comprise administering to said subject an adenosine receptor modulating agent. Other nucleoside reverse transcriptase inhibitors can be used including, by way of example but not limitation, those disclosed in U.S. Patent No. 9,326,983, which is incorporated herein by reference, lamivudine, zidovudine, stavudine, cordycepin, azido thymidine, abacavir, compounds of the structure

/x /

/

(Formula I), compounds of the structure

(Formula II), chemical derivatives thereof, pharmaceutically acceptable salts thereof, and combinations thereof.

[236] In the foregoing embodiments, by way of example but not limitation, said one or more primary treatment cycles can be between 2 weeks and 5 weeks, 2 weeks and 4 weeks, 2 weeks and 3 weeks, 3 weeks and 4 weeks, or 4 weeks and 5 weeks, and any value between such as, by way of example but not limitation, 2 weeks, 3 weeks, 4 weeks, or 5 weeks. Said method can comprise two or more primary treatment cycles, wherein each of said two or more primary treatment cycles is separated by 0 to 2 weeks. By way of example but not limitation, each of said two or more primary treatment cycles is separated by 0 to 1 weeks or 1 to 2 weeks, and any value between such as, by way of example but not limitation, 1 day, 1 week, or 2 weeks.

[237] However, if the ITREG therapy is administered in a steady-state manner (that is, no host conditioning with the PC regimen), the ITREG therapy can be administered on a more frequent basis depending on the patient clinical monitoring. It can be envisioned that even daily administration of ITREG cells may be beneficial in emergent clinical scenarios.

[238] In the foregoing embodiments, the method may further comprise, prior to said one or more primary treatment cycles: harvesting peripheral lymphocytes from said subject. The method may further comprise, after harvesting peripheral lymphocytes from said subject: culturing said peripheral lymphocytes to yield said manufactured TREG cells. The method may further comprise, after said one or more primary treatment cycles: harvesting peripheral lymphocytes from said subject. The method may further comprise, after harvesting peripheral lymphocytes from said subject after said one or more primary treatment cycles: culturing said peripheral lymphocytes to yield said manufactured TREG cells. The method may further comprise, after each of said one or more primary treatment cycles: measuring absolute lymphocyte count (ALC) in said subject and, if ALC < 750 per pi proceeding to said one or more immune therapy treatment cycles. In some embodiments that target ALC value can vary and, by way of example but not limitation, be 0, 250, 500, 750, 1000, 1250 or 1500 cells per microliter.

[239] In the foregoing embodiments, a first of said one or more immune therapy treatment cycles and a last of said one or more primary treatment cycles are separated by 0 to 2 weeks. By way of example but not limitation, each of said two or more immune therapy treatment cycles is separated by 0 to 1 weeks or 1 to 2 weeks, and any value between such as, by way of example but not limitation, 0 weeks, 1 week, or 2 weeks.

[240] In the foregoing embodiments, by way of example but not limitation, the dose of pentostatin can be a dose of 0.5 mg/m² to 4 mg/m², 1 mg/m² to 4 mg/m², 2 mg/m² to 4 mg/m² and any value between such as, by way of example but not limitation 0.5 mg/m², 1 mg/m², 1.5 mg/m², 2 mg/m², 2.5 mg/m², 3 mg/m², 3.5 mg/m² and 4 mg/m². Said pentostatin can be administered on any days of each of said one or more primary treatment cycles. By way of example, but not limitation, pentostatin can be administered to a subject on day 1 or days 1 and 4 of each of said one or more primary treatment cycles. By way of further example, but not limitation, the pentostatin can be administered 1, 2, 3, 4, 5 or more times per each primary treatment cycle.

[241] In the foregoing embodiments, cyclophosphamide can be administered to the subject at a dose of 50 mg to 400 mg. By way of example but not limitation, the dose of cyclophosphamide can be a dose of between any combination of 50, 100, 150, 200, 250, 300, 350, or 400 mg and 400, 350, 300, 250, 200, 150, 100, or 50 mg and any value between such as, by way of example but not limitation 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, or 400 mg. By way of example but not limitation, cyclophosphamide can be administered on days 1, 2 and 3 or days 1, 2, 3, 4, and 5 of each of said one or more primary treatment cycles.

[242] In the foregoing embodiments, said pentostatin and cyclophosphamide can be administered to said subject in a single composition. Said single composition can be administered to said subject intravenously. Said steps of administering to said subject pentostatin and cyclophosphamide can comprise: administering to said subject a first composition comprising pentostatin; and administering to said subject a second composition comprising cyclopho sphamide .

[243] In the foregoing embodiments, said lamivudine can be administered to said subject at a dose between 150 mg daily and 150 mg twice daily.

[244] In the foregoing embodiments, said manufactured TREG cells can be administered to said subject during each of said one or more immune therapy treatment cycles at a dose between, by way of example and not limitation, 1 x 10⁶ cells per kg of the subject’s body weight and 5 x 10⁶ cells per kg of the subject’s body weight, 2 x 10⁶ cells per kg of the subject’s body weight and 5 x 10⁶ cells per kg of the subject’s body weight, 3 x 10⁶ cells per kg of the subject’s body weight and 5 x 10⁶ cells per kg of the subject’s body weight, 4 x 10⁶ cells per kg of the subject’s body weight and 5 x 10⁶ cells per kg of the subject’s body weight, 1 x 10⁶ cells per kg of the subject’s body weight and 4 x 10⁶ cells per kg of the subject’s body weight, 1 x 10⁶ cells per kg of the subject’s body weight and 3 x 10⁶ cells per kg of the subject’s body weight, 1 x 10⁶ cells per kg of the subject’s body weight and 2 x 10⁶ cells per kg of the subject’s body weight, and any values between such as, by way of example but not limitation, 1 x 10⁶ cells per kg of the subject’s body weight, 2 x 10⁶ cells per kg of the subject’s body weight, 3 x 10⁶ cells per kg of the subject’s body weight, 4 x 10⁶ cells per kg of the subject’s body weight, or 5 x 10⁶ cells per kg of the subject’s body weight. By way of example, but not limitation, from about 1 x 10⁶ to about 200 x 10⁶ cells/infusion of manufactured TREG cells can be administered. By way of further example, but not limitation, from about 1 x 10⁶ to about 200 x 10⁶, 10 x 10⁶ to about 200 x 10⁶, 50 x 10⁶ to about 200 x 10⁶, 100 x 10⁶ to about 200 xlO⁶, at least 1 x 10⁶, 10 x 10⁶, 50 x 10⁶, 100 x 10⁶, or 200 x 10⁶ cells/infusion of manufactured TREG cells can be administered. In some embodiments, about 40 x 10⁶ cells/infusion can be administered. In some embodiments, about 120 x 10⁶ cells/infusion can be administered. In some embodiments, about 160 x 10⁶ cells/infusion can be administered. Said manufactured TREG cells can comprise a ratio of central memory to effector memory cells selected from 1:1, 3:1, 10:1, 1:3 and 1:10. Said composition comprising manufactured TREG cells can further comprise normal TREG cells. Said manufactured TREG cells can be administered to said subject on day 8 of each of said one or more immune therapy treatment cycles. In some embodiments, ITREGS and nT_REGS can be administered to a subject in combination.

[245] In some embodiments, a method can comprise a first treatment cycle, a second treatment cycle, optionally, one or more additional treatment cycles, and one or more immune therapy treatment cycles, said first treatment cycle comprising: administering pentostatin to said subject, and/or administering cyclophosphamide to said subject; said second treatment cycle comprising: administering pentostatin to said subject, and/or administering cyclophosphamide to said subject; each of said one or more additional treatment cycles comprising: administering pentostatin to said subject, and/or administering cyclophosphamide to said subject each of said one or more immune therapy treatment cycles comprising: administering pentostatin to said subject, and/or administering cyclophosphamide to said subject, and administering manufactured TREG cells to said subject.

[246] In the foregoing embodiments, said first treatment cycle can be 14 days long. Said step of administering pentostatin to said subject can be performed on day 1 of said first treatment cycle. Pentostatin can be administered to said subject at a dose of 1 mg/m² during said first treatment cycle. Cyclophosphamide can be administered to said subject at a dose of 100 mg during said first treatment cycle. Said step of administering cyclophosphamide to said subject can be repeated during said first treatment cycle, by way of example but not limitation, said step of administering cyclophosphamide to said subject can be performed on days 1, 2, and 3 of said first treatment cycle.

[247] In the foregoing embodiments, said second treatment cycle can be 14 days long. Said step of administering pentostatin to said subject during said second treatment cycle can be performed on day 1 of said second treatment cycle. Pentostatin can be administered to said subject at a dose of 2 mg/m² during said second treatment cycle. Said step of administering cyclophosphamide to said subject during said second treatment cycle can be repeated during said second treatment cycle. By way of example but not limitation, said step of administering cyclophosphamide to said subject during said second treatment cycle can be performed on days 1, 2, and/or 3 of said second treatment cycle. Cyclophosphamide can be administered to said subject at a dose of 100 mg during said second treatment cycle.

[248] In the foregoing embodiments, said subject can be subjected to said one or more additional treatment cycles. Each of said one or more additional treatment cycles can be each 14 days long. Said one or more additional treatment cycles can be separated by 0 to 2 weeks. By way of example but not limitation, each of said two or more additional treatment cycles can be separated by 0 to 1 weeks or 1 to 2 weeks, and any value between such as, by way of example but not limitation, 0 weeks, 1 week, or 2 weeks. Said step of administering pentostatin to said subject during each of said one or more additional treatment cycles can be performed on days 1 and/or 4 of said one or more additional treatment cycles. Pentostatin can be administered to said subject at a dose of 2 mg/m² during each of said one or more additional treatment cycles. Said step of administering cyclophosphamide to said subject can be repeated during each of said one or more additional treatment cycles. Said step of administering cyclophosphamide to said subject during each of said one or more additional treatment cycles can be performed on days 1, 2, 3, 4 and/or 5 of each of said one or more additional treatment cycles. Cyclophosphamide can be administered to said subject at a dose of 100 mg to 200 mg during each of said one or more additional treatment cycles. Said additional cycle can further comprise prior to administering pentostatin to said subject during each of said one or more additional treatment cycles: measuring the creatinine clearance (CrCl) of said subject and adjusting a dose of pentostatin to be administered to said subject based on the CrCl, wherein pentostatin is administered at 2 mg/m² when CrCl > 60 mL/min/1.73 m², wherein pentostatin is administered at 1 mg/m² when 60 mL/min/1.73 m² > CrCl > 30 mL/min/1.73 m², and wherein pentostatin is not administered when CrCl < 30 mL/min/1.73 m². Said additional cycle can further comprise prior to administering cyclophosphamide to said subject during each of said one or more additional treatment cycles: measuring absolute neutrophil count (ANC) and adjusting a dose of cyclophosphamide to be administered to said subject based on ANC, wherein cyclophosphamide is administered at a dose of 100 mg when ANC > 1000 per microliter, wherein cyclophosphamide is administered at a dose of 50 mg when ANC is 500-999 per microliter, and wherein cyclophosphamide is not administered when ALC < 50 per microliter or ANC < 500 per microliter. Said one or more additional treatment cycles can comprise at least two additional treatment cycles, a final of said at least two additional treatment cycles comprising prior to administering cyclophosphamide to said subject during said final of said at least two treatment cycles: measuring absolute lymphocyte count (ALC) and absolute neutrophil count (ANC) and adjusting a dose of cyclophosphamide to be administered to said subject based on the ALC and ANC, wherein cyclophosphamide can be administered at a dose of 200 mg when ALC > 1250 per microliter, wherein cyclophosphamide can be administered at a dose of 100 mg when ANC > 1000 per microliter and 750 < ALC < 1250 per microliter, wherein cyclophosphamide can be administered at a dose of 50 mg when ANC is 500-999 per microliter, and wherein cyclophosphamide may not be administered when ANC < 500 per microliter and/or ALC < 750 per microliter.

[249] In the foregoing embodiments, said treatment cycle, said second treatment cycle and each of said one or more additional treatment cycles can be separated by 0 to 2 weeks. By way of example but not limitation, said treatment cycle, said second treatment cycle and each of said one or more additional treatment cycles can be separated by 0 to 1 weeks or 1 to 2 weeks, and any value between such as, by way of example but not limitation, 0 weeks, 1 week, or 2 weeks. [250] In the foregoing embodiments, the method can further comprise prior to administering pentostatin to said subject in said first treatment cycle: measuring the creatinine clearance (CrCl) of said subject and adjusting a dose of pentostatin to be administered to said subject based on the CrCl, wherein pentostatin is administered at 1 mg/m² when CrCl > 60 mL/min/1.73 m², wherein pentostatin is administered at 0.5 mg/m2 when 60 mL/min/1.73 m² > CrCl > 30 mL/min/1.73 m², and wherein pentostatin is not administered when CrCl < 30 mL/min/1.73 m².

[251] In the foregoing embodiments, the method can further comprise prior to administering cyclophosphamide to said subject in said first treatment cycle: measuring absolute neutrophil count (ANC) and adjusting a dose of cyclophosphamide to be administered to said subject based on the ALC and ANC, wherein cyclophosphamide is administered at a dose of 100 mg when ANC > 1000 per microliter, wherein cyclophosphamide is administered at a dose of 50 mg when ANC is 500-999 per microliter, and wherein cyclophosphamide is not administered when ANC < 500 per microliter.

[252] In the foregoing embodiments, the method can further comprise prior to administering pentostatin to said subject during said second treatment cycle: measuring the creatinine clearance (CrCl) of said subject and adjusting a dose of pentostatin to be administered to said subject based on the CrCl, wherein pentostatin is administered at 2 mg/m² when CrCl > 60 mL/min/1.73 m², wherein pentostatin is administered at 1 mg/m² when 60 mL/min/1.73 m² > CrCl > 30 mL/min/1.73 m², and wherein pentostatin is not administered when CrCl < 30 mL/min/1.73 m².

[253] In the foregoing embodiments, the method can further comprise prior to administering cyclophosphamide to said subject during said second treatment cycle: measuring absolute neutrophil count (ANC) and adjusting a dose of cyclophosphamide to be administered to said subject based on the ANC, wherein cyclophosphamide can be administered at a dose of 100 mg when ANC > 1000 per microliter, wherein cyclophosphamide can be administered at a dose of 50 mg when ANC is 500-999 per microliter, and wherein cyclophosphamide may not be administered when ANC < 500 per microliter.

[254] In the foregoing embodiments, the method can further comprise, prior to each of said one or more additional treatment cycles: measuring absolute lymphocyte count (ALC) in said subject and adjusting the treatment of said subject based on the ALC, wherein if ALC < 750 per microliter, administering to said subject a maintenance treatment cycle comprising subjecting said patient to said one or more immune therapy treatment cycles, and wherein if ALC > 750 per microliter subjecting patient to said one or more additional treatment cycles.

[255] In the foregoing embodiments, the method can further comprise, prior to each of said one or more additional treatment cycles: measuring absolute lymphocyte count (ALC) in said subject and adjusting the treatment of said subject based on the ALC, wherein if ALC < 750 per microliter, administering to said subject a maintenance treatment cycle comprising administering to said subject a nucleoside reverse transcriptase inhibitor and no further of said one or more additional treatment cycles prior to said maintenance treatment cycle, and wherein if ALC > 750 per microliter continuing to subject patient to said one or more additional treatment cycles.

[256] In the foregoing embodiments, each of said one or more immune therapy treatment cycles can be, by way of example but not limitation, 18 weeks long. In some embodiments, immune therapy treatment cycles can be separated by 0 to 4 weeks. Immune therapy treatment cycles can be repeated, including indefinitely. Repeating of the immune therapy cycles can be according to a regimen or in the event of relapse. By way of example but not limitation, the immune therapy cycles can occur 1-4 times per year. Pentostatin can be administered to said subject on days 1 and 4 of each of said one or more immune therapy treatment cycles at a dose of 2 mg/m². Cyclophosphamide can be administered to said subject on days 1, 2, 3, 4, and/or 5 of each of said one or more immune therapy treatment cycles at a dose of 100 mg. Each of said one or more immune therapy treatment cycles can further comprise: administering to said subject a nucleoside reverse transcriptase inhibitor. Said nucleoside reverse transcriptase inhibitor can be lamivudine. Said lamivudine can be administered to said subject during each of said one or more immune therapy treatment cycles at a dose of 150 mg daily to 150 mg twice daily. Each of said one or more immune therapy treatment cycles can further comprise: during each of said one or more immune therapy treatment cycles: measuring the creatinine clearance (CrCl) of said subject and adjusting a dose of lamivudine to be administered to said subject based on the CrCl, wherein lamivudine is administered at 150 mg twice daily when CrCl > 50 mL/min/1.73 m², wherein lamivudine is administered at 150 mg daily when 50 mL/min > CrCl > 30 mL/min/1.73 m², and wherein lamivudine is not administered when CrCl < 30 mL/min/1.73 m².

[257] In the foregoing embodiments, a method can comprise administering to said subject a therapeutically effective amount of manufactured TREG cells.

[258] In the foregoing embodiments, said manufactured TREG cells can be administered to said subject on day 8 of each of said one or more immune therapy treatment cycles. By way of example but not limitation, manufactured TREG cells can be administered to the subject on any day of said immune therapy cycles such as days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15.

[259] In the foregoing embodiments, said manufactured TREG cells can be administered at a dose between 1 x 10⁶ cells per kg of the subject’s body weight and 5 x 10⁶ cells per kg of the subject’s body weight, by way of example and not limitation, 1 x 10⁶ cells per kg of the subject’s body weight and 5 x 10⁶ cells per kg of the subject’s body weight, 2 x 10⁶ cells per kg of the subject’s body weight and 5 x 10⁶ cells per kg of the subject’s body weight, 3 x 10⁶ cells per kg of the subject’s body weight and 5 x 10⁶ cells per kg of the subject’s body weight, 4 x 10⁶ cells per kg of the subject’s body weight and 5 x 10⁶ cells per kg of the subject’s body weight, 1 x 10⁶ cells per kg of the subject’s body weight and 4 x 10⁶ cells per kg of the subject’s body weight, 1 x 10⁶ cells per kg of the subject’s body weight and 3 x 10⁶ cells per kg of the subject’s body weight, 1 x 10⁶ cells per kg of the subject’s body weight and 2 x 10⁶ cells per kg of the subject’s body weight, and any values between such as, by way of example but not limitation, 1 x 10⁶ cells per kg of the subject’s body weight, 2 x 10⁶ cells per kg of the subject’s body weight, 3 x 10⁶ cells per kg of the subject’s body weight, 4 x 10⁶ cells per kg of the subject’s body weight, or 5 x 10⁶ cells per kg of the subject’s body weight. By way of example, but not limitation, from about 1 x 10⁶ to about 200 x 10⁶ cells/infusion of manufactured TREG cells can be administered. By way of further example, but not limitation, from about 1 x 10⁶ to about 200 x 10⁶, 10 x 10⁶ to about 200 x 10⁶, 50 x 10⁶ to about 200 x 10⁶, 100 x 10⁶ to about 200 xlO⁶, at least 1 x 10⁶, 10 x 10⁶, 50 x 10⁶, 100 x 10⁶, or 200 x 10⁶ cells/infusion of manufactured TREG cells can be administered. In some embodiments, about 40 x 10⁶ cells/infusion can be administered. In some embodiments, about 120 x 10⁶ cells/infusion can be administered. In some embodiments, about 160 x 10⁶ cells/infusion can be administered. Said manufactured TREG cells can comprise a ratio of central memory to effector memory cells selected from 1:1, 3:1, 10:1, 1:3 and 1:10. Said composition comprising manufactured TREG cells can further comprise normal TREG cells.

[260] Each of said one or more treatment cycles can further comprise: administering to said subject pentostatin; and/or administering to said subject cyclophosphamide. Pentostatin can be administered to said subject at a dose of between 1 mg/m² and 2 mg/m², and any value between such as, by way of example but not limitation 1 mg/m², 1.5 mg/m², or 2 mg/m². A dose of said cyclophosphamide can be between 100 mg and 200 mg, and any value between such as, by way of example but not limitation 100 mg, 150 mg, or 200 mg. Said pentostatin can be administered to said subject on days 1 and 4 of each of said one or more treatment cycles. Said cyclophosphamide can be administered to said subject on days 1, 2, 3, 4 and/or 5 of each of said one or more treatment cycles. Said subject can have been previously treated with pentostatin and cyclophosphamide. Each of said one or more treatment cycles can further comprise administering to said subject a nucleoside reverse transcriptase inhibitor. Said nucleoside reverse transcriptase inhibitor can be an inhibitor of the NLRP3 inflammasome. Said nucleoside reverse transcriptase inhibitor can be lamivudine. Each of said one or more treatment cycles can be 4 weeks apart.

[261] In the foregoing embodiments, the method can further comprise administering to said subject normal TREG cells simultaneously with said manufactured TREG cells. In the foregoing embodiments, the method can further comprise prior to said one or more treatment cycles: harvesting peripheral lymphocytes from said subject. In the foregoing embodiments, the method can further comprise, after harvesting peripheral lymphocytes from said subject: culturing said peripheral lymphocytes to yield said manufactured TREG cells.

[262] In any of the foregoing embodiments, the manufactured TREG cells can be from the same subject that is being treated or can be allogenic, from another subject or subjects.

[263] In any of the foregoing methods of treatment and preventing, the methods can be used to treat or prevent pro-inflammatory diseases and conditions. By way of example, pro- inflammatory diseases and conditions can include infection such as bacterial or viral infections, such as a coronavirus virus infection such as COVID-19; graft-versus-host disease; automimmune diseases such as inflammatory bowel disease, systemic lupus erythematosus, multiple sclerosis and type I diabetes mellitus; nervous system pathologies such as Guillan-Barre syndrome, traumatic brain injury, stroke, Alzheimer’s disease and Parkinson’s disease; end- organ failure such as pulmonary failure with acute respiratory distress syndrome (ARDS), liver failure, cardiac failure, and renal failure; graft rejection after hematopoietic cell transplation or organ transplantation such as liver, kidney, lung or cardiac transplantation; and pro-thrombotic cardiovascular events that can occur in COVID-19 disease and other pro-inflammatory diseases and conditions, including but not limited to myocardial injury, myocarditis, acute myocardial infarction, heart failure, dysrhythmias, and venous thromboembolic events (Long B et al; American Journal of Emergency Medicine, 2020; Apr 18: Cardiovascular complications in COVID-19). By way of further example, but not limitation, pro-inflammatory diseases that can be treated include but are not limited to (1) cardiovascular (all manifestations of atherosclerosis; myocardial injury, myocarditis, acute myocardial infarction, heart failure, autoimmune vasculitis, dysrhythmias, and venous thromboembolic events [Long B et al; American Journal of Emergency Medicine, 2020; Apr 18: Cardiovascular complications in COVID-19]; (2) pancreatic (including acute or chronic pancreatitis due to pancreatic duct obstruction, trypsinogen gene mutation, alcoholism); (3) liver (including any form of bacterial viral hepatitis, alcoholic or nonalcoholic steatohepatitis, drug-induced liver injury, and ischemia/reperfusion injury); (4) lung (inflammation due to various bacterial or viral causes, acute respiratory distress syndrome [ARDS] due to any cause, cystic fibrosis, chronic obstructive pulmonary disease ([COPD], and asthma); (5) kidney (progressive renal injury in the form of glomerulonephritis, end-stage renal disease, acute or chronic kidney disease, infection-related kidney damage, ischemia/reperfusion injury, immune complex formation/deposition, or complement pathway dysregulation); (6) intestinal tract (including the inflammatory bowel diseases (IBD) Crohn disease and ulcerative colitis, idiopathic IBD); (7) Reproductive (endometriosis, pelvic inflammatory disease); (8) Brain (autoimmune brain diseases such as multiple sclerosis or Guillan-Barre syndrome, neurodegenerative brain disease (Alzheimers, Parkinsons, amyotrophic lateral sclerosis, Huntingtons], traumatic brain injury, stroke); (9) Ophthalmology conditions (including all forms of conjunctivitis, uveitis, scleritis, ocular mucous membrane pemphigoid, diabetic retinopathy, and macular degeneration); and (10) muscular diseases (including muscular dystrophy, inflammatory myopathy of any etiology). By way of still further example, other pro- inflammatory disease or conditions that can be treated by the methods of the present disclosure include systemic metabolic disease, including diabetes (both type I and type II) and nonalcoholic steatohepatitis (NASH), other autoimmune diseases such as systemic lupus erythematous (SLE), rheumatoid arthritis, and psoriasis, systemic processes such as transplantation complications, including graft-versus-host disease or graft rejection after hematopoietic cell transplantation or solid organ transplantation, including liver, kidney, cardiac, lung, or intestinal transplant, and systemic inflammatory infectious diseases, including that due to COVID-19 or other viral etiology; any form of systemic inflammatory response syndrome (SIRS; which can be cause by bums, trauma, surgery complications, acute aspiration, substance abuse and related intoxications, medication adverse reactions, intestinal ischemia, disseminated fungal infection, toxic shock syndrome).

[264] By way of even further example, but not limitation, where the viral infection is a COVID-19 infection, the methods of treatment can be administered to a subject suffering from Stage 3 COVID-19 disease. In some embodiments, the Stage 3 COVID-19 disease is post intubation Stage 3 COVID-19 disease, i.e. the subject has been intubated. By way of further example, but not limitation, conditions to be treated or prevented can include pneumonia, ARDS, tissue damage (including but not limited to cardiac and renal), other cardiovascular complications (including but not limited to myocardial infarction and stroke), and elevated inflammatory markers such as CRP, LDH, IL-6, D-dimer, ferritin, troponin, and NT-proBNP. Thus, in some emobdiments, the method can result in a reduction of the elevated inflammatory markers.

[265] In any of the foregoing methods of treatment or prevention, the ITREG cells can be administered as a combination therapy. By way of example, but not limitation, the combination therapy can include, in addition to the ITREG cells, adminstering a corticosteroid, human immunoglobin, a cytokine inhibitor such as an IL-6 inhibitor, an IL-2 inhibitor, an mTOR inhibitor or a JAK inhibitor, an anti- viral agent such as remdesivir, hydroxychloroquine, or plasma transfusion.

[266] It should be understood that in any of the foregoing embodiments, the treatment with pentostatin and cyclophosphamide and/or lamivudine can be omitted. Thus, in some embodiments, the method includes a step of administering manufactured TREG cells to the subject. The manufactured TREG cells can be administered once or repeated and can be administered at a therapeutically effective dose or any of the foregoing recited doses.

[267] It should be further understood that in any of the foregoing embodiments for treating a pro-inflammatory disease or condition, the manufactured TREG cells administered can be those of any of the embodiments disclosed in the present disclosure and having the properties disclosed associated therewith.

EXAMPLES

[268] The following examples are provided to better illustrate the methods of the present disclosure and the resultant de-differentiated and ITREG or re-differentiated T cells. These examples are not intended to be limiting or to otherwise alter the scope of the methods, cells and compositions disclosed in the present disclosure.

Example 1: Combination Vitamin D and Temsirolimus Reduces T Cell Effector Molecules

[269] We directly evaluated the individual effect of Vitamin D, mTOR inhibition (using the parenteral form of rapamycin, temsirolimus), and the combination of Vitamin D plus temsirolimus on human T cell effector molecule expression (see FIGURE 1).

[270] FIGURES 1A-1D illustrate that the combination of Vitamin D and temsirolimus reduces effector molecule expression in human CD4⁺ and CD8⁺ T cells. For columns #2 through #5, T cells were subjected to a 3-day de-differentiation interval that included a low-level of anti- CD3/anti-CD28 co-stimulation (bead-to-T cell ratio; 1:3); a high-dose of temsirolimus (1 pM); vitamin D (0.1 or 1.0 nM); and culture in X-Vivo 20 media. The first column represents a control culture (no temsirolimus, no Vitamin D, use of a bead-to-T cell ratio of 3:1; and inclusion of the type I polarizing cytokine IFN-oc (20,000 IU/mL, unless otherwise stated, this amount is used in the following examples 1-11 for the control culture)). The second column represents the culture that had the low bead-to-T cell ratio and temsirolimus but did not contain Vitamin D; in contrast, the third column represents the culture that had Vitamin D (0.1 nM) but no temsirolimus. The fourth column represents the culture with high-dose (“HD”) vitamin D (1.0 nM) but no temsirolimus. The fifth column represents the culture that had both a high-dose of vitamin D (1.0 nM) combined with temsirolimus. At the end of the de-differentiation interval, cells were harvested, RNA was isolated, and RNA expression analysis was performed by Luminex Quantigene method. All results shown represent relative RNA expression, with results normalized to a value of 1.0 for the Thl/Tcl control culture.

[271] A 3-day culture interval was used that included a low level of T cell co-stimulation (anti-CD3/anti-CD28 bead-to-T cell ratio of 1:3; typical ratio used in literature is the inverse, 3:1), temsirolimus (1 mM), Vitamin D at doses of either 0.1 or 1.0 nM, or the combination of temsirolimus and the higher-dose of Vitamin D. After culture, RNA was harvested and the level of effector molecule expression was compared to the control culture.

[272] As FIGURE 1A shows, the various cultures had similar RNA expression of housekeeping control genes, including GAPDH. In marked contrast, relative to the control Thl/Tcl cell culture that did not receive Vitamin D or temsirolimus, the culture addition of temsirolimus, Vitamin D, or the combination of temsirolimus plus Vitamin D resulted in the reduction in the RNA expression of T cell effector molecules, including the cytotoxic molecule Granzyme B (FIGURE IB) and the cytokine molecules IL-10 (a Th2 cytokine; FIGURE 1C) and IFN-gamma (a Thl cytokine; FIGURE ID). Thus, Granzyme B and IFN-g as markers of de differentiation indicate that Vitamin D is effective at concentrations from 0.1 to 1.0 nM. Temsirolimus at a dose of 1 mM acts alone beneficially as an agent of de-differentiation (column 2, reduction in granzyme B and IFN-gamma) and does not abrogate the effect of Vitamin D when used in combination (column 5).

[273] As such, using low-level co-stimulation (1:3 ratio of anti-CD3/anti-CD28 beads to T cells) and a short 3-day culture interval, the addition of temsirolimus, Vitamin D, or the combination of temsirolimus plus Vitamin D can be utilized to reduce both Thl and Th2 cytokine effectors and cytotoxic effector mechanisms.

Example 2: Combination Vitamin D and Temsirolimus Alters Key Transcription Factors Associated With De-Differentiation

[274] We also evaluated the effect of Vitamin D, temsirolimus, or the combination on the expression of key transcription factors after a low-level of co-stimulation. [275] FIGURES 2A-2D illustrate that the combination of Vitamin D and temsirolimus increases expression of stem cell-associated transcription factors and the primitive T cell molecule IL-7 receptor- alpha in human CD4⁺ and CD8⁺ T cells. The combination of Vitamin D and temsirolimus reduces effector molecule expression in human CD4⁺ and CD8⁺ T cells. For columns #2 through #5, T cells were subjected to a 3-day de-differentiation interval that included a low-level of anti-CD3/anti-CD28 co- stimulation (bead-to-T cell ratio; 1:3); a high-dose of temsirolimus (1 pM); vitamin D (0.1 or 1.0 nM); and culture in X-Vivo 20 media. The first column represents a control culture (no temsirolimus, no Vitamin D, use of a bead-to-T cell ratio of 3:1; and inclusion of the type I polarizing cytokine IFN-oc). The second column represents the culture that had the low bead-to-T cell ratio and temsirolimus but did not contain Vitamin D; in contrast, the third column represents the culture that had Vitamin D (0.1 nM) but no temsirolimus. The fourth column represents the culture with high-dose (“HD”) vitamin D (1.0 nM) but no temsirolimus. The fifth column represents the culture that had both a high-dose of vitamin D (1.0 nM) combined with temsirolimus. At the end of the de-differentiation interval, cells were harvested, RNA was isolated, and RNA expression analysis was performed by Luminex Quantigene method. All results shown represent relative RNA expression, with results normalized to a value of 1.0 for the Thl/Tcl control culture.

[276] As FIGURE 2A shows, temsirolimus or the combination of temsirolimus plus Vitamin D resulted in up-regulation of the Nanog transcription factor, which is recognized as one of the few key factors required for somatic cell de-differentiation towards an iPSC state. Previously, in human fibroblasts, mTOR inhibition using rapamycin was found to increase Nanog expression; in contrast, Vitamin D receptor signaling was found to reduce the expression of transcription factors associated with the iPSC state.

[277] As such, using a low-level of co- stimulation, temsirolimus increases the iPSC transcription factor Nanog; this promoting effect of temsirolimus is not abrogated by Vitamin D at concentrations ranging from 0.1 to 1.0 nM.

[278] By comparison, neither temsirolimus nor Vitamin D alone increased the RNA expression of the KLF4 molecule, which is also one of the classical transcription factors associated with the iPSC state. However, the combination of temsirolimus plus Vitamin D (1.0 nM) increased KLF4 RNA expression. As such, it is preferable to include both temsirolimus and Vitamin D in T cell de-differentiation attempts. As FIGURE 2B shows, although neither temsirolimus or Vitamin D acts alone to beneficially up-regulate the de-differentiation molecule KLF4, the combination of temsirolimus (1 mM) and Vitamin D (1.0 nM) synergistically up- regulate KLF4.

[279] A related transcription factor, KLF10, was also up-regulated when the combination of temsirolimus plus Vitamin D (1.0 nM) was utilized. As FIGURE 2C shows, temsirolimus at a dose of 1 mM acts alone to beneficially up-regulate the de-differentiation molecules KLF10, Nanog, and IL-7 receptor alpha; although Vitamin D does not act alone to up-regulate these molecules, it does not abrogate the effect of temsirolimus when used in combination (column 5).

[280] Finally, we evaluated cultured cells for RNA expression of IL-7 receptor alpha, which is up-regulated in T cells having a reduced differentiation status. Importantly, temsirolimus alone but not Vitamin D alone was capable of up-regulating IL-7 receptor alpha. Nonetheless, the combination of Vitamin D (1.0 nM) plus temsirolimus resulted in IL-7 receptor alpha up- regulation, as shown in FIGURE 2D.

[281] In sum, these data indicate that low-level co-stimulation combined with temsirolimus can be used to enforce T cell de-differentiation; preferably, culture should include temsirolimus plus Vitamin D for a more complete pattern of de-differentiation.

Example 3: Combination Vitamin D and Temsirolimus Reduces Key Transcription Factors Associated With Thl Differentiation While Maintaining HIF-1 - a expression

[282] We also evaluated the effect of Vitamin D, temsirolimus, or the combination on the expression of key transcription factors associated with Thl -type differentiation, namely T-BET and STATE

[283] FIGURE 3A-3C illustrate that the combination of Vitamin D and temsirolimus reduces expression of transcription factors associated with effector Thl/Tcl cells without reducing expression of a transcription factor associated with T cell survival, HIF-1-a. The combination of Vitamin D and temsirolimus reduces effector molecule expression in human CD4⁺ and CD8⁺ T cells. For columns #2 through #5, T cells were subjected to a 3-day de-differentiation interval that included a low-level of anti-CD3/anti-CD28 co- stimulation (bead-to-T cell ratio; 1:3); a high-dose of temsirolimus (1 mM); vitamin D (0.1 or 1.0 nM); and culture in X-Vivo 20 media. The first column represents a control culture (no temsirolimus, no Vitamin D, use of a bead-to-T cell ratio of 3:1; and inclusion of the type I polarizing cytokine IFN-oc). The second column represents the culture that had the low bead-to-T cell ratio and temsirolimus but did not contain Vitamin D; in contrast, the third column represents the culture that had Vitamin D (0.1 nM) but no temsirolimus. The fourth column represents the culture with high-dose (“HD”) vitamin D (1.0 nM) but no temsirolimus. The fifth column represents the culture that had both a high-dose of vitamin D (1.0 nM) combined with temsirolimus. At the end of the de-differentiation interval, cells were harvested, RNA was isolated, and RNA expression analysis was performed by Luminex Quantigene method. All results shown represent relative RNA expression, with results normalized to a value of 1.0 for the Thl/Tcl control culture.

[284] Importantly each agent or the combination of agents down-regulated both T-BET RNA (FIGURE 3A) and STAT1 RNA (FIGURE 3B). As shown in FIGURES 3A-3C, Vitamin D at a dose of 0.1 to 1.0 nM acts alone to beneficially down-regulate the differentiation molecules T- BET and STATE Temsirolimus at a dose of 1 mM does not detrimentally down-regulate the pro survival transcription factor, HIF-1 alpha, even when combined with 1.0 nM Vitamin D. Yet, temsirolimus at a dose of 1 mM acts alone to beneficially down-regulate the differentiation molecules T-BET and STAT1; combination with Vitamin D yields a similar result (these two agents are not antagonistic).

[285] In marked contrast, temsirolimus at a dose of 1 pM, Vitamin D at a dose of 0.1 to 1.0 nM, or the combination did not down-regulate the key transcription factor HIF-1 -a (FIGURE 3C), which is important as a T cell survival factor that is critical for anti-tumor effects.

[286] In sum, these data indicate that the combination of low-level co-stimulation, temsirolimus, and Vitamin D can be used to reduce transcription factors required for Thl generation without inhibiting a key transcription factor required for overall T cell survival, HIF- 1-a. Example 4: The Combination Vitamin D, Temsirolimus, and an Anti-IL-2 Receptor Monoclonal Antibody Increases An Autophagy Signature

[287] We also evaluated the effect of Vitamin D, temsirolimus, or the combination on the process of autophagy, which is critical for promotion of a stem-like, de-differentiated state. The level of autophagy can be determined in-part by the subsequent up-regulation of the autophagy substrate, p62, by western blot analysis.

[288] FIGURE 4 illustrates that the combination of Vitamin D, temsirolimus, and anti-IL-2 receptor blockade induces expression of the autophagy-related molecule, p62. Human CD4⁺ and CD8⁺ T cells were subjected to the de-differentiation protocol, which involved a 3-day culture using low level co-stimulation (1:3 bead-to-T cell ratio), temsirolimus (“TEM”, as indicated in FIGURE 4; concentration of 1.0 or 0.3 mM), Vitamin D (“D”, as indicated; concentration of 0.01, 0.03, 0.1, 0.3, or 1.0 nM), and an anti-IL-2 receptor monoclonal antibody (Daclizumab, 50 pg/ml; “DAC”, as indicated). After the 3-day culture interval, the T cells were harvested, and protein was isolated and subjected to western blot analysis for the autophagy-related gene, p62, and the housekeeping gene, Actin.

[289] As FIGURE 4 demonstrates, inclusion of Vitamin D in the T cell culture was critical for increasing autophagy, as measured by up-regulated p62. Vitamin D at a dose of 0.01 to 0.1 nM works in concert with temsirolimus at a concentration of 0.3 to 1.0 mM to beneficially up- regulate the autophagy marker p62 during de-differentiation. That is, in FIGURE 4, culture #6 (fifth column), there was very little p62 expression on western blot analysis, consistent with a low level of autophagy; as the figure legend indicates, this culture condition received a low-level of co-stimulation, temsirolimus, the anti-IL-2 receptor monoclonal antibody daclizumab, but did not receive Vitamin D.

[290] In marked contrast, the other culture conditions each received Vitamin D supplementation and each had increased p62 expression (effective dose range of Vitamin D, 0.01 nM to 1.0 nM). This FIGURE 4 also demonstrates that Vitamin D without anti-IL-2 receptor monoclonal antibody addition and Vitamin D without temsirolimus addition was sufficient for induction of T cell autophagy. [291] In sum, these data indicate that inclusion of Vitamin D with low-level co-stimulation is an efficient method for the induction of T cell autophagy either alone or in combination with other T cell inhibitors, namely the anti-IL-2 receptor reagents or the mTOR inhibitor temsirolimus.

Example 5: The Combination Vitamin D, Temsirolimus, and an Anti-IL-2 Receptor Monoclonal Antibody Results In Optimal Disruption of the mTORCl Complex

[292] We also evaluated the effect of the various T cell culture conditions on expression of Raptor, which is a critical component of the mTORCl signaling complex. Importantly, inhibition of mTORCl has recently been discovered to be critical for somatic cell reprogramming to an iPSC state.

[293] FIGURE 5 illustrates that the combination of Vitamin D, temsirolimus, and anti-IL-2 receptor blockade reduces expression of the mTORCl -related molecule, Raptor. Human CD4⁺ and CD8⁺ T cells were subjected to the de-differentiation protocol, which involved a 3-day culture using low level co- stimulation (1:3 bead-to-T cell ratio), temsirolimus (“TEM”, as indicated in FIGURE 5; concentration of 1.0 or 0.3 mM), Vitamin D (“D”, as indicated; concentration of 0.01, 0.03, 0.1, 0.3, or 1.0 nM), and an anti-IL-2 receptor monoclonal antibody (Daclizumab, 50 ng/ml; “DAC”, as indicated). After the 3-day culture interval, the T cells were harvested, and protein was isolated and subjected to western blot analysis for the mTORCl complex protein, Raptor, and the housekeeping gene, Actin.

[294] As FIGURE 5 demonstrates, optimal inhibition of the mTORCl complex, as indicated by reduction in Raptor expression, occurred when T cells were co- stimulated at a low bead-to-T cell ratio (1:3) in combination with temsirolimus (1.0 pM), Vitamin D (0.1 nM), and the anti-IL- 2 receptor monoclonal antibody daclizumab (50 pg/nl) (first column shown; culture 1).

[295] As FIGURE 5 demonstrates, the omission of daclizumab resulted in a modest increase in Raptor expression, thereby indicating a role for an anti-IL-2 receptor reagent for optimal mTORCl inhibition. Thus, anti-IL-2 receptor monoclonal antibody Daclizumab (dose, 50 pg/ml) plays a beneficial role in suppressing the mTORCl sub-unit molecule, Raptor (column 2) [296] As FIGURE 5 demonstrates, the optimal inhibition of mTORCl sub-unit molecule Raptor by Vitamin D is a Vitamin D dose between 0.03 to 0.1 nM; concentrations lower than or higher than this range led to less optimal suppression of Raptor. Thus, levels of Vitamin D as low as 0.03 nM are sufficient for optimal inhibition of Raptor; reducing the Vitamin D level to 0.01 nM, however, results in a sub-optimal Raptor inhibition. Furthermore, increasing the Vitamin D level beyond the 0.1 nM concentration can be detrimental, as indicated by culture 7 (0.3 nM concentration of Vitamin D), which had a higher level of Raptor expression.

[297] Furthermore, as FIGURE 5 indicates, the optimal down-regulation of Raptor requires the combination of Vitamin D plus temsirolimus, with the temsirolimus dose optimally being 1.0 mM, as culture 9 that was supplemented with temsirolimus at the concentration of 0.3 mM had higher levels of Raptor expression.

Example 6: The Combination of Vitamin D, Temsirolimus, and an Anti-IL-2 Receptor Monoclonal Antibody Disrupts Both the mTORCl Complex and the mTORC2 Complex

[298] We also evaluated the mTORC2 complex, which is not directly sensitive to the inhibitory effects of rapamycin but can be influenced by conditions that result in prolonged mTORCl blockade. Importantly, inhibition of mTORC2 can promote a stem- like state.

[299] FIGURE 6 illustrates that the combination of Vitamin D, temsirolimus, and anti-IL-2 receptor blockade reduces expression of the mTORCl -related molecule, Raptor, and the mTORC2-related molecule, Rictor. Human CD4⁺ and CD8⁺ T cells were subjected to the de differentiation protocol, which involved a 3-day culture using low level co- stimulation (1:3 bead- to-T cell ratio), temsirolimus (“TEM”, as indicated in FIGURE 6; concentration of 1.0 pM), Vitamin D (“D”, as indicated; concentration of 0.03, 0.1, 0.3, or 1.0 nM), and an anti-IL-2 receptor monoclonal antibody (Daclizumab, 50 ng/ml; “DAC”, as indicated). After the 3-day culture interval, the T cells were harvested, and protein was isolated and subjected to western blot analysis for the mTORCl complex protein, Raptor; the mTORC2 complex protein, Rictor; the post-mTORCl protein p70S6K; the post-mTORC2 protein, SGK1; and the housekeeping gene, GAPDH. [300] As FIGURE 6 illustrates, relative to the control culture that did not contain any of the three inhibitors, T cell culture in media containing temsirolimus, Vitamin D, and the anti-IL-2 receptor antibody daclizumab had a reduction in both the mTORCl molecule Raptor and the mTORC2 molecule Rictor. Levels of the post-mTORCl molecule p70S6K and the post- mTORC2 molecule SGK1 were relatively preserved. Thus, Vitamin D (concentration between 0.03 and 1.0 nM) was effective during combination agent de-differentiation for down-regulation of the mTORC2 sub-unit, Rictor. And, temsirolimus at a concentration of 1 mM was effective during combination agent de-differentiation for down-regulation of the mTORC2 sub-unit, Rictor. Moreover, anti-IL-2 receptor monoclonal antibody Daclizumab (dose, 50 pg/ml) did not abrogate the ability of temsirolimus and Vitamin D to down-regulate the mTORC2 sub-unit Rictor.

[301] As such, T cell culture using a low level of co- stimulation and a three -part inhibitory regimen of temsirolimus, Vitamin D, and anti-IL-2 receptor monoclonal antibody represents a novel method to reduce both Raptor and Rictor subunits.

Example 7: The Combination of Vitamin D, Temsirolimus, and an Anti-IL-2 Receptor Monoclonal Antibody Reduces Expression of the Pro-Apoptotic Bcl2-family Member Gene, BIM

[302] As a result of autophagy at the level of the mitochondria (mitophagy), the quality of the mitochondrial proteins can be altered; in particular, with mitophagy, there can be an advantageous shift in the bcl2-family member genes from pro-apoptotic family members such as BIM towards anti-apoptotic family member genes. In addition, culture methods that reduce the apoptotic tendency are associated with an increased capacity for de-differentiation.

[303] FIGURE 7 illustrates that the combination of Vitamin D, temsirolimus, and anti-IL-2 receptor blockade reduces expression of the pro-apoptosis molecule, BIM. Human CD4⁺ and CD8⁺ T cells were subjected to the de-differentiation protocol, which involved a 3-day culture using low level co-stimulation (1:3 bead-to-T cell ratio), temsirolimus (“TEM”, as indicated in FIGURE 7; concentration of 1.0 or 0.3 mM), Vitamin D (“D”, as indicated; concentration of 0.01, 0.03, 0.1, 0.3, or 1.0 nM), and an anti-IL-2 receptor monoclonal antibody (Daclizumab, 50 ng/ml; “DAC”, as indicated). After the 3-day culture interval, the T cells were harvested, and protein was isolated and subjected to western blot analysis for the pro-apoptosis-related gene, BIM, and the housekeeping gene, Actin.

[304] To assess this, we measured BIM levels in the T cells cultured with a low-strength of co stimulation (1:3 bead-to-T cell ratio) and presence of the various inhibitors. As FIGURE 7 illustrates, the T cell culture that contained the combination of temsirolimus, Vitamin D (0.1 nM), and the anti-IL-2 receptor monoclonal antibody daclizumab had the lowest level of BIM expression. But still, FIGURE 7 shows that anti-IL-2 receptor monoclonal antibody Daclizumab (dose, 50 pg/ml) plays a beneficial role in suppressing the pro-apoptotic molecule, BIM (column 2). Each of the three inhibitors appeared to play a role in BIM inhibition because absence of any single inhibitor increased the BIM level.

[305] As such, we conclude that the combination inhibitor regimen represents a method for inducing a favorable shift in the mitochondrial control of apoptotic tendency.

Example 8: The Three Inhibitor De-differentiation Regimen Results in T Cells With Subsequent Proliferative Capacity After Removal of Inhibitors

[306] To demonstrate that the 3-day regimen comprised of a low-level of co- stimulation, temsirolimus, Vitamin D, and anti-IL-2 receptor monoclonal antibody resulted in a state of de differentiation capable of re-differentiation, we performed experiments to re-stimulate the cells on day 3 of culture using a high-level of co-stimulation (3:1 bead-to-T cell ratio) after removal of the inhibitors from culture. After 10 days (13 days of total culture), the T cells were harvested, enumerated, and evaluated by flow cytometry.

[307] FIGURE 8 illustrates the effect of culture components during the de-differentiation interval on subsequent T cell yield (at day 13 of culture). Human CD4⁺ and CD8⁺ T cells were subjected to a 3-day de-differentiation interval that included a low-level of anti-CD3/anti-CD28 co-stimulation (bead-to-T cell ratio; 1:3 or 1:1, as indicated); a temsirolimus (1 mM; or, low-dose [“Lo”], 0.1 pM); vitamin D (0.1 nM; or, high-dose [“HD’] of 1.0 nM; or, low-dose of 0.01 nM); an anti-IL-2 receptor monoclonal antibody (daclizumab, 50 pg/ml); and culture in X-Vivo 20 media supplemented with 5% human AB serum. The first column represents a control culture (no temsirolimus, Vitamin D, or anti-IL-2R antibody). The second column represents the culture with no anti-IL-2R antibody; the fourth column represents the culture with no serum supplementation; the fifth column represents low-dose Vitamin D whereas the sixth column represents results using high-dose Vitamin D; the seventh column represents results using low- dose temsirolimus; and the eighth column represents the culture with no temsirolimus; and the ninth column represents results using the higher ratio of beads. After the 3-day interval, media was exchanged to fresh X-Vivo 20 without inhibitors, high-level co- stimulation was provided (3:1 bead-to-T cell ratio), and the T cell growth cytokines IL-2 (100 IU/ml) and IL-7 (10 ng/ml) were added. At day 13 of culture, viable T cells were enumerated and the overall yield is shown relative to day 0 input number.

[308] FIGURE 8 shows the T cell counts after the re-differentiation stage. As these data show (column #3), T cells that were initially maintained for the first 3-day de-differentiation interval using a low-level of co-stimulation, temsirolimus, Vitamin D, and anti-IL-2 receptor monoclonal antibody had a satisfactory T cell yield (more than 250% of culture input).

[309] In marked contrast, a very low yield was observed in the culture represented in column #4, which did not receive serum supplementation during the initial 3-day culture interval; as such, this data demonstrates that the initial day 3 culture interval must include X-Vivo 20 culture media supplemented with 5% AB serum.

[310] Also, reduction in the Vitamin D concentration to 0.01 nM or increase in the Vitamin D concentration to 1.0 nM resulted in a very low yield (data shown in column #5 and #6, respectively). As such, the preferable concentration of Vitamin D is 0.1 nM.

[311] Furthermore, reduction of the temsirolimus concentration to 0.1 mM reduced the resultant T cell yield (column #7). As such, the preferable concentration of temsirolimus is 1.0 mM.

[312] Finally, if the co-stimulation level was increased in the de-differentiation interval (change in bead-to-T cell ratio from 1:3 to 1:1; results shown in last column, column #9), then the resultant T cell count was very low. As shown in FIGURE 8, it is necessary to use a low- level of co- stimulation during de-differentiation (1:3 co- stimulation bead-to-T cell ratio) as increasing ratio to 1 : 1 results in a greatly reduced ability to manufacture T cells from the de- differentiated state (last column). As such, the preferable bead-to-T cell ratio during the de differentiation stage of culture is 1:3.

Example 9: The Initial Three-Component Culture Interval Results in the Generation ofCD4⁺ T Cells Expressing Cell Surface Molecules Consistent With Reduced Differentiation

[313] At various times during the re-differentiation stage of culture, the resultant CD4⁺ T cells were evaluated for expression of memory markers by flow cytometry.

[314] FIGURES 9A-9C illustrate the effect of culture components during the de differentiation interval on CD4⁺ T cell expression of memory markers (at day 13 of culture). Human CD4⁺ and CD8⁺ T cells were subjected to a 3-day de-differentiation interval that included (as indicated in above FIGURES 9A-9C) a low-level of anti-CD3/anti-CD28 co stimulation (bead-to-T cell ratio; 1:3); temsirolimus (1 mM or 0.1 mM [low-dose; “Lo”]);

Vitamin D (0.1 nM; or, 0.01 nM [low-dose; “Lo”]); an anti-IL-2 receptor monoclonal antibody (daclizumab, 50 pg/ml); and culture in X-Vivo 20 media supplemented with 5% human AB serum. After the 3-day interval, media was exchanged to fresh X-Vivo 20 without inhibitors, high-level co-stimulation was provided (3:1 bead-to-T cell ratio), and the T cell growth cytokines IL-2 (100 IU/ml) and IL-7 (10 ng/ml) were added. T cells were subjected to flow cytometry for evaluation of co-expression of CD4⁺ and CD45RA⁺ markers (results shown in top panel; evaluated at day 13 of culture); co-expression of CD4⁺, CD62L⁺, and CCR7⁺ markers (bottom left panel; evaluated at day 3 of culture); and co-expression of CD4⁺, CD62L⁺, CCR7⁺, and CD127⁺ markers (bottom right panel; evaluated at day 10 of culture). All results are shown relative to the value of CD4⁺ T cells at culture initiation (last column in FIGURES 9A-9C; “Day 0 Input Value”).

[315] As shown in FIGURE 9A, relative to values from Day 0 input T cells, T cells initially propagated in the combination of temsirolimus, Vitamin D, and anti-IL-2 receptor monoclonal antibody had relatively preserved expression of the CD45RA marker that is expressed on naive T cells (column #3). In marked contrast, absence of these three molecules during the initial culture interval resulted in depletion of the naive T cell population (culture #1). Furthermore, elimination of temsirolimus during the initial culture interval resulted in depletion of the naive T cell population (culture #6).

[316] As shown in FIGURE 9B, each of the T cell cultures that were initially propagated in the 3-day interval that incorporated a low-level of co-stimulation had an increase in T cell expression of the central memory molecules CD62L and CCR7.

[317] Finally, as shown in FIGURE 9C, T cells initially propagated in the combination of temsirolimus, Vitamin D, and anti-IL-2 receptor monoclonal antibody had greatly increased expression (relative to the Day 0 input cells) of T cells that were triple-positive for CD62L, CCR7, and IL-7 receptor alpha (CD 127). Elimination of the three inhibitors during the initial 3- day culture (column #1) abrogated the ability of the initial culture interval to promote the expansion of this triple-positive population. In addition, reducing or eliminating only temsirolimus from the initial culture interval also greatly reduced the frequency of triple-positive T cells (columns #5 and 6).

[318] In sum, these data indicate that the three-drug initial culture interval results in the conversion of CD4⁺ T cells from primarily an end- stage, effector memory population towards a less-differentiated T cell population, including co-expression of CD62L, CCR7, and CD 127, which is a state of very limited T cell differentiation.

Example 10: The Initial Three-Component Culture Interval Results in the Generation of CD8⁺ T Cells Expressing Cell Surface Molecules Consistent With Reduced Differentiation

[319] At various times during the re-differentiation stage of culture, the resultant CD8⁺ T cells were evaluated for expression of memory markers by flow cytometry.

[320] FIGURES 10A-10B illustrates the effect of culture components during the de differentiation interval on CD8⁺ T cell expression of memory markers. Human CD4⁺ and CD8⁺

T cells were subjected to a 3-day de-differentiation interval that included (as indicated in above FIGURES 10A-10B) a low-level of anti-CD3/anti-CD28 co-stimulation (bead-to-T cell ratio; 1:3); temsirolimus (1 mM or 0.1 mM [low-dose; “Lo”]); Vitamin D (0.1 nM; or, 0.01 nM [low- dose; “Lo”]); an anti-IL-2 receptor monoclonal antibody (daclizumab, 50 pg/ml); and culture in X-Vivo 20 media supplemented with 5% human AB serum. After the 3-day interval, media was exchanged to fresh X-Vivo 20 without inhibitors, high-level co-stimulation was provided (3:1 bead-to-T cell ratio), and the T cell growth cytokines IL-2 (100 IU/ml) and IL-7 (10 ng/ml) were added. T cells were subjected to flow cytometry for evaluation of co-expression of CD8⁺, CD62L⁺, and CCR7⁺ markers (left panel; evaluated at day 10 of culture); and co-expression of CD8⁺, CD62L⁺, CCR7⁺, and CD127⁺ markers (right panel; evaluated at day 10 of culture). All results are shown relative to the value of CD8⁺ T cells at culture initiation (last column in FIGURES 10A-10B; “Day 0 Input Value”).

[321] As shown in FIGURE 10A, each of the T cell cultures that were initially propagated in the 3-day interval that incorporated a low-level of co-stimulation had an increase in CD8⁺ T cell expression of the central memory molecules CD62L and CCR7.

[322] Finally, as shown in FIGURE 10B, T cells initially propagated in the combination of temsirolimus, Vitamin D, and anti-IL-2 receptor monoclonal antibody had greatly increased expression (relative to the Day 0 input cells) of CD8⁺ T cells that were triple-positive for CD62L, CCR7, and IL-7 receptor alpha (CD 127). Elimination of the three inhibitors during the initial 3 -day culture (column #1) abrogated the ability of the initial culture interval to promote the expansion of this triple-positive population. In addition, reducing or eliminating only temsirolimus from the initial culture interval also greatly reduced the frequency of triple-positive T cells (columns #5 and 6).

[323] In sum, these data indicate that the three-drug initial culture interval results in the conversion of CD8⁺ T cells from primarily an end-stage, effector memory population towards a less-differentiated T cell population, including co-expression of CD62L, CCR7, and CD 127, which is a state of very limited T cell differentiation.

Example 11: De-differentiated T Cells Have an Inherent Bias Towards Low Cytokine Potential

[324] FIGURES 1 lA-1 ID highlight the components of the de-differentiation process, including use of: a low-level of co- stimulation (an anti-CD3/anti-CD28 bead to T cell ratio of 1:3, which is reduced relative to conventional methods as described in Kalamasz D, Long SA, Taniguchi R, Buckner JH, Berenson RJ, Bonyhadi M. Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and Anti-CD28 antibodies) Journal of immunotherapy (Hagerstown, Md: 1997). 2004;27(5):405-418.; the mTOR inhibitor temsirolimus; vitamin D; and an anti-IL-2 receptor monoclonal antibody.

[325] FIGURES 11A-11D depict the inflammatory Thl/Thl7 cytokine analysis of cultured de differentiated T cells in polarization-neutral media. Human CD4⁺ and CD8⁺ T cells were subjected to a 3-day de-differentiation procedure that included the following culture components, as indicated: temsirolimus (Y, indicates concentration of 1 mM; Y, Lo, indicates concentration of 0.1 mM); Vitamin D (Y, indicates concentration of 0.1 nM; Y, Lo, indicates concentration of 0.01 nM); an anti-IL-2 receptor monoclonal antibody (Daclizumab, 50 pg/ml); co- stimulation with anti- CD3/anti-CD28 (3/28) coated magnetic beads at a low ratio (bead-to-T cell ratio, 1:3), and supplementation with 5% human serum. After 3-days, the de-differentiated T cells were co stimulated (typical bead-to-T cell ratio of 3:1) in media supplemented with the T cell growth cytokines rhu IL-2 (100 IU/ml) and rhu IL-7 (10 ng/ml), which are not potent in terms of inducing T cell polarization. After 10 days in culture (total, day 13 of culture), the T cells were harvested, washed, and re-stimulated with 3/28 beads (3:1 ratio) for 24 hr; the resultant supernatant was harvested and tested for cytokine content by Luminex multi-analyte method. All results shown are expressed as cytokine level in pg per ml per 1 x 10⁶ cells/ml/24 hr.

[326] To assess whether the de-differentiated T cell state manifested an inherent bias towards a particular cytokine secretion pattern, we cultured the de-differentiated T cells using a high-level of co- stimulation (bead-to-T cell ratio, 3:1) and maintenance in media that did not contain any inhibitor and only contained the T cell growth cytokines IL-2 and IL-7.

[327] As FIGURES 11A-11D detail, the resultant T cells that were re-differentiated from each of the de-differentiated precursor states had very low levels of secretion of inflammatory cytokines, including IFN-g (most values below 1000 pg/ml), TNF-a (most values below 100 pg/ml), and IL-17 (all values below 10 pg/ml). Of note, GM-CSF was secreted in some conditions at much higher levels, in some cases, greater than 10,000 pg/ml. The GM-CSF value was moderated in the de-differentiated condition that was comprised of higher dose temsirolimus (1.0 mM) and higher dose vitamin D (0.1 nM); as such, for resultant moderation of T cell cytokine secretion of GM-CSF, it is desirable to expand T cells from a de-differentiation method that incorporates these higher concentrations of temsirolimus and vitamin D.

[328] Notably, inclusion of a low concentration of vitamin D (0.01 nM) during the de differentiation interval also resulted in somewhat higher levels IFN-g and TNF-a relative to use of a higher concentration of vitamin D (0.1 nM). As such, with respect to moderating resultant T cell secretion of the inflammatory cytokine IFN-g, it is preferable to use a concentration of vitamin D that is approximately 0.1 nM.

[329] Furthermore, as shown in FIGURES 12A-12D, the resultant T cells that were re differentiated from each of the de-differentiated precursor state T cells had very low level secretion of IL-2, although again, the level was lower in the condition that incorporated the higher concentrations of temsirolimus and vitamin D relative to the conditions that used a lower concentration of these agents.

[330] FIGURES 12A-12D depicts the IL-2 and Th2-type cytokine analysis of cultured de differentiated T cells in polarization-neutral media. Human CD4⁺ and CD8⁺ T cells were subjected to a 3-day de-differentiation procedure that included the following culture components, as indicated: temsirolimus (Y, indicates concentration of 1 mM; Y, Lo, indicates concentration of 0.1 mM); Vitamin D (Y, indicates concentration of 0.1 nM; Y, Lo, indicates concentration of 0.01 nM); an anti-IL-2 receptor monoclonal antibody (Daclizumab, 50 pg/ml); co- stimulation with anti- CD3/anti-CD28 (3/28) coated magnetic beads at a low ratio (bead-to-T cell ratio, 1:3), and supplementation with 5% human serum. After 3-days, the de-differentiated T cells were co stimulated (typical bead-to-T cell ratio of 3:1) in media supplemented with the T cell growth cytokines rhu IL-2 (100 IU/ml) and rhu IL-7 (10 ng/ml), which are not potent in terms of inducing T cell polarization. After 10 days in culture (total, day 13 of culture), the T cells were harvested, washed, and re-stimulated with 3/28 beads (3:1 ratio) for 24 hr; the resultant supernatant was harvested and tested for cytokine content by Luminex multi-analyte method. All results shown are expressed as cytokine level in pg per ml per 1 x 10⁶ cells/ml/24 hr.

[331] The resultant T cells also had very low level secretion of the Th2-type cytokine IL-4 (values less than 20 pg/ml) and the Th2-type cytokine IL-5 (values less than 60 pg/ml). However, the levels of IL-13 were elevated in several of the T cell culture conditions, with lower cytokine secretion detected in the condition that incorporated the higher concentrations of temsirolimus and vitamin D relative to the conditions that used a lower concentration of these agents.

[332] In sum, these data indicate that re-differentiation of T cells in media that contains T cell growth cytokines (IL-2 and IL-7) without strong polarization signals (no addition of IFN-a, IL-4, or TGF-b) after a step 1 de-differentiation process has an inherent bias towards T cells of low cytokine potential; in particular, we demonstrated low levels of the deleterious cytokines IFN-g, TNF-a, and IL-17. This observation is particularly strong if the de-differentiation step incorporates low-level co-stimulation and propagation in media that contains temsirolimus at a concentration of 1.0 mM, vitamin D at a concentration of 0.1 nM, and inclusion of an anti-IL-2 receptor monoclonal antibody.

Example 12: Favorable Expansion of De-differentiated T Cells in a Elybrid Tiu:c//h2 Polarization Condition and in the Presence of the Novel Pharmaceutical Agent Pemetrexed

[333] We evaluated the effect of de-differentiation components when T cell re-differentiation incorporated TREG polarizing cytokines IL-2 and TGF-b, or a Thl polarizing cytokine, IFN-a.

[334] Indeed, either TBET or GATA3 has been shown to maintain TREG cell capacity for maintaining immune tolerance. Nonetheless, in spite of this evidence for a role of either TBET or GATA3 in TREG cell function, we have elected to prioritize GATA3 expression in manufactured TREG cells because of the very strong linkage of TBET and consequent Thl-type pathways in autoimmunity. As such, we evaluated whether the step 1 de-differentiation process followed by a step 2 re-differentiation process that included both TREG polarizing signals (IL-2, TGF-b) and the main Th2 polarizing signal (IL-4) might generate a human “hybrid” TREG-T1I2 cell. Literature results from experimental murine models are mixed in this regard, as purposeful addition of IL-4 to a TREG cell ex vivo culture was shown to either promote or suppress the TREG phenotype. In addition to this conflicting murine literature pertaining to the role of exogenous IL-4 in TREG cell manufacturing, there is a paucity of information pertaining to the ex vivo role of IL-4 on human TREG cells, although one study found that IL-4 preserved human TREG cell function. [335] Human ITREG cells with a hybrid Th2 component may be favorable for adoptive T cell therapy because ITREG cells have been characterized as having a propensity to in vivo differentiation plasticity whereby an ITREG cells can convert to a pathogenic Thl-type or Th 17- type subset. On the other hand, if differentiation towards a Th2-type phenotype is encoded within the ITREG manufacturing, the Th2 bias will predictably limit plasticity towards the Thl/Thl7 phenotypes.

[336] In addition, we evaluated whether the pharmaceutical agent pemetrexed might be beneficial for promoting an ITREG cell phenotype. There exists a precedent for the use of pharmaceutical agents for preferential ITREG cell generation; most notably, the mTOR inhibitor rapamycin has been associated with a shift towards ITREG cells. However, pemetrexed has not been characterized as having an iT_REG-promoting effect. Pemetrexed has a complex mechanism of action as a folate anti-metabolite.

[337] FIGURE 13 depicts favorable expansion of de-differentiated T cells in hybrid T1I2/T_REG polarization condition relative to Thl polarization condition. Human CD4⁺ and CD8⁺ T cells were subjected to a 3-day de-differentiation procedure (“STEP 1”). As indicated in FIGURE 13, this STEP 1 de-differentiation intervention variably included: no inhibitor (“no”); temsirolimus alone (“T”; 1.0 mM); Vitamin D alone (“D”; 0.1 nM); the anti-IL-R monoclonal antibody Basiliximab alone (“B”; 10 pg/ml); or various combinations of the inhibitors (T, D; or T, D, B) After 3-days, the de-differentiated T cells were co-stimulated (typical bead-to-T cell ratio of 3:1) in media variably supplemented with: Thl polarization condition (rhu IFN-oc; 10,000 IU/ml); T_REG polarization (rhu IL-2, 100 IU/ml; rhu TGF-b, 10 ng/ml); or a hybrid T1I2-T_REG polarization condition (IL-2, TGF-b, plus addition of rhu IL-4 [1000 IU/ml]). In addition, the T cell culture in the presence of the variable polarization conditions was performed without the novel inhibitory molecule, pemetrexed (“0”) or in the presence of variable concentrations of pemetrexed, as indicated (10 nM [“10”]; 33 nM [“33”]; or 100 nM [‘TOO’’]. After a total of 10 days of culture, the n=24 cultures were harvested and live cells were enumerated and graphed above (y-axis indicated number of cells x 10⁶; input cell number was 1.5 x 10⁶ cells). [338] As FIGURE 13 shows, an ability to re-differentiate T cells after step 1 de-differentiation depended on: the specific components added during de-differentiation; the specific cytokines added during re-differentiation; and the presence of pemetrexed during re-differentiation.

[339] Remarkably, attempts to re-differentiate a sufficient number of T cells after step 1 de differentiation were unsuccessful in conditions of Thl-type polarization (see FIGURE 13, cultures #9 through #16; all T cell yields below T cell input number). The greatly limited ability to re- differentiate along a Thl-type pathway was observed if the de-differentiation conditions included temsirolimus and vitamin D either alone or in combination with an anti-IL-2 receptor reagent and was also observed if pemetrexed was either not added during step 2 culture or added at concentrations ranging from 10 to 100 nM.

[340] In marked contrast, attempts to re-differentiate a sufficient number of T cells after step 1 de-differentiation were successful in conditions of hybrid TREG-T1L2 polarization (see FIGURE 13, cultures #2 and #5). Remarkably, in the most stringent de-differentiation condition (inclusion of temsirolimus, vitamin D, and anti-IL-2 receptor monoclonal antibody), sufficient T cells in the TREG-T1L2 polarization condition were only observed if pemetrexed was added to step 2 culture at a concentration of 10 nM.

[341] Using this most stringent de-differentiation step 1 condition, attempts to re-differentiate a sufficient number of T cells during step 2 in a pure TREG polarizing condition (IL-2 plus TGF-b without IL-4) were unsuccessful, even in the presence of pemetrexed (cultures #20 and #21).

[342] In sum, successful T cell re-differentiation, from a numerical perspective, is optimally performed using TREG-T1L2 hybrid polarization conditions (IL-2, TGF-b, and IL-4) AND using the pharmaceutical agent pemetrexed at a concentration of 10 nM.

Example 13: Culture of De-differentiated T Cells in the Hybrid T_REc/Th2 Condition Results in the Generation ofCD4⁺ AND CD8⁺ T Cells of Limited Differentiation Status

[343] We also evaluated the effect of this step 1 de-differentiation process followed by step 2 re differentiation in various cytokine polarizing conditions/various pemetrexed conditions on T cell memory status. That is, studies show that T cells of limited differentiation status have improved therapeutic utility for adoptive cell therapy; thus, limited T cell differentiation would be a favorable feature of the step 1/step 2 T cell manufacturing method.

[344] FIGURES 14A-14C illustrates that the culture of de-differentiated T cells in hybrid Th2/T_REG polarization condition results in the generation of naive and triple-positive T central memory CD4⁺ T cells. Human CD4⁺ and CD8⁺ T cells were subjected to a 3-day de-differentiation procedure and subsequent culture in media containing variable polarization culture conditions and variable presence of pemetrexed, as described in FIGURE 13. Out of the total of n=24 culture conditions, only the cultures with favorable cell yields were further evaluated; all cultures shown that contained pemetrexed (“+”) were at the concentration of 10 nM. The TREG conditions above all contained IL-2, TGF-b, and IL-4 (“TReg”) unless indicated (“TReg, No IL4”). After a total of 10 days of culture, cultures were harvested and evaluated by flow cytometry for content of: naive CD4⁺ T cells (expressed as % of total CD4⁺ T cells that co-expressed CD45RA; FIGURE 14A); central-memory CD4⁺ T cells (expressed % of total CD4⁺ T cells that co-expressed both CD62L and CCR7; FIGURE 14B); and triple-positive central-memory CD4⁺ T cells (expressed % of total CD4⁺ T cells that co-expressed CD62L, CCR7, and CD127; FIGURE 14C).

[345] As shown in FIGURE 14A, step 2 re-differentiation in the hybrid TREG-T1I2 condition (with or without pemetrexed at the 10 nM concentration) resulted in a high frequency of the CD4⁺CD45RA⁺ naive T cell subset that was favorable in experimental murine models of adoptive T cell therapy.

[346] In addition, as shown in FIGURE 14C, step 2 re-differentiation in the hybrid TREG-T1I2 condition (with or without pemetrexed at the 10 nM concentration) resulted in a high frequency of CD4⁺ T cells that had triple positive co-expression of the memory markers CD62L, CCR7, and CD127. This triple-positive memory phenotype is a marker of T cells having a very primitive differentiation status.

[347] As shown in FIGURE 14C, the frequency of CD4⁺ T cells that were triple positive for CD62L, CCR7, and CD 127 was higher in the hybrid TREG-T1I2 polarizing condition relative to the pure TREG polarizing condition. [348] Also, as shown in FIGURE 14C, use of the more stringent step 1 de-differentiation condition that included not only temsirolimus and vitamin D but also an anti-IL-2 receptor monoclonal antibody yielded the highest frequency of CD4 cells that were triple positive for CD62L, CCR7, and CD 127 using the hybrid TREG-T1I2 polarizing condition.

[349] FIGURES 15A-15B illustrate that culture of de-differentiated T cells in hybrid Th2/TReg polarization condition results in the generation of triple-positive T central memory CD8⁺ T cells. Human CD4⁺ and CD8⁺ T cells were subjected to a 3-day de-differentiation procedure and subsequent culture in media containing variable polarization culture conditions and variable presence of pemetrexed, as described in FIGURE 13. Out of the total of n=24 culture conditions, only the cultures with favorable cell yields were further evaluated; all cultures shown that contained pemetrexed (“+”) were at the concentration of 10 nM. The TREG conditions above all contained IL-2, TGF-b, and IL-4 (“TReg”) unless indicated (“TReg, No IL4”). After a total of 10 days of culture, cultures were harvested and evaluated by flow cytometry for content of: central- memory CD8⁺ T cells (expressed % of total CD8⁺ T cells that co-expressed both CD62L and CCR7; FIGURE 15A); and triple-positive central-memory CD8⁺ T cells (expressed % of total CD8⁺ T cells that co-expressed CD62L, CCR7, and CD127; FIGURE 15B).

[350] Also, as shown in FIGURE 15B, the frequency of CD8 cells that were triple positive for CD62L, CCR7, and CD 127 was higher in the hybrid TREG-T1I2 polarizing condition relative to the pure TREG polarizing condition. Furthermore, as shown in FIGURES 15A-15B, use of the more stringent step 1 de-differentiation condition that included not only temsirolimus and vitamin D but also an anti-IL-2 receptor monoclonal antibody yielded the highest frequency of CD8⁺ T cells that were triple positive for CD62L, CCR7, and CD 127 using the hybrid TREG-T1I2 polarizing condition.

[351] In sum, these data indicate that T cell re-differentiation using hybrid TREG-T1I2 cytokine polarization (IL-2, TGF-b, and IL-4) AND using pemetrexed (10 nM) after step 1 de differentiation results in CD4⁺ and CD8⁺ T cells of a favorable, limited differentiation status. Example 14: Culture of De-dijferentiated T Cells in the Hybrid T_REc/Th2 Polarizing Condition Results in T Cells With a Primitive Th2 Cell Cytokine Phenotype

[352] T cells re-differentiated in the step 2 culture conditions after step 1 de-differentiation were also evaluated for cytokine secretion pattern. Cytokine secretion is an indicator of T cell effector function, and as such, it is generally desirable that TREG cells have reduced cytokine secretion potential, particularly with respect to key inflammatory cytokines such as IL-17, IFN-g and TNF- a. In the case of the proposed hybrid TREG-T1I2 cell population, it would be expected that such cells would also secrete some distribution of Th2 cytokines.

[353] FIGURES 16A-16C illustrate that the culture of de-differentiated T cells in hybrid Th2/TReg polarization condition results in the generation of T cells with a primitive Th2 cell cytokine phenotype: as indicated by high levels of IL-2 and IL-4 secretion and a low level of IL-5 secretion. Human CD4⁺ and CD8⁺ T cells were subjected to a 3 -day de-differentiation procedure and subsequent culture in media containing variable polarization culture conditions and variable presence of pemetrexed, as described in FIGURE 13. Out of the total of n=24 culture conditions, only the cultures with favorable cell yields were further evaluated; all cultures shown that contained pemetrexed (“+”) were at the concentration of 10 nM. The TREG conditions above all contained IL-2, TGF-b, and IL-4 (“TReg”) unless indicated (“TReg, No IL4”). After a total of 10 days of culture, the T cells were harvested, washed, and re-stimulated with 3/28 beads (3:1 ratio) for 24 hr; the resultant supernatant was harvested and tested for cytokine content by Luminex multi-analyte method. All results shown are expressed as cytokine level in pg per ml per 1 x 10⁶ cells/ml/24 hr.

[354] As shown in FIGURE 16A, T cells re-differentiated in the hybrid TREG-T1I2 cytokine polarizing condition (IL-2, TGF-b, and IL-4) with or without pemetrexed added to culture had the highest values for IL-2 secretion. This result is consistent with the prior understanding that IL-2 secretion in T cells is a characteristic of T cells in an early state of differentiation, which T cells re-differentiated in the hybrid culture conditions possess.

[355] FIGURES 17A-17C illustrate that the culture of de-differentiated T cells in hybrid Th2/T_Re polarization condition results in the generation of T cells with a primitive Th2 cell cytokine phenotype: as indicated by low levels of IL-10, IL-13, and IL-17 secretion. Human CD4⁺ and CD8⁺ T cells were subjected to a 3-day de-differentiation procedure and subsequent culture in media containing variable polarization culture conditions and variable presence of pemetrexed, as described in FIGURE 13. Out of the total of n=24 culture conditions, only the cultures with favorable cell yields were further evaluated; all cultures shown that contained pemetrexed (“+”) were at the concentration of 10 nM. The TREG conditions above all contained IL-2, TGF-b, and IL- 4 (“TReg”) unless indicated (“TReg, No IL4”). After a total of 10 days of culture, the T cells were harvested, washed, and re-stimulated with 3/28 beads (3:1 ratio) for 24 hr; the resultant supernatant was harvested and tested for cytokine content by Luminex multi-analyte method. All results shown are expressed as cytokine level in pg per ml per 1 x 10⁶ cells/ml/24 hr.

[356] FIGURES 18A-18C illustrates that the culture of de-differentiated T cells in hybrid T1I2/TREG polarization condition results in the generation of T cells with a primitive Th2 cell cytokine phenotype: as indicated by low levels of IFN-gamma, TNF-alpha, and GM-CSF secretion. Human CD4⁺ and CD8⁺ T cells were subjected to a 3 -day de-differentiation procedure and subsequent culture in media containing variable polarization culture conditions and variable presence of pemetrexed, as described in FIGURE 13. Out of the total of n=24 culture conditions, only the cultures with favorable cell yields were further evaluated; all cultures shown that contained pemetrexed (“+”) were at the concentration of 10 nM. The TREG conditions above all contained IL-2, TGF-b, and IL-4 (“TReg”) unless indicated (“TReg, No IL4”). After a total of 10 days of culture, the T cells were harvested, washed, and re-stimulated with 3/28 beads (3:1 ratio) for 24 hr; the resultant supernatant was harvested and tested for cytokine content by Luminex multi-analyte method. All results shown are expressed as cytokine level in pg per ml per 1 x 10⁶ cells/ml/24 hr.

[357] Furthermore, as shown in FIGURE 16B, T cells re-differentiated in the hybrid TREG-T1I2 condition (IL-2, TGF-b, and IL-4) with or without pemetrexed added to culture had the highest values for IL-4 secretion. Because IL-4 is the key cytokine that dictates Th2 polarization, T cells manufactured in the hybrid condition are indeed Th2 polarized. On the other hand, consistent with their limited differentiation state, cells re-differentiated in the hybrid condition did not secrete high levels of effector Th2 cytokine (IL-5, see FIGURE 16C; IL-10, see FIGURE 17A; IL-13, see FIGURE 17B) or effector Thl/Thl7 cytokines (IFN-g, see FIGURE 18A; TNF-alpha, see FIGURE 18B; GM-CSF, see FIGURE 18C; IL-17, see FIGURE 17C).

[358] Importantly, lack of IL-4 inclusion in the T cell re-differentiation process resulted in higher levels of the inflammatory cytokines IFN-g, TNF-a, and GM-CSF (see FIGURES 18A-18C).

[359] In sum, these data indicate that re-differentiation of T cells towards a TREG phenotype from step 1 de-differentiated cells optimally should utilize the hybrid TREG-T1L2 polarizing conditions because T cells emanating from this condition have a greatly reduced capacity for secretion of cytokines associated with inflammatory disease.

Example 15: Culture of De-differentiated T Cells in the Hybrid T_KIC;/ΊΊΊ2 Condition Results in T Cells With an Enhanced Hybrid T_REc Th2 Transcription Factor Profile

[360] T cell cytokine phenotype is determined by key transcription factors. The association of transcription factors with T cell subsets is as follows: FOXP3 dictates TREG cell development; TBET dictates Thl-type cell development; and GATA3 dictates Th2-type development.

[361] To evaluate these transcription factors in our manufacturing method, T cells were first subjected to the step 1 de-differentiation procedure and then re-differentiated in the hybrid TREG- Th2 culture condition (IL-2, TGF-b, and IL-4). In addition, we compared the effects of pemetrexed with a classical mTOR inhibitor. In our experiment, instead of using the oral formulation of the mTOR inhibitor (rapamycin; Sirolimus®), we utilized the water soluble parental form of the drug, temsirolimus (Toracel®).

[362] The ITREG phenotype is considered to be unstable; as such, we evaluated the stability of T cells re-differentiated using the hybrid TREG-T1L2 culture condition at delayed time points, including days 20 and 32 of culture. In addition, to test phenotype stability in a rigorous manner, between day 24 and day 32 of culture, T cells received a high level of co- stimulation (3:1 bead-to- T cell ratio) and were propagated in media without cytokines or pharmacologic agents.

[363] FIGURES 19A-19D illustrate that extended culture of de-differentiated T cells in the hybrid T1L2/T_REG polarization condition containing pemetrexed results in the generation of CD4⁺ T cells expressing FOXP3 and GATA3 transcription factors. Human CD4⁺ and CD8⁺ T cells were subjected to a 3-day de-differentiation procedure and subsequently were co-stimulated (3:1 bead- to-T cell ratio) and propagated in media containing the hybrid T1I2/TREG polarizing condition (IL- 2; TGF-b; IL-4) either without or with the pharmacologic inhibitors temsirolimus (1.0 mM) or pemetrexed (10 nM). Cultures were restimulated with 3/28 beads at both day 14 and day 24 of culture; at day 24 of culture, to evaluate stability of the transcription factor expression, the culture media did not contain exogenous cytokines or pharmacologic inhibitors. At days 12, 20, and 32 of culture, T cells were harvested and subjected to surface flow cytometry (CD4 marker) and intra cellular staining for the following transcription factors, FOXP3, Tbet, and GATA3. The data above show the percent CD4 cells out of the total cultured population (FIGURE 19A); the percent of CD4 cells that expressed the TREG transcription factor FOXP3 (FIGURE 19B); the percent of CD4 cells that expressed the Thl transcription factor Tbet (FIGURE 19C); and the percent of CD4 cells that expressed the Th2 transcription factor GATA3 (FIGURE 19D).

[364] As FIGURES 19A-19D detail, T cells re-differentiated in the TREG-T1I2 condition had a gradual shift towards CD4 cell predominance over time in culture (FIGURE 19A). As shown in FIGURE 19B, CD4 cells expressed FOXP3 at a high frequency and in a stable manner from day 12 through day 32 of culture independent of temsirolimus or pemetrexed presence in culture.

[365] As FIGURE 19C, there was a very low frequency of contamination with the Thl transcription factor TBET even without pharmacologic inhibitor presence. However, the most consistently reduced TBET values were observed in the hybrid polarization conditions that also included pemetrexed. Finally, as shown in FIGURE 19D, the highest end-of-culture Th2- associated GATA3 expression was observed in the T cells manufactured in the hybrid TREG-T1I2 condition that was supplemented with pemetrexed.

[366] FIGURES 20A-20D illustrate that extended culture of de-differentiated T cells in the hybrid T1I2/TREG polarization condition containing pemetrexed results in the generation of CD8⁺ T cells expressing FOXP3 and GATA3 transcription factors. Human CD4⁺ and CD8⁺ T cells were subjected to a 3-day de-differentiation procedure and subsequently were co-stimulated (3:1 bead- to-T cell ratio) and propagated in media containing the hybrid T1I2/TREG polarizing condition (IL- 2; TGF-b; IL-4) either without or with the pharmacologic inhibitors temsirolimus (1.0 mM) or pemetrexed (10 nM). Cultures were restimulated with 3/28 beads at both day 14 and day 24 of culture; at day 24 of culture, to evaluate stability of the transcription factor expression, the culture media did not contain exogenous cytokines or pharmacologic inhibitors. At days 12, 20, and 32 of culture, T cells were harvested and subjected to surface flow cytometry (CD8 marker) and intra cellular staining for the following transcription factors, FOXP3, Tbet, and GATA3. The data above show the percent CD8 cells out of the total cultured population (FIGURE 20A); the percent of CD8 cells that expressed the TREG transcription factor FOXP3 (FIGURE 20B); the percent of CD8 cells that expressed the Thl transcription factor Tbet (FIGURE 20C); and the percent of CD8 cells that expressed the Th2 transcription factor GATA3 (FIGURE 20D).

[367] As shown in FIGURE 20A, CD8 cell content gradually and modestly diminished over time in culture. It should be noted that, although TREG cell function is generally attributed to the CD4 cell subset, CD8⁺ TREG cells have also been well described; it is possible that use of a TREG population that contains both CD4⁺ and CD8⁺ T cell subsets may be advantageous due to diversification of antigen- specificity. As such, the method we describe is potentially advantageous in-part because it generates both CD4- and CD8-type TREGS.

[368] As FIGURE 20B shows (upper right panel), the CD8⁺ T cells manufactured using this method were indeed enriched for FOXP3 expression, which was stable over time in culture and stable independent of pharmacologic inhibitor presence.

[369] As FIGURE 20C shows (lower left panel), re-differentiation in the TREG-T1L2 polarization condition in general led to CD8⁺ T cell expression of low levels of the Thl transcription factor TBET; however, the lowest levels were observed most consistently in the presence of pemetrexed.

[370] Finally, as FIGURE 20D shows (lower right panel), re-differentiation in the TREG-T1L2 condition indeed resulted in CD8⁺ T cells that were also shifted towards Th2-type differentiation, as indicated by increased expression of the GAT A3 transcription factor.

[371] FIGURES 40A-40B also depict flow cytometry of GATA3 and FOXP3 for the re differentiated TREG-Th2 cells in both the CD4⁺ and CD8⁺ subsets. [372] In sum, these transcription factor analyses indicate that re-differentiation in the hybrid TREG-T1I2 culture condition plus pemetrexed addition can be optimal because it can preserve both CD4⁺ and CD8⁺ T cells that express both FOXP3 and GATA3, with limited expression of TBET.

Example 16: Culture of De-differentiated T Cells in the Hybrid T_REc/Th2 Condition Results in T Cells With an Enhanced Th2 Cytokine Secretion Profile

[373] In addition to transcription factor measurement, we also evaluated the T cells re differentiated in the hybrid TREG-T1L2 polarizing condition for cytokine secretion capacity. As shown in FIGURES 21A-21D, all re-differentiation cultures propagated in the TREG-T1L2 polarization condition yielded T cells capable of IL-4 secretion, thereby demonstrating the inherent capability of this method to achieve Th2 polarity even in the absence of pharmacologic inhibitors.

[374] FIGURES 21A-21D illustrates that extended culture of de-differentiated T cells in the hybrid T1L2/TREG polarization condition results in the generation of T cells expressing with a predominant Th2 cytokine phenotype: IL-4, IL-5, and IL-13 secretion. Human CD4⁺ and CD8⁺ T cells were subjected to a 3-day de-differentiation procedure and subsequently were co-stimulated (3:1 bead-to-T cell ratio) and propagated in media containing the hybrid T1L2/TREG polarizing condition (IL-2; TGF-b; IL-4) either without or with the pharmacologic inhibitors temsirolimus (1.0 mM) or pemetrexed (10 nM). Cultures were restimulated with 3/28 beads at both day 14 and day 24 of culture; at day 24 of culture, to evaluate stability of the transcription factor expression, the culture media did not contain exogenous cytokines or pharmacologic inhibitors. At days 12, 20, and 32 of culture, the T cells were harvested, washed, and re-stimulated with 3/28 beads (3:1 ratio) for 24 hr; the resultant supernatant was harvested and tested for cytokine content by Luminex multi-analyte method. All results shown are expressed as cytokine level in pg per ml per 1 x 10⁶ cells/ml/24 hr. The Th2 cytokine IL-10 was also evaluated: all values were less than 20 pg/ml per 1 x 10⁶ cells/ml/24 hr.

[375] Of note, whereas temsirolimus blunted the ability of T cells re-differentiated in the TREG- Th2 condition to secrete the effector Th2 cytokines IL-5 (FIGURE 2 IB) and IL-13 (FIGURE 21C), use of pemetrexed fully preserved the ability of T cells to secrete IL-5 and IL-13. As such, these data provide further evidence that the use of pemetrexed is favorable relative to use of conventional T_REG-promoting agents such as the mTOR inhibitor temsirolimus because pemetrexed is more compatible with the manufacture of the T_REG-T1I2 hybrid subset.

[376] Furthermore, all T cells re-differentiated in the T_REG-T1I2 polarizing condition had relatively low level expression of IL-2 (FIGURE 22A), IFN-g, (FIGURE 22B), IL-17 (all values less than 20 pg/ml), and TNF-a (all values less than 20 pg/ml).

[377] FIGURES 22A-22D illustrate that extended culture of de-differentiated T cells in the hybrid T1I2/T_REG polarization condition results in the generation of T cells expressing with a predominant Th2 cytokine phenotype: IL-2, IFN-g, and GM-CSF secretion. Human CD4⁺ and CD8⁺ T cells were subjected to a 3-day de-differentiation procedure and subsequently were co stimulated (3:1 bead-to-T cell ratio) and propagated in media containing the hybrid T1I2/T_REG polarizing condition (IL-2; TGF-b; IL-4) either without or with the pharmacologic inhibitors temsirolimus (1.0 mM) or pemetrexed (10 nM). Cultures were restimulated with 3/28 beads at both day 14 and day 24 of culture; at day 24 of culture, to evaluate stability of the transcription factor expression, the culture media did not contain exogenous cytokines or pharmacologic inhibitors. At days 12, 20, and 32 of culture, the T cells were harvested, washed, and re-stimulated with 3/28 beads (3:1 ratio) for 24 hr; the resultant supernatant was harvested and tested for cytokine content by Luminex multi-analyte method. All results shown are expressed as cytokine level in pg per ml per 1 x 10⁶ cells/ml/24 hr. The inflammatory cytokines IL-17 and TNF-a were also evaluated: all values were less than 20 pg/ml per 1 x 10⁶ cells/ml/24 hr.

[378] Of note, GM-CSF secretion was observed to a higher degree in T cell re-differentiated in the T_REG-T1I2 hybrid culture condition that was further supplemented with pemetrexed (10 nM; FIGURE 22C). Extrapolating from experimental studies in the literature, it is not clear whether the capacity for enhanced GM-CSF within a T_REG-T1I2 hybrid population would necessarily be either detrimental or beneficial.

[379] In sum, these data indicate that T cell re-differentiation in the T_REG-T1I2 polarizing condition is favorable because it results in T cells with a low level of capacity for secretion of the Thl- and Thl7-type cytokines associated with inflammatory disease. Inclusion of pemetrexed to the hybrid T_REG-T1I2 polarizing condition is advantageous because it results in an increased capacity for Th2 cytokine production, which will further provide a hedge against differentiation plasticity towards the Thl- and Thl7-type subsets.

Example 17: Use of Select anti-TNF- a reagents prior to lymphocyte collection by apheresis to beneficially alter the input T cell TCR repertoire

[380] FIGURES 23A & 23B depict the use of RNA-based T cell receptor sequencing to detect a widespread up- and down-regulation of T cell TCR specificities after therapy with the TNF-a inhibitor, etanercept. In FIGURE 23, RNA was isolated from peripheral blood mononuclear cells from an patient pre- and post-therapy with etanercept therapy. The RNA was subjected to TCR repertoire profiling, as previously described by Rosati E, Dowds CM, Liaskou E, Henriksen EKK, Karlsen TH, Franke A. Overview of methodologies for T-cell receptor repertoire analysis. BMC Biotechnol. 2017; 17(1):61. In FIGURE 23A it is demonstrated that approximately 25% of TCR specificities were up-regulated in the post-therapy sample (as indicated in red); in marked contrast, approximately 25% of TCR specificities were down-regulated in the post-therapy sample (as indicated in blue). As indicated in the upper right figure (B), etanercept therapy resulted in marked T cell clonal expansion, as several T cell clones increased from frequencies of 0.01 pre-etanercept (near the detection limit of the assay) to post-treatment values ranging from 247 to 486, thereby consistent with a more than 4-log T cell expansion. As indicated in the lower right FIGURE 23B, etanercept therapy resulted in marked T cell clonal contraction, as several T cell clones decreased from frequencies of 259 to 598 pre-etanercept to post-treatment values of 0.01, thereby consistent with a more than 4-log T cell clonal contraction.

[381] FIGURES 23A-B indicates that anti-TNF-oc therapy with etanercept, which preferentially inhibits the serum, cell-free form of TNF-a that promotes TNFR1 -expressing Thl-type cells, is associated with widespread changes in T cell receptor up- and down-regulation. These observations indicate that pre-treatment of a subject with etanercept or any other anti-TNF-a therapeutic that preferentially inhibits the serum, cell-free form of TNF-a (such as the monoclonal antibody, adalimumab) can be utilized to shift the T cell receptor repertoire away from T cells of Thl-type phenotype on an antigen- specific basis, thereby enriching for T cells of a TREG phenotype on an antigen- specific basis. Example 18: Characterization of the TREG-Th2 hybrid population as a cell product enriched for expression of CD25, CD27, 2B4, BTLA, and CTEA4.

[382] FIGURE 24 illustrates that the manufactured iTREG/Th2 hybrid population has increased expression of CD25, CD27, 2B4, BTLA, and CTLA4 relative to control Thl/Tcl cultures. In FIGURE 24, the iTREG/Th2 hybrid population was generated by the method previously detailed using an initial phase of T cell de-differentiation followed by re-differentiation in media containing IL-2, TGF-b, and IL-4. At day 11 of iTREG/Th2 manufacturing, the cells were harvested and subjected to flow cytometry for assessment of CD4+ and CD8+ T cell expression of molecules of relevance, namely CD25, CD27, 2B4, BTLA, and CTLA4; comparison was made to three separate control conditions evaluating Thl/Tcl polarization.

[383] FIGURE 24 indicates that hybrid TREG-Th2 cells manufactured according to the described conditions have increased expression of the following cell surface molecules by flow cytometry relative to control Thl/Tcl cells: CD25, CD27, 2B4, BTLA, and CTLA4.

[384] As FIGURE 24 illustrates, the iTREG/Th2 hybrid cell product has CD4+ and CD8+ T cells that express at least 10% and more preferably 50% higher levels of CD25, CD27, 2B4, BTLA, and CTLA4 relative to control Thl/Tcl cells.

[385] CD25, the IL-2 receptor, is critical for the ability of TREG cells to control autoimmunity, in particular CD8+ T cell driven responses. Therefore, expression of CD25 on the iTREG/Th2 manufactured cell product is a desirable characteristic.

[386] CD27, a co-stimulatory molecule with increased expression on TREG cells, has been shown to contribute to the inhibitory function of TREGS. Therefore, expression of CD27 on the iTREG/Th2 manufactured cell product is a desirable characteristic.

[387] 2B4 (CD244) has recently been shown to inhibit CD8+ T cell responses by attenuation of glycolysis and cell division. Therefore, expression of 2B4 on the iTREG/Th2 manufactured cell product is a desirable characteristic.

[388] BTLA (CD272) is a co-inhibitory receptor, and the ligation of BTLA with the herpesvirus- entry mediator HVEM promotes TREG cell induction and inhibition of effector immune responses. Therefore, expression of BTLA on the iTREG/Th2 manufactured cell product is a desirable characteristic.

[389] CTLA4 is a critical effector molecule of TREG cells, as recently evidenced by its ability to limit immunity to malarial infection. Therefore, expression of CTLA4 on the iTREG/Th2 manufactured cell product is a desirable characteristic.

Example 19: Characterization of the TREG-Th2 hybrid population as a cell product enriched for expression ofTIGIT, TIM3, ICOS, EAIR1, and 0X40.

[390] FIGURE 25 illustrates that the manufactured iTREG/Th2 hybrid population has increased expression of TIGIT, TIM3, ICOS, LAIR1, and 0X40 relative to control Thl/Tcl cultures. In FIGURE 25, the iTREG/Th2 hybrid population was generated by the method previously detailed using an initial phase of T cell de-differentiation followed by re-differentiation in media containing IL-2, TGF-b, and IL-4. At day 11 of iTREG/Th2 manufacturing, the cells were harvested and subjected to flow cytometry for assessment of CD4+ and CD8+ T cell expression of molecules of relevance, namely TIGIT, TIM3, ICOS, LAIR1, and 0X40; comparison was made to three separate control conditions evaluating Thl/Tcl polarization. FIGURE 25 indicates that hybrid TREG-Th2 cells manufactured according to the described conditions have increased expression of the following cell surface molecules by flow cytometry relative to control Thl/Tcl cells: TIGIT, TIM3, ICOS, LAIR1, and 0X40.

[391] As FIGURE 25 illustrates, the iTREG/Th2 hybrid cell product has CD4+ and CD8+ T cells that express at least 10% and more preferably 50% higher levels of TIGIT, TIM3, ICOS, LAIRl, and 0X40 relative to control Thl/Tcl cells.

[392] TIGIT is a cell surface co-inhibitory receptor molecule that associates with regulatory T cell function. Therefore, expression of TIGIT on the iTREG/Th2 manufactured cell product is a desirable characteristic.

[393] TIM3 is a co-inhibitory receptor that mediates an inhibitory effect of TREG cells.. Therefore, expression of TIM3 on the iTREG/Th2 manufactured cell product is a desirable characteristic. [394] ICOS is a co-stimulatory molecule that was recently determined to help maintain immune suppression by regulatory T cells for control of immune reactivity in the central nervous system. Therefore, expression of ICOS on the iTREG/Th2 manufactured cell product is a desirable characteristic.

[395] LAIR1 (CD305) is a multi-faceted inhibitory molecule that can block inflammation at multiple steps, including the suppression of activated, effector memory T cells. Therefore, expression of LAIR1 on the iTREG/Th2 manufactured cell product is a desirable characteristic.

[396] 0X40 is a co- stimulatory molecule. Therefore, expression of 0X40 on the iTREG/Th2 manufactured cell product is a desirable characteristic.

Example 20: Characterization ofGATA3 and FOXP3 Expression of the TREG/Th2 hybrid population

[397] A steady-state apheresis sample was obtained and enriched for lymphocytes by a Ficoll gradient and then plated in a G-Rex culture vessel and incubated in complete media containing Vitamin D (0.3 nM), temsirolimus (3.0 mM) and basiliximab (30 pg/mL). After an initial de differentiation interval, the T cells were co-stimulated at a 3:1 bead-to-T cell ratio with anti- CD3/anti-CD28-coated magnetic beads and cytokines were added (IL-4 (1000 IU/mL), IL-2 (10,000 IU/mL) and TGF-b (100 ng/mL)). After the 6-day culture, the T cells were harvested, stained for surface markers (CD4 and CD8) and intracellular molecule expression (GATA3 and FOXP3) and evaluated by flow cytometry. Results in FIGURES 26A-B show the FOXP3 and GATA3 expression for CD4+ and CD8+ T cells at the start of culture and after culture (Th2/TREG) as measured by flow cytometry. The percentages provided indicate the amount of cells considered positive for CD4+ or CD8+ and the intracellular marker (shown in boxes).

[398] The results shown in FIGURES 26A-B show results that are indicative of the phenotype of the manufactured Th2/TREG cell product. T cells of type II cytokine phenotype can be characterized in part by their expression of the transcription factor GAT A3 whereas regulatory T cell populations can be identified in part by their expression of FoxP3 transcription factor. At culture initiation, a very low frequency of T cells expressed either GAT A3 or FoxP3. In marked contrast, the T cell product manufactured in the Th2/TREG culture conditions expressed a high frequency of T cells that were either single-positive for GATA3, single -positive for FOXP3, or double-positive for both GATA3 and FOXP3 (not shown); importantly, as shown, this transcription factor profile was expressed in both manufactured CD4+ (top panels) and CD8+ (bottom panels) T cells. A control manufacturing culture that did not include IL-4 resulted in a greatly reduced frequency of GAT A3 -positive T cells, thereby demonstrating the important role of IL-4 in the manufacture of the Th2/TREG hybrid population (not shown).

[399] The majority of the phenotype characterization of the T cell product manufactured according to the TREG/Th2 method detailed in this disclosure can be ascertained at the end of culture. However, it is important to note that the T cell product can be cryopreserved, and as such, phenotypic characterization of T cells in the post-thaw state reflect the actual product to be adoptively transferred to the subject. The TREG/Th2 cells in the post-thaw state can be characterized by the following relative to control Thl/Tcl cells: (a) increased expression of CD25, CD27, 2B4, BTLA, CTLA4, TIGIT, TIM3, ICOS, LAIR1, and 0X40 by flow cytometry; (b) reduced IFN-g and TNF-a and increased secretion of IL-4 by Luminex cytokine secretion analysis; and (c) altered expression of T cell fate transcription factors, namely reduced TBET and increased FOXP3 and GATA3.

Example 21: Characterization of CD73 and CD 103 Expression of the TREG/Th2 hybrid population

[400] A steady- state apheresis sample was obtained and enriched for lymphocytes by a Ficoll gradient and then plated in a G-Rex culture vessel and incubated in complete media containing Vitamin D (0.3 nM), temsirolimus (3.0 mM) and basiliximab (30 pg/mL). After an initial de differentiation interval, the T cells were co-stimulated at a 3:1 bead-to-T cell ratio with anti- CD3/anti-CD28-coated magnetic beads and cytokines were added (IL-4 (1000 IU/mL), IL-2 (10,000 IU/mL) and TGF-b (100 ng/mL)). After the 6-day culture, the T cells were harvested, stained for surface markers (CD4 and CD8) and the ectonucleotidase molecule, CD73, or the integrin molecule, CD103, and evaluated by flow cytometry. Results in FIGURES 27A-B show the CD73 and CD 103 expression for CD4+ and CD 8+ T cells at the start of culture and after culture (Th2/TREG) as measured by flow cytometry. The percentages provided indicate the amount of cells considered positive for CD4+ or CD8+ and the ectonucleotidase molecule or integrin molecule, respectively (shown in boxes).

[401] Regulatory T cell populations can suppress pathogenic effector T cell populations by several defined mechanisms, including through expression of CD39 and CD73 ectonucleotidase molecules, which act to hydrolyse pro -inflammatory ATP towards the immune suppressive adenosine substrate. Indeed, TREG cells that express CD39 possess increased suppressive function and have been associated with resolution of inflammatory bowel disease. Furthermore, suppressive function of human TREG cells is mediated in part by CD73. As shown below in FIGURE 27 A, T cells manufactured in the Th2/TREG culture condition can have an increase in expression of the TREG-associated effector molecule, CD73; CD39 was also highly expressed on the TREG/Th2- manufactured T cells (not shown). In addition to the CD39/CD73 ectonucleotidases, TREG cell function has also been correlated with expression of CD 103, which is an integrin that dictates epithelial lymphocyte localization Indeed, CD 103 and IL-2 receptor signaling cooperate to maintain immune tolerance in the gut mucosa; furthermore, CD 103 -expressing TREG cells are critical for amelioration of experimental chronic GVHD. As shown below in FIGURE 27B, T cells manufactured in the Th2/TREG culture condition can have an increase in expression of the TREG- associated effector molecule, CD 103.

Example 22: Characterization of CD150 and CD27/CD95 Expression of the TREG/Th2 hybrid population

[402] A steady-state apheresis sample was enriched for lymphocytes by a Ficoll gradient, plated into a G-Rex culture vessel, and incubated in complete media containing Vitamin D (0.3 nM), temsirolimus (3.0 mM) and basiliximab (30 pg/mL). After this initial de-differentiation interval, the T cells were co-stimulated at a 3:1 bead:T cell ratio with anti-CD3/anti-CD28-coated magnetic beads and cytokines were added (IL-4 (1000 IU/mL), IL-2 (10,000 IU/mL) and TGF-b (100 ng/mL)). After the 6-day culture, the T cells were harvested, stained for surface markers, and subjected to multi-color flow cytometric analysis for CD4, CD8, CD150, CD27, CD95, CD45RA, CD62L, and CCR7. Results are shown in FIGURES 28A-B. [403] T cell cultured in the TREG (RAPA-501) condition were compared to the culture input T cells (“Day 0”) and also compared to control culture T cells that were propagated without mTOR inhibitors (“Control”). As shown in FIGURE 28 A, both CD4+ and CD8+ T cell subsets contained within the RAPA-501 cell product had greatly increased expression of the stem cell marker CD150 relative to culture input T cells and relative to control cultured T cells. As shown in FIGURE 28B, the RAPA-501 cell product was also enriched for a T stem cell memory (TSCM) phenotype relative to culture input cells; the control culture was devoid of this population, as the resultant T cells in this condition were effector memory, CD45RO+ (not shown). The left panel (culture input T cells) and the right panel (RAPA-501 cells) show expression of the TSCM markers CD95 and CD27 after gating on the TSCM markers CD45RA, CD62L, and CCR7; a similar difference in expression of these TSCM markers was observed for CD8+ T cells (not shown).

[404] In experimental models, the efficacy of adoptive T cell therapy is dependent upon successful engraftment and in vivo persistence of the T cell population. Importantly, the T cell differentiation state helps dictate in vivo persistence, with less differentiated cells having increased persistence. In our initial studies, murine rapamycin-resistant T cells, which expressed a T central memory (TCM) phenotype, had increased in vivo engraftment potential relative to control T cells; in addition, human rapamycin-resistant T cells also had increased engraftment in a human-into- murine model of xenogeneic graft-versus-host disease. Other investigators have determined that T cells with reduced differentiation relative to the T effector memory (TEM) population have increased in vivo persistence and mediate increased in vivo effects, including the TCM subset, the naive T cell subset, and more recently, the T stem cell memory (TSCM) subset. This relationship between T cell differentiation status and in vivo T cell function is operational relative to TREG cells, as: (1) TREG cells of TCM phenotype were more effective at reducing experimental GVHD relative to TREG cells of TEM phenotype; and (2) TREG cells that expressed the stem cell marker CD 150 were highly effective for the prevention of stem cell graft rejection. As shown below in FIGURE 28A, T cells manufactured in the Th2/TREG culture condition were enriched for cells a reduced differentiation state consistent with a T stem cell subset, including expression of the CD 150 marker.

Example 23: Characterization of Cytokine Secretion of the TREG/Th2 hybrid population [405] A steady-state apheresis sample was enriched for lymphocytes by a Ficoll gradient, plated into a G-Rex culture vessel, and incubated in complete media containing Vitamin D (0.3 nM), temsirolimus (3.0 mM) and basiliximab (30 pg/mL). After an initial de-differentiation interval, the T cells were co-stimulated at a 3:1 bead:T cell ratio with anti-CD3/anti-CD28-coated magnetic beads and cytokines were added (IL-4 (1000 IU/mL), IL-2 (10,000 IU/mL) and TGF-b (100 ng/mL)). This culture is termed Condition “A.” Condition “B” was the same culture condition but without IL-4 addition. Condition “C” reflects the standard TREG culture condition of rapamycin (1 pM), IL-2 (100 IU/mL), and TGF-b (10 ng/mL). Condition “D” reflects a Thl-type control culture manufactured in the presence of IFN-a without mTOR inhibitors. After culture, the T cells were harvested, stimulated with anti-CD3/anti-CD28 beads, and the resultant supernatant was tested for cytokine content by Luminex assay.

[406] It can be important to assess cytokine secretion of the manufactured Th2/TREG cells. First, it is critical that the cell product can secrete IL-4, which is the driver cytokine for subsequent Th2 differentiation. Second, it is desirable that an adoptively transferred T cell population is capable of secreting IL-2, as this capacity indicates a progenitor function that permits T cells to expand more readily in vivo without the need for exogenous IL-2. Finally, it is important that the Th2/TREG cell population has reduced secretion of the Thl- or Thl7-type cytokines IFN-a, TNF-a, IL-17, and GM-CSF. As FIGURE 29 illustrates, the manufactured Th2/TREG cell product secreted IL-4 and IL-2 with minimal secretion of Thl- or Thl7-type cytokines.

Example 24: Characterization ofThl/Tcl Suppression by the TREG/Th2 hybrid population

[407] A steady-state apheresis sample was enriched for lymphocytes by a Ficoll gradient, plated into a G-Rex culture vessel, and incubated in complete media containing Vitamin D (0.3 nM), temsirolimus (3.0 pM) and basiliximab (30 pg/mL). After an initial de-differentiation interval, the T cells were co-stimulated at a 3:1 bead:T cell ratio with anti-CD3/anti-CD28-coated magnetic beads and cytokines were added (IL-4 (1000 IU/mL), IL-2 (10,000 IU/mL) and TGF-b (100 ng/mL)) for ex vivo manufacture of Th2/TREG cells. In parallel, T cells were cultured in the presence of the type I polarizing cytokine IFN-a to generate effector Thl/Tcl cells; the Thl/Tcl culture was generated from the same donor as the RAPA-501 cell culture (autologous; “AUTO”) or from an unrelated donor (allogeneic; “ALLO”). After ex vivo culture, the Thl/Tcl effector T cells were plated in the bottom chamber of a transwell plate and co-stimulated with anti-CD3/anti- CD28 coated beads at a bead-to-T cell ratio of 3:1. After 24 hours of Thl/Tcl cell co- stimulation, RAPA-501 cells were added to the top chamber of the transwell plate at a Thl/Tcl-to-RAPA 501 ratio of 1:1. (A) RAPA-501 modulation of cytokine content. At 24 hours (prior to addition of RAPA-501 cells to the upper chamber) and at 48 hours of culture (either with or without addition of RAPA-501 cells), the culture supernatant was harvested and tested for cytokine content by Luminex assay. Results are expressed for IL-2, IFN-g, GM-CSF, and TNF-a content in pg/ml/24 hours/1 x 10⁶ cells/ml. (B) RAPA-501 cell modulation of Thl/Tcl cell expression of PD1 occurs in an antigen-independent manner. At 48 hours, the autologous or allogeneic Thl/Tcl cells were harvested after either addition or no addition of RAPA-501 cells at the 24-hour time point; the Thl/Tcl cells were then subjected to flow cytometry for evaluation of PD1 expression.

[408] During development of the RAPA-501 cell product, we performed experiments to characterize the molecular mechanism of the observed T cell suppression. One method to evaluate potential mechanisms is the transwell assay, whereby effector T cells and RAPA-501 cells are separated by a filter that prevents cell-to-cell contact but allows cell communication by small soluble mediators such as cytokines. FIGURES 30A-B illustrate that the RAPA-501 cells modulate effector T cells in a contact- independent manner (experiments performed in a transwell vessel). RAPA-501 cells acted in a T cell receptor independent manner to suppress the cytokine secretion capactiy of effector T cells; that is, because no co- stimulation beads were added to the transwell chamber containing the RAPA-501 cells, RAPA-501 cells did not require co- stimulation in order to modulate inflammatory cytokine levels, including IL-2, IFN-g, GM-CSF, and TNF-a (FIGURE 30A). The ability of TREG cells to consume IL-2 is a commonly described phenomenon, although previous studies identified the requirement of cell-to-cell contact for IL-2 consumption. As such, RAPA-501 cells appear to be somewhat uniquely capable of modulating the level of multiple inflammatory cytokines in a contact- independent manner. These results suggest that RAPA-501 cells represent a suitable candidate for neutralization of cytokines. Second, we found that RAPA- 501 cells modulated additional aspects of effector T cell biology in a contact- independent manner (use of transwell experiments), namely, the promotion of programmed death- 1 (PD-1) checkpoint molecule expression on the effector T cells. Importantly, as shown in FIGURE 30B, RAPA-501 cells up-regulated PD1 expression on both autologous and allogeneic Thl/Tcl cells, thereby further clarifying that one mechanism of RAPA-501 cell suppressive function occurs in a TCR- independent manner by soluble mediators.

Example 25: Characterization ofCNS Microglial Cell Cytokine Secretion Suppression by the TREG/Th2 hybrid population

[409] Human microglial cells (HMC3 cell line) were first activated with IFN-g (10 ng/ml; 24 hr) and then activated with LPS (10 ng/ml; 3 hr); the treated HMC3 cells were then plated into the lower chamber of a transwell, either without (left panel) or with (right panel) addition of RAPA- 501 cells, made as previously described, into the upper chamber (RAPA-501 to HMC3 ratio, 1:40). The RAPA-501 cells were generated using methods described in the patent application to generate T cells of a hybrid Th2/TREG phenotype. After 24 hours, cell free supernatants were harvested and evaluated for content of IL-6, IFN-g, and IP- 10 by Luminex assay (cytokine secretion measured in pg/ml/1 x 10⁶ cell per ml/24 hr). Results are shown in FIGURE 31.

[410] Microglial cells are CNS -resident antigen-presenting-cells that can develop into pro- inflammatory factors. The ability of a manufactured human Th2/TREG cell to suppress human microglial cell inflammation has not been previously reported to our knowledge. To address this, we induced a human microglial cell line HMC3 into a pro-inflammatory state by sequential culture in IFN-g followed by LPS endotoxin. As FIGUES 31A-31B demonstrate, the addition of the RAPA-501 Th2/TREG cell product to the pro-inflammatory microglial cells reduced the culture supernatant content of the pro-inflammatory cytokines IL-6, IP- 10, and IFN-g. In this experiment, the observed immune suppressive effect occurred in a transwell vessel and at a very dilute TREG to inflammatory microglial cell ratio of l-to-40, thereby indicated that the RAPA-501 cells can reduce CNS inflammation in a contact independent manner (as indicated by the transwell design) and with a high degree of potency (as indicated by the 1:40 TREG-to-microglial cell ratio).

Example 26: ITREG Cell Therapy of Pro-Inflammatory Diseases or Conditions Using The

Pentostatin, Cyclophosphamide, and Lamivudine Host Conditioning Platform.

[411] This example provides a treatment regimen for a pro-inflammatory disease or conditions. This example should not be construed as limited to any particular disease or condition. [412] FIGURE 32 details the PC Regimen and the overall therapeutic approach. The PC regimen will be administered in 2-week cycles, with escalating doses of pentostatin or cyclophosphamide over cycles 1 to 4, as indicated (8 weeks total duration of the PC regimen). Pentostatin is administered either on day 1 or on days 1 and 4 of the 14-day cycle; cyclophosphamide (Cy) is administered either on days 1, 2, and 3 or on days 1, 2, 3, 4, and 5 of the 14-day cycle. For cycle 4, if the ALC is < 1250 cells per microliter, the Cy dose will be increased to 200 mg per day. After immune depletion and immune suppression is realized through administration of the PC regimen, the first ITREG cell infusion will occur at week 8 of therapy. The inflammasome inhibitor lamivudine will be administered continuously at a dose of 150 mg BID from protocol week 8 to week 26.

[413] FIGURE 33 provides further details regarding the ITREG cell manufacturing, depicting lymphocyte collection by apheresis pre- and post-PC regimen. Lymphocytes from healthy volunteers will be collected (for allogeneic ITREG cell applications) and from the subject suffereing from the inflammatory disease or condition (for autologous ITREG cell applications) by steady-state apheresis (10- to 15-liter collection), which will be performed either just before or just after the PC regimen. The collection prior to the PC regimen may be more advantageous for ITREG manufacturing because the T cells will be found in higher numbers and will not be immune suppressed; by comparison, the collection after the PC regimen may be advantageous because inflammatory Thl/Tcl cells that will contaminate the ITREG culture will be depleted in vivo prior to manufacturing. After ITREG manufacturing, the product will be cryopreserved in therapeutic doses to allow repetitive dosing of ITREG cells, as indicated by infusions #2, #3, and #4.

[414] FIGURE 34 further details the strategy of multiple ITREG cell infusions, depicting sequencing of the PC regimen prior to each of the repetitive doses of ITREG cells. The PC regimen will be administered prior to each ITREG infusion to: (1) deplete and suppress inflammatory Thl/Tcl cells that contribute to disease pathogenesis; and (2) increase the in vivo levels of homeostatic cytokines such as IL-7 and IL-15, which will allow in vivo expansion of the adoptively transferred ITREG populations. The PC regimen will consist of pentostatin at a dose of 2 mg/m² on days 1 and 4 combined with cyclophosphamide at a flat dose of 100 mg per day on days 1 through 5. After two days of rest, the ITREG cells will be administered (day 8 of the regimen). The inflammasome inhibitor lamivudine will be continuously administered from week 8 onward to limit the inflammatory drive during ITREG cell therapy.

[415] FIGURE 35 provides further details regarding monitoring of patients treated with ITREG cells, illustrating that monitoring of will be by clinical monitoring and immune labs which will be assessed approximately monthly, as indicated. For treatment of other pro-inflammatory conditions, appropriate clinical monitoring and lab monitoring tools will be employed.

Apheresis for ITREG Generation.

[416] Prior to therapy with the pentostatin/cyclophosphamide regimen, subjects will undergo a lymphocyte apheresis procedure. The purpose of this peripheral lymphocyte collection will be to manufacture ITREG cells for adoptive T cell therapy. However, allogenic ITREG cells may be used.

[417] Apheresis will consist of a 10- to 15-liter collection on CS-3000 or equivalent machine. The apheresis product will be sent to the protocol sponsor, Rapa Therapeutics, and the ITREG cells will be manufactured by ex vivo culture using specialized culture conditions.

Study Objectives

[418] Primary Objectives. Determine the safety of ITREG cell infusion in the context of the PC regimen and maintenance lamivudine therapy in the inflammatory subset patients. Alternatively, in some clinical studies, the primary objective will be to evaluate the safety of ITREG cell infusion in the steady-state (without administration of medications such as the PC regimen).

[419] Secondary Objectives. Determine the ability of the ITREG therapy to inhibit inflammatory markers in patients. In a preliminary manner, determine the effect of ITREG therapy on various disease-related clinical parameters.

Eligibility Criteria.

[420] Subjects with a pro-inflammatory disease will be enrolled. Age > 18 years and less than or equal to 75 years. Kamofsky performance status of 70% or greater. Ejection fraction by MUGA or 2-D echocardiogram within institution normal limits. Serum creatinine less than or equal to 2.0 mg/dl. AST and ALT less than or equal to 3 times the upper limit of normal. Bilirubin less than or equal tol.5 (except if due to Gilbert’s disease). Corrected DLCO greater than or equal to 50% on Pulmonary Function Tests.

[421] To assess secondary study endpoints, patient must have evidence of inflammatory markers in peripheral blood cell populations after evaluation of at least two separate blood samples during the screening interval. The assays used to assess the inflammatory status of a potential patient will include: flow cytometry; cytokine secretion analysis; and cell signaling events by Western Blot analysis. Other tests may include tests of T cell receptor repertoire or in vitro sensitization to potential self-antigens. Cytokine secretion will be evaluated without stimulation (autonomous cytokine secretion) and with stimulation from various modalities, including but not limited to: anti-CD3/anti-CD28 co-stimulation; LPS endotoxin exposure; CD40 ligand exposure; adenosine A2_A and A3 receptor agonism and antagonism; T cell (PD1, TIM-3) and monocyte (CD47, CD200) checkpoint inhibition; and assessment of T cell receptor clonality by RNA sequencing. The decision as to whether a potential subject will be considered to have sufficient inflammation to warrant inclusion in the study will be based on a matrix analysis of all of these tests, with the decision being made by the study PI or Lead Associate Investigator in consultation with the Medical Director of the Rapa Therapeutics Lab where the immune assays will be performed.

[422] The following will also represent exclusion criteria: receipt of any investigational intervention within 30 days of protocol; pulmonary vital capacity measurement < 60% of predicted; active uncontrolled infection; hypertension not adequately controlled by 3 or less medications; history of cerebro-vascular accident within 6 months of enrollment; history of documented pulmonary embolus within 6 months of enrollment; or clinically significant cardiac pathology (as defined by myocardial infarction within 6 months prior to enrollment; Class III or IV heart failure according to NYHY; uncontrolled angina; severe uncontrolled ventricular arrhythmias; or electrocardiographic evidence of acute ischemia or active conduction system abnormalities). Patients with a history of coronary artery bypass grafting or angioplasty will receive a cardiology evaluation and will be considered on a case-by-case basis. Patients who are seropositive for HIV, hepatitis B, or hepatitis C will be excluded. Patients known or found to be pregnant will be excluded, as will be patients of childbearing age who are unwilling to practice contraception. Patients may be excluded at the discretion of the PI or if it is deemed that allowing participation would represent an unacceptable medical or psychiatric risk.

Treatment of Subjets Patients With The PC Regimen.

[423] The purpose of the 8-week PC regimen is to cause a partial depletion and suppress the Thl/Tcl cells that contribute to disease pathogenesis. In addition, at week 8 and at later time points when the PC regimen is immediately followed by iT_REG cell infusion, the PC regimen is also intended to acutely result in the creation of an increase in T cell homeostatic cytokines, in particular, IL-7 and IL-15.

[424] The PC Regimen will be administered as 14-day cycles; however, up to a two-week additional delay between cycles may be permitted in the event of logistical obstacles or additional time is required to evaluate and/or treat any adverse events. For cycle #1, pentostatin (1 mg/m² i.v. on day 1) will be administered in combination with cyclophosphamide (100 mg p.o. daily on days 1, 2, and 3). Cycle #2, which will be administered as long as no dose limiting toxicity has occurred, will consist of an increased dose of pentostatin (2 mg/m² i.v. on day 1) in combination with the same dose of cyclophosphamide (100 mg p.o. daily on days 1, 2, and 3). Cycles #3 and #4, which will be administered as long as no dose limiting toxicity has occurred AND the absolute lymphocyte count is greater than 750 cells per microliter, will consist of two doses of pentostatin (2 mg/m² i.v. on day 1 and day 4) in combination with five days of cyclophosphamide (100 mg p.o. daily on days 1, 2, 3, 4, and 5).

[425] If the ALC count is 750 cells per microliter or less prior to cycle #3 or cycle #4, then no further cycles will be administered and the patient will proceed to maintenance therapy with lamivudine. In the event that the absolute lymphocyte count is greater than 1250 cells per microliter prior to cycle #4, then the dose of cyclophosphamide will be doubled (200 mg p.o. daily on days 1, 2, 3, 4, and 5).

[426] Specifics relating to pentostatin administration: (a) Preparation: pentostatin will be reconstituted by the Pharmacy Department to a concentration of 2 mg/ml as per vial instructions. The appropriate patient specific dose will then be added to 0.9% sodium chloride to make up a total volume of 50 mL; (b) Dose and Administration: pentostatin dosing will be adjusted for renal dysfunction (see below); each dose of pentostatin will be administered intravenously over 30-60 minutes; (c) Premedication and Anti-emetic therapy: prior to infusion, infuse 1 liter of 0.9% sodium chloride over 30-60 minutes. Pentostatin can be emetogenic. Anti-emetic regimen guidelines are as follows (variations are allowed at the discretion of the PI): (1) Dexamethasone 12 mg by IV infusion 60 minutes prior to each dose of pentostatin; (2) In addition, oral dexamethasone may be administered in the first five days of each cycle, if needed for emesis control; (3) Ondansetron may be administered at a dose of 8 mg by IV infusion 60 minutes prior to each dose of pentostatin; (4) For the remainder of treatment, ondansetron may be administered at an oral dose of 8 mg (tablets) every 12 hours for as long as required during the cycle on Days 1 through 14; and (5) Aprepitant may be added as needed to the anti-emetic regimen in patients with uncontrolled nausea and vomiting.

[427] Specifics relating to pentostatin dose reductions: serum creatinine levels will be obtained prior to each scheduled dose of pentostatin and CrCl calculated. The CrCl will be obtained either by 24-hour urine or calculated by the Cockcroft-Gault formula. If a subject experiences an increase in creatinine level during the pentostatin and cyclophosphamide therapy, subsequent dosing will be modified as follows: for CrCl > 60 (mL/min/1.73m²): administer 100% of intended pentostatin dose (1 mg/m² of pentostatin for cycles #1, #2; 2 mg/m² for cycles #3, #4); for CrCl < 60 but > 30: administer 50% of intended pentostatin dose (0.5 mg/m² of pentostatin for cycles #1, #2; 1 mg/m² for cycles #3, #4); for CrCl < 30: hold pentostatin.

[428] Because pentostatin is rarely associated with neurologic toxicity (seizure, coma), special attention should be paid towards evaluating CNS toxicity. If the PC regimen is associated with any new neurologic toxicity of grade 2 or greater severity or worsening of any pre-existing neurologic toxicity, the institutional PI should be contacted to discuss whether further pentostatin therapy and further protocol therapy is warranted.

[429] Specific aspects of cyclophosphamide administration: hydration. Because cyclophosphamide can cause cystitis, it is important for patients to stay well hydrated. At a minimum, patients should drink at least 2 to 4 liters of fluid per day to maintain a clear color to the urine. It is also especially important to void the bladder prior to sleeping. Oral cyclophosphamide will be given at a fixed dose of 100 mg per day on days 1, 2, and 3 (for cycles #1 and #2) or on days 1, 2, 3, 4, and 5 (for cycles #3 and #4). However, for patients who do not have substantial reduction in the ALC prior to cycle #4 (as defined by an ALC greater than 1250 cells per microliter), the cyclophosphamide dose for cycle #4 will be increased to 200 mg per day for days 1, 2, 3, 4, and 5. IV infusion of cyclophosphamide will be allowed if a patient is unable to tolerate oral therapy; the IV dose will be the same as the intended oral dose. For IV infusion, cyclophosphamide will be reconstituted by the HUMC Pharmacy Department to a concentration of 20 mg/ml as per vial instructions. The appropriate dose (100 mg or 200 mg) will then be diluted in 100 ml of D5W or 0.9% sodium chloride and infused intravenously over 30 minutes.

[430] It is not anticipated that the PC cycles will result in substantial reductions in the absolute neutrophil count. However, if the ANC below certain values at the determination just prior to the next cycle, then the dose of cyclophosphamide will be adjusted as follows: (1) for an ANC value of 1000 or greater cells per microliter, 100% of the intended dose will be administered; (2) for an ANC value of between 500 and 999 cells per microliter, 50% of the intended dose will be administered; and (3) if the ANC value is less than 500 cells per microliter, then the cyclophosphamide will not be administered. In addition, for ANC values less than 500 cells per microliter, the decision to start G-CSF therapy may be considered by the PI.

[431] The quantitative goal of the 8-week PC regimen is to reduce the ALC value to approximately 750 cells per microliter. It is our hypothesis that this degree of depletion and suppression of the T cells contributing to disease pathogenesis will allow for successful engraftment and biologic activity of the ITREG cells to control the neuro-inflammatory process. However, it is possible that more stringent reductions in the host Thl/Tcl cells might be required to allow the ITREG cells to exert their fully suppressive function; in such a case, the PC regimen can be intensified or prolonged in order to target lower ALC values prior to ITREG cell therapy, such as 500, 250, or 0 ALC per microliter. On the other hand, it is possible that the ITREG cell therapy will be so effective that even an ALC value of 750 cells per microliter might be considered too stringent; in such cases, the PC regimen can be de-intensified or shortened in duration to target higher ALC values such as 1000, 1250, or 1500 cells per microliter.

Implementation Relating to Lamivudine Maintenance Therapy. [432] Upon completion of the PC regimen, patients will proceed to maintenance therapy with lamivudine, which will continue until the end-of-study date at 6-months of the protocol. Lamivudine (oral tablets) will be administered at a dose of 150 mg p.o BID. In the event that the estimated creatinine clearance is reduced below 50 ml/min, lamuvidine will be reduced to a dose of 150 mg p.o. once daily; lamivudine will be discontinued for estimated creatine clearance values below 30 ml/min.

[433] As stated previously, the stated objective of the lamivudine is to down-regulate the NLRP3 inflammasome. As such, we envision that other inflammasome inhibitors will be suitable or perhaps preferable for use on our protocol platform; for example, inflammasome inhibitors with a potentially improved risk: benefit ratio have been developed.

[434] It is important to note that lamivudine is not predicted to be antagonistic to FTREG cell therapy because their mechanisms of action in fact are complimentary. This complimentary contrasts to other interventions proposed for TREG cell therapy, such as rapamycin (which can inhibit a wide variety of T cell responses) and IL-2 (which has a narrow therapeutic window in terms of promoting TREG expansion in vivo and can promote inflammatory T cell populations).

Supportive Care Therapy.

[435] Patients will not be required to be on systematic antibiotic prophylaxis if neutropenic. The decision to initiate antibiotics will reside with the protocol PI.

[436] All patients will be placed on oral anti-viral prophylaxis for HSV or VZV with Acyclovir (or its pro-drug Valacyclovir) at the time of initiation of protocol therapy through end-of-study.

[437] All patients will be placed on oral anti-fungal prophylaxis (first line: fluconazole) at the time of initiation of protocol therapy through the end-of-study visit. Substitutions are allowed, as per the protocol PI approval.

[438] All patients will initiate pneumocystis PJP prophylaxis at study entry (continued to end-of- study visit). Patients will be placed on oral Cotrimoxazole (Trimethoprim 160 mg/Sulfamethoxazole 800 mg): one tablet po on Mondays, Wednesday and Fridays; alternative schedules or substitutions are allowed, as per the protocol PI approval. Treatment of Subjects With TTREG Cells: Manufacturing and Phenotype of the Product.

[439] As previously detailed, the ITREG cell product will be manufactured from allogenic T cells or from autologous T cells that are collected by apheresis either at the time of study entry prior to the PC regimen or at the completion of the 8-week PC regimen. Each apheresis collection may have inherent advantages: the initial collection will have a higher T cell yield whereas the post-PC collection will be comprised of a T cell population that is relatively depleted of Thl/Tcl cells.

[440] Because the ITREG cells are manufactured based on the principles of effector T cell conversion from an inflammatory phenotype to an anti-inflammatory TREG phenotype, there will be no need for expensive and laborious natural TREG purification steps that require either monoclonal antibody/column selection methods or flow cytometry to obtain the relatively rare nT_REG population that is typically characterized as CD4⁺, CD25⁺, and low expression of CD 127. In addition, there will be no need to eliminate CD8⁺ T cells from the ITREG cell population because CD8⁺ TREG cells have been shown to mediate immune suppression and may be beneficial in terms of providing increased diversity to the ITREG cell therapy.

[441] It has been shown that TREG cells of limited differentiation status, which can be defined as being of central memory type based on expression of cell surface markers such as CD62L and CCR7, have increased in vivo regulatory function. On the other hand, it is also known that TREG cell acquisition of a more differentiated effector memory status allows up-regulation of molecules that mediate suppressive function such as: IL-10; CTLA-4; the ecto-nucleotidase molecules CD39 and CD73; and cytolytic molecules such as perforin and fas ligand. These data indicate that it will be beneficial to infuse an ITREG cell product that contains populations of both central and effector memory subsets, and as such, the ITREG cell product that we will utilize will have representation from both subsets.

[442] In addition, it is necessary that the ITREG cells express FoxP3, which is the transcription factor that dictates the regulatory T cell differentiation program. Furthermore, because it has been shown that FoxP3 expression and consequent regulatory function can deteriorate over time, the ITREG cell product must have stable FoxP3 expression over extended periods of time in culture. [443] Furthermore, it has been shown in humans that FoxP3 alone is not sufficient for identification of a regulatory T cell phenotype because it can be transiently expressed by bona fide inflammatory T cell subsets. As such, it is critical to manufacture an ITREG cell product that expresses FoxP3 but also is relatively devoid of co-expression of molecules associated with inflammatory T cell subsets, such as the Thl/Tcl-type transcription factor TBET or Thl-type cytokines IL-2 or IFN-g.

[444] Finally, it is important that the ITREG cell product have reduced capacity for differentiation plasticity from a regulatory phenotype towards an inflammatory phenotype. That is, it has been well documented that TREG cells can be relatively unstable in their suppressive phenotype, which can result in transformation to an inflammatory T cell subset that can actually contribute to the mediation of neuro-degenerative disease. As such, the ITREG cell product must stably express FoxP3 and also show a reduced propensity to conversion to the Thl/Tcl subsets. As an additional safeguard against TREG cell differentiation plasticity into the Thl-type subset, we will purposefully incorporate IL-4 into the ITREG cell manufacturing process such that any such differentiation will be directed towards the Th2-type lineage, which: appears to be important of TREG cell maintenance and TREG cell suppressor function; has been described as a default pathway for TREG cells; and can mediate anti-inflammatory effects. In spite of this evidence for the potentially beneficial role of a Th2-like state of regulatory T cells, manufacturing methods for TREG cell therapy have not included the purposeful addition of exogenous IL-4 during culture (as illustrated in a recent example of TREG manufacturing).

[445] At the end of manufacturing, the ITREG cell product will be cryopreserved into at least four single-use aliquots at the therapeutic cellular dose (between 1 and 5 x 10⁶ cells/kg).

Treatment of Subjects With ITREG Cells: Combination of TREG Cell Populations.

[446] The ITREG cell populations will be infused at a dose of between 1 and 5 x 10⁶ cells per kg recipient body weight. This dosage of TREG cell therapy, which is relatively low compared to previous studies, is facilitated by several factors: the PC regimen will provide sufficient immunologic space for engraftment of the ITREG cells; the ITREG cells will express a memory profile that is associated with cellular persistence after adoptive transfer; and the ITREG cell product will be cryopreserved into at least four clinically-relevant therapeutic doses, thereby permitting multiple cycles of therapy.

[447] As previously detailed, the ITREG cell product will contain a diversity of memory differentiation status (central memory [CM] plus effector memory [EM]), thereby allowing both long-term and immediate control of neuro-inflammation, respectively. It will be possible to control the ratio of such central and effector memory populations for optimal results, depending on the clinical situation; that is, based on clinical parameters, the ITREG distribution of CM:EM cells might be 1:1, 3:1, 10:1, 1:3, or 1:10.

[448] In a similar manner, depending on the clinical situation, it will be possible to control the ratio of CD4⁺ITREG cells to CD8⁺ITREG cells for improved therapeutic effect.

[449] Finally, because ITREG and UTREG cells express different T cell receptor repertoires and therefore can be complimentary in terms of mediating immune suppression, we envision that optimal therapy using ITREG cells might be attained by co-administration of UTREG cells.

Treatment of Subjects With ITREG Cells: Combination With Pharmaceutical Agents

[450] It is possible that the ITREG cell therapy, when combined with a platform that includes the immune modulation effect of the PC regimen and the inflammasome inhibitory effect of lamivudine, may be sufficient to control neuro-inflammation.

[451] However, we envision that ITREG cell therapy might be optimized by alteration of the platform. By way of example but not limitation, the therapy could be optimized by changing the intensity of the PC regimen; substitution of cyclophosphamide with another agent to work in synergy with pentostatin; or addition of a third component to the PC regimen, for example, low- dose IL-2 therapy after anti-TNF therapy, which we reason will predictably increase TREG cells in vivo. By way of example but not limitation, low-dose IL-2 therapy as described in Pham MN, von Herrath MG, Vela JL. Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 Diabetes. Frontiers in Immunology. 2015;6:651.

[452] Furthermore, we envision that the lamivudine might be replaced with a more potent or more specific inflammasome inhibitor similar to molecules that have recently been synthesized. [453] We will combine ITREG cell therapy with rapamycin for promotion of autophagy using the following parameters: use of intermittent rapamycin therapy to limit drug toxicity and to limit the potential for rapamycin inhibition of ITREG cells (by way of example but not limitation, one week on mTOR inhibition therapy plus three weeks of recovery off of mTOR therapy); use of variable dosing of rapamycin, including a loading dose of rapamycin, in combination serum testing of rapamycin levels to ensure homogenous drug levels for more consistent inhibition of the mTOR pathway; and use of high-dose rapamycin therapy to achieve serum rapamycin levels of 30 ng/ml in preference to the typical target of ~ 5 to 12 ng/ml. See Mossoba ME, Halverson DC, Kurlander R, et al. High-Dose Sirolimus And Immune Selective Pentostatin Plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-Versus-Tumor Responses. Clinical cancer research. 2015;21(19):4312-4320.

[454] Furthermore, it is likely that rapamycin therapy may be sub-optimal for promotion of autophagy in neurodegenerative due to insufficient penetration of the drug into the central nervous system; to this point, even intravenous therapy with the rapamycin analog temsirolimus did not result in significant levels of drug in the cerebrospinal fluid. To overcome this limitation, we envision that we will administer temsirolimus through an indwelling Ommaya reservoir, in a manner similar to that utilized for therapy of lysosomal storage disease, to achieve consistent CSF drug levels of the mTOR inhibitor for optimal promotion of autophagy in the setting of neurodegenerative disease.

Treatment of Subjects With ITREG Cells: Immune Monitoring.

[455] In the context of ITREG cell therapy, it will be important to quantify the success of the cellular therapy in terms of its ability to modulate the inflammatory pathways associated with the disease. That is, monitoring of the clinical course of disease may not be sufficient given the wide degree of variability in disease progression across patient cohorts. An ability to optimally treat the inflammation will require multiple infusions of ITREG cells, including in combination with a variety of pharmacologic agents; as such, it will be critical to utilize immune biomarkers to assist in the guidance of therapeutic decisions.

[456] Therapeutic decisions pertaining repetitive dosing of ITREG cell infusions and associated pharmacologic agents will be based upon specialized testing of peripheral blood mononuclear cells that we have developed. These tests address several key issues relating to inflammatory monitoring, including: spontaneous cytokine measurement; T cell and monocyte cooperativity in cytokine measurement; role of recombinant human CD40 ligand, T cell checkpoint inhibitor pathways, and monocyte checkpoint pathways in the unmasking of cytokine secretion; assessment of inflammasome activation by various techniques such as protein quantification by Western Blot; evaluation of adenosine receptor biology of peripheral T cells as an indicator for inflammatory events; use of flow cytometry to assess FoxP3 transcription factor co-expression with the Thl- related molecules TBET, IL-2, or IFN-g; characterization of the T cell receptor repertoire by RNA sequencing; and detection of antigen- specific T cell responses against potential neurologic auto antigens, such as the protein aggregates that develop during disease pathogenesis.

Protocol Evaluation.

[457] Clinical evaluation by a physician or mid-level provider will be conducted on day 1 of each cycle of the PC regimen, which are intended to be 14-day cycles. Patients will also be seen by their local provider once during the 14-day PC cycles (ideally, around day 8 of the cycle). On these visits, a CBC with differential and complete metabolic panel (complete metabolic panel typically includes approximately 14 tests, including electrolytes, creatinine, liver transaminases, and bilirubin; specific panel to be used is not protocol-mandated) will be obtained and laboratory results will be sent to the protocol investigators.

[458] At the completion of the interval encompassing the PC regimen (approximately month 2), the patient will then be seen monthly at months 3, 4, 5, and 6; the visit at month 6 will represent the end-of-study visit. Tests to be performed at the time of these clinical evaluations will include: (1) interim history and physical examination; (2) CBC with differential and platelet count; (3) complete metabolic panel; and (4) immune subset enumeration (TBNK panel).

[459] To monitor research immune parameters, a peripheral blood sample will be sent to Rapa Therapeutics to allow for centralized monitoring and more in-depth analyses. Blood samples will consist of 30 ml in a green top heparinized tube (for cellular assays) and 5 ml in a red top tube (for serum assays) sent to Rapa Therapeutics. [460] Using the same samples sent to Rapa Therapeutics, we will investigate the effect of the PC regimen and the lamivudine maintenance therapy on: pro-inflammatory or anti-inflammatory cytokines or cellular subsets as measured by RNA expression, supernatant/Luminex assay, flow cytometry, and cell signaling events by phosphorylation analysis by Western Blot.

[461] Serum will be evaluated for potential bio-markers inflammation or disease. By way of example but not limitation, such as those biomarkers described in Beach TG. A Review of Biomarkers for Neurodegenerative Disease: Will They Swing Us Across the Valley? Neurology and Therapy. 2017;6(Suppl 1):5- 13.

[462] We will characterize the TCR repertoire of patients and evaluate whether the therapeutic interventions influence the repertoire.

[463] In vitro studies will fall under the general category of “Immune Characterization Studies”. They will focus on separation of distinct cell subsets by multi-parameter FACS analysis or separation by magnetic beads with subsequent characterization. Specifically, peripheral blood mononuclear cells (PBMC) will be analyzed by flow cytometry for expression of markers indicative of hematopoietic lineage, immune functional subsets, cytokine production, and activation state. Cell subsets will be analyzed for T cell receptor repertoire diversity. Cells may be activated in vitro with a number of different stimuli including specific antigens and mitogens which are known to activate distinct pathways of T lymphocyte or monocyte function. Assays may include T cell proliferation, cytokine production and gene expression. The specific assays to be used for the on-going data analyses are subject to be modified, deleted or replaced as technology and knowledge in the field evolve during the course of the study without constituting a change in research aims.

Toxicity Criteria

[464] Toxicity will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE) of the NCI (available at: http://ctep.info.nih.gov). A copy of the CTCAE version 4.0 can be downloaded from the CTEP home page. All treatment areas and personnel involved in the study should have access to a copy of the CTCAE version 4.0. [465] Any grade 4 or 5 toxicity (CTCAE version 4.0) with the attributions of probably or definitely related to the study drugs (pentostatin, cyclophosphamide, lamivudine) will be considered a dose limiting toxicity (DLT). The following toxicities will not be considered DLTs: biochemical grade 4 toxicity (except for renal and hepatic values); grade 4 emesis; grade 4 fever; and grade 4 toxicity related to infection that resolves within 7 days.

Statistical Considerations.

[466] The study design incorporates a standard 3+3 method to evaluate safety of the pentostatin and cyclophosphamide regimen and maintenance lamivudine therapy (the platform). In the first three patients, if no patient develops a DLT through completion of the pentostatin/cyclophosphamide regimen, then the regimen will be determined safe for expansion of the cohort to a total of n=10 patients. On the other hand, if one out of three of the first patients develops a DLT, then accrual will be increased to a total of n=6 patients. In such a case, accrual to the n=10 number in the cohort can proceed if no more than 1 out of the first 6 patients develops a DLT.

[467] Once this platform is successfully developed, we will evaluate the safety and potential efficacy of ITREG cell infusion. Initially, a pilot study will be performed to assess the ability of multiple infusions of ITREG cells to inhibit the neuro-inflammatory pathways associated with disease.

[468] Once an ability to effectively modulate the biomarkers associated with inflammation has been documented, we will perform phase II clinical trials (using either historical control data or a randomized cohort design) to assess whether the ITREG cell therapy can improve the clinical outcome in patients.

Risk/Benefit Analysis.

[469] The estimated survival of patients accrued to this study are anticipated to be approximately two to four years from study entry.

[470] The first protocol component consists of four cycles of an immune depletion and immune suppression regimen consisting of pentostatin and cyclophosphamide (PC regimen). We hypothesize that the PC regimen will eliminate and suppress immune cells; as such, it is possible that patient’ s may benefit from this effect in the form of improved quality of life or ultimately, decreased progression of disease. However, there may be unexpected toxicities of the PC regimen in terms of the central nervous system. It is possible that the PC regimen may have a paradoxical effect and actually increase the rate of disease progression or cause some other toxicity. Pentostatin in rare cases can also cause toxicity in other organs such as the heart or kidney. The most common toxicity to be expected from the PC regimen will be lymphocyte depletion, although this effect is part of the therapeutic rationale; on the other hand, the PC regimen may eliminate myeloid cells, thereby increasing the chance of bacterial or fungal infection. The PC regimen is anticipated to be associated with T cell immune suppression, and as such, opportunistic viral infections may occur.

[471] The second protocol component consists of maintenance therapy with the anti- viral drug, lamivudine. Patients may benefit from this therapy if the drug works as hypothesized to reduce inflammation. Lamivudine is generally a very well tolerated drug outside of primarily gastro intestinal side effect and pancreatitis.

[472] The third protocol component consists of multiple infusions of ITREG cells. Patients may benefit from this therapy because cellular therapy to control inflammation occurs directly in the microenvironment where inflammation is initiated, because cellular therapy operates through multiple molecular mechanisms of action that cannot be easily replicated through drug therapy, and because the effects of cellular therapy can be long-lasting due to memory cell effects.

Alternative Protocol Design

[473] FIGURE 39 provides an alternative protocol design. Lymphocytes will be collected by steady-state apheresis or obtained as allogenic, off-the-shelf T cells; the apheresis product will be shipped to the Rapa Therapeutics (Rockville, MD). After RAPA-501 cell manufacturing, n=4 doses of RAPA-501 cells will be cryopreserved in single-use infusion bags at the clinically- indicated cell dose. The treatment interval will be 6-months, followed by a 6-month observation interval. Cohort #1 will receive RAPA-501 cells, administered over 4 cycles at a dose of 40 x 10⁶ cells/infusion. Cohort #1 represents a safety cohort and will utilize a standard 3+3 design; advancement to Cohort #2 will occur if 0/3 or not more than 1/6 patients experience a dose-limiting toxicity (DLT). Cohort #2 will receive the same four cycles of RAPA-501 cells as in the previously discussed study protocol except that the T cell dose will be increased to 120 x 10⁶ cells/infusion. Cohort #3 will evaluate the highest dose of RAPA-501 cells that can be safely administered as a single-agent (as per Cohorts #1 or #2, either 40 or 120 x 10⁶ cells/infusion, respectively) plus host conditioning with the PC regimen prior to each of the four RAPA-501 cell infusions. The PC regimen will consist of pentostatin (2 mg/m² on days 1 and 4), cyclophosphamide (100 mg per day, days 1 through 5), no therapy on days 6 and 7, and RAPA-501 cell infusion on day 8.

Example 27: Use of Select anti-TNF - a reagents prior to lymphocyte collection by apheresis to beneficially alter the input T cell TCR repertoire

[474] FIGURES 36A-36B indicate that anti-TNF- a therapy with etanercept, which preferentially inhibits the serum, cell-free form of TNF-oc that promotes TNFR1 -expressing Thl-type cells, is associated with widespread changes in T cell receptor up- and down-regulation. FIGURES 36A- 36B depict use of RNA-based T cell receptor sequencing to detect a widespread up- and down- regulation of T cell TCR specificities after therapy with the TNF-oc inhibitor, etanercept. In FIGURES 36A-36B, RNA was isolated from peripheral blood mononuclear cells from a patient pre- and post-therapy with etanercept therapy. The RNA was subjected to TCR repertoire profiling, as previously described by Rosati E, Dowds CM, Liaskou E, Henriksen EKK, Karlsen TH, Franke A. Overview of methodologies for T-cell receptor repertoire analysis. BMC Biotechnol. 2017; 17(1):61. As shown in FIGURE 36A, it is demonstrated that approximately 25% of TCR specificities were up-regulated in the post-therapy sample (as indicated in red); in marked contrast, approximately 25% of TCR specificities were down-regulated in the post-therapy sample (as indicated in blue). As indicated in FIGURE 36B, etanercept therapy resulted in marked T cell clonal expansion, as several T cell clones increased from frequencies of 0.01 pre-etanercept (near the detection limit of the assay) to post-treatment values ranging from 247 to 486, thereby consistent with a more than 4-log T cell expansion. As indicated in FIGURE 36B, etanercept therapy resulted in marked T cell clonal contraction, as several T cell clones decreased from frequencies of 259 to 598 pre-etanercept to post-treatment values of 0.01, thereby consistent with a more than 4-log T cell clonal contraction These observations indicate that pre-treatment of a subject with etanercept or any other anti-TNF-oc therapeutic that preferentially inhibits the serum, cell-free form of TNF-oc (such as the monoclonal antibody, adalimumab) can be utilized to shift the T cell receptor repertoire away from T cells of Thl-type phenotype on an antigen- specific basis, thereby enriching for T cells of a TREG phenotype on an antigen-specific basis.

Example 28: Characterization of the T_REc-Th2 hybrid population as a cell product enriched for expression of CD25, CD27, 2B4, BTLA, and CTLA4.

[475] FIGURE 37 indicates that hybrid TREG-T1I2 cells manufactured according to the described conditions have increased expression of the following cell surface molecules by flow cytometry relative to control Thl/Tcl cells: CD25, CD27, 2B4, BTLA, and CTLA4. In FIGURE 37, The iT_REG/Th2 hybrid population was generated by the method previously detailed using an initial phase of T cell de-differentiation followed by re-differentiation in the hybrid TREG/T1I2 media containing IL-2, TGF-b, and IL-4; the cells were harvested and subjected to flow cytometry for assessment of CD4⁺ and CD8⁺ T cell expression of molecules of relevance, namely CD25, CD27, 2B4, BTLA, and CTLA4; comparison was made to three separate control conditions evaluating Thl/Tcl polarization.

[476] As FIGURE 37 illustrates, the iT_REG/Th2 hybrid cell product has CD4⁺ and CD8⁺ T cells that express at least 10% and more preferably 50% higher levels of CD25, CD27, 2B4, BTLA, and CTLA4 relative to control Thl/Tcl cells.

[477] CD25, the IL-2 receptor, is critical for the ability of TREG cells to control autoimmunity, in particular CD8⁺ T cell driven responses. Therefore, expression of CD25 on the iT_REG/Th2 manufactured cell product is a desirable characteristic.

[478] CD27, a co-stimulatory molecule with increased expression on TREG cells, has been shown to contribute to the inhibitory function of TREGS. Therefore, expression of CD27 on the iT_REG/Th2 manufactured cell product is a desirable characteristic.

[479] 2B4 (CD244) has recently been shown to inhibit CD8⁺ T cell responses by attenuation of glycolysis and cell division. Therefore, expression of 2B4 on the iT_REG/Th2 manufactured cell product is a desirable characteristic. [480] BTLA (CD272) is a co-inhibitory receptor, and the ligation of BTLA with the herpesvirus-entry mediator HVEM promotes TREG cell induction and inhibition of effector immune responses. Therefore, expression of BTLA on the IT_REG/TLZ manufactured cell product is a desirable characteristic.

[481] CTLA4 is a critical effector molecule of TREG cells, as recently evidenced by its ability to limit immunity to malarial infection. Therefore, expression of CTLA4 on the iT_REG/Th2 manufactured cell product is a desirable characteristic.

Example 29: Characterization of the T_REc-Th2 hybrid population as a cell product enriched for expression ofTIGIT, TIM3, ICOS, LAIR1, and 0X40.

[482] FIGURE 38 indicates that hybrid TREG-T1I2 cells manufactured according to the described conditions have increased expression of the following cell surface molecules by flow cytometry relative to control Thl/Tcl cells: TIGIT, TIM3, ICOS, LAIR1, and 0X40. In FIGURE 38, the iT_REG/Th2 hybrid population was generated by the method previously detailed using an initial phase of T cell de-differentiation followed by re-differentiation in media containing IL-2, TGF-b, and IL-4. At day 11 of iT_REG/Th2 manufacturing, the cells were harvested and subjected to flow cytometry for assessment of CD4⁺ and CD8⁺ T cell expression of molecules of relevance, namely TIGIT, TIM3, ICOS, LAIR1, and 0X40; comparison was made to three separate control conditions evaluating Thl/Tcl polarization.

[483] As FIGURE 38 illustrates, the iT_REG/Th2 hybrid cell product has CD4⁺ and CD8⁺ T cells that express at least 10% and more preferably 50% higher levels of TIGIT, TIM3, ICOS, LAIR1, and 0X40 relative to control Thl/Tcl cells.

[484] TIGIT is a cell surface co-inhibitory receptor molecule that associates with regulatory T cell function, including for example, contribution to the immunosuppressive environment in B cell non-Hodgkin lymphoma. Therefore, expression of TIGIT on the iT_REG/Th2 manufactured cell product is a desirable characteristic.

[485] TIM3 is a co-inhibitory receptor that mediates an inhibitory effect of T_REG cells, including for example, suppression of T cells that infiltrate head and neck squamous cell carcinoma. Therefore, expression of TIM3 on the iT_REG/Th2 manufactured cell product is a desirable characteristic.

[486] ICOS is a co-stimulatory molecule that was recently determined to help maintain immune suppression by regulatory T cells for control of immune reactivity in the central nervous system. Therefore, expression of ICOS on the iT_REG/Th2 manufactured cell product is a desirable characteristic.

[487] LAIR1 (CD305) is a multi-faceted inhibitory molecule that can block inflammation at multiple steps, including the suppression of activated, effector memory T cells. Therefore, expression of LAIR1 on the iT_REG/Th2 manufactured cell product is a desirable characteristic.

[488] 0X40 is a co-stimulatory molecule. Therefore, expression of 0X40 on the iT_REG/Th2 manufactured cell product is a desirable characteristic.

[489] The majority of the phenotype characterization of the T cell product manufactured according to the TREG/T1I2 method detailed in this disclosure can be ascertained at the end of culture. However, it is important to note that the T cell product can be cryopreserved, and as such, phenotypic characterization of T cells in the post-thaw state reflect the actual product to be adoptively transferred to the subject. The TREG/T1I2 cells in the post-thaw state can be characterized by the following relative to control Thl/Tcl cells: (a) increased expression of CD25, CD27, 2B4, BTLA, CTLA4, TIGIT, TIM3, ICOS, LAIR1, and 0X40 by flow cytometry; (b) reduced IFN-g and TNF-a and increased secretion of IL-4 by Luminex cytokine secretion analysis; and (c) altered expression of T cell fate transcription factors, namely reduced TBET and increased FOXP3 and GAT A3.

Example 30: Treatment of COVID-19 with TTREG cells

[490] We will perform a clinical trial investigation of allogeneic RAPA-501 cells for therapy of severe, post-intubation Stage 3 COVID-19 disease. A bank of cryopreserved allogeneic RAPA- 501 cells will be generated for off-the-shelf cell therapy of COVID-19. RAPA-501 cells will be manufactured from healthy volunteer steady-state apheresis samples and cryopreserved in single use bags at the protocol-defined doses (either 40 or 160 x 10⁶ cells; flat dose). It should be understood that this protocol can also be applied to treatment or prevention of other pro- inflammatory diseases and conditions.

[491] It is important to consider each cellular therapy product independently, including relating to the following critical parameters: (1) nature of the cellular product, including T cell receptor specificity (open repertoire vs. antigen-specific) and T cell cytokine phenotype; (2) the use or absence of host conditioning chemotherapy or radiation therapy (conditioning lowers host-versus- graft rejection responses, thereby increasing the chance of durable engraftment and subsequent GVHD); (3) level of host immune competence (reduced competence correlates with increased cell product in vivo persistence and increased risk of GVHD); and (4) degree of HLA-disparity between donor and recipient (increased chance of cell product persistence and GVHD risk with increased degree of HLA-matching).

[492] Given that the RAPA-501 cell product is allogeneic relative to the study participant, the protocol should monitor for the possibility that GVHD may occur. That is, even red blood cell (RBC) transfusions that are not leukocyte-reduced can result in microchimerism in up to 15% of trauma patients, who are known to have a suppressed immune system; however, it is important to note that such microchimerism is typically without clinical sequelae. Nonetheless, RBC infusions can rarely cause a high level of donor T cell expansion and transfusion-associated (TA) GVHD; importantly, TA-GVHD typically occurs within the first month of transfusion, occurs more frequent if donor and recipient are not fully HLA-disparate, and is typically lethal (Manduzio, 2018). Allogeneic RAPA-501 off-the-shelf therapy may not be associated with a significant risk of TA-GVHD because of several factors, namely: (1) use of HLA-disparate donors; (2) absence of host conditioning in the protocol; and (3) expression of a TREG and Th2 phenotype, which have an inherent low propensity for induction of GVHD.

[493] Graft rejection is the immunologic mirror image of GVHD; the host-versus-graft rejection response responsible for graft rejection will most likely limit the durable engraftment of the HLA- mismatched RAPA-501 cells. In the setting of severe COVID-19, the duration of in vivo engraftment of the RAPA-501 cell infusion required to exert a beneficial immune modulation effect is not known. However, it is reasonable to project that an anti-inflammatory and tissue protective effect that lasts up to one week might yield significant disease improvement. This time frame appears to be within the interval observed in a recent study involving HLA-disparate T cell infusion in the setting of HIV infection, where donor T cell in vivo persistence was documented for approximately one-week post-infusion (Migueles et ah, 2019). It is certainly possible that RAPA-501 cells might have more durable engraftment due to: (1) the TREG and Th2 phenotype, which are known to prevent rejection; (2) expression of CD73 and CD 150, which provide immune privilege; and (3) expression of T central memory and T stem memory markers, which associate with persistent engraftment.

[494] COVID-19 disease has been characterized as having three stages (Siddiqi & Mehra, 2020), with each stage having unique clinical signs and symptoms, differential pathophysiologic mechanisms, and novel potential therapeutic interventions. These COVID-19 stages are as follows: Stage 1, early infection; Stage 2, pulmonary phase; and Stage 3, hyperinflammation phase. As indicated in Figure 1 below, we propose that allogeneic, off-the-shelf RAPA-501 TREG/T1I2 Therapy will be most appropriately applied to the hyperinflammatory Stage 3 COVID-19 disease. However, with proven safety and efficacy, we propose that allogeneic RAPA-501 therapy will also be applicable to the earlier stage 1 and stage 2 disease stages to prevent severe disease progression. In the most generalized application, allogeneic RAPA-501 therapy may be used to treat the general population, including individuals not yet exposed to COVID-19, to help ensure that any future immune response to viral exposure will be balanced by the anti-inflammatory RAPA-501 TREG/T1I2 cell population.

[495] As illustrated in FIGURE 43, other medical interventions may ultimately prove advantageous for therapy of COVID-19 disease, including but not limited to anti-viral agents (such as remdesivir, hydroxychloroquine, plasma transfusions) and immune modulation agents (IL-6 inhibitors, mTOR inhibitors, Janus Kinase inhibitors). It is envisioned that allogeneic RAPA-501 cell therapy might be utilized either alone or in combination with any of these other potential therapeutics.

[496] As such, given the current state of very limited therapeutic options for the COVID-19 pandemic, there exists a great need to evaluate novel therapeutic strategies. In this application, we describe a novel treatment approach of COVID-19 disease that centers around allogeneic, off-the- shelf T_REG/T1I2 cell therapy using the RAPA-501 cell product. [497] ITREG cells used in this example can be manufactured by any of the methods disclosed herein and have the properties and/or combinations of properties described herein. The ITREG cells can be from the same subject, however, allogenic (“off-the-shelf’) cells derived from other persons will be used in the current study. Thus, the source of the culture input T cell-containing populations will be isolated from healthy volunteer donors rather than patients and the manufactured RAPA-501 cell product from a multitude of healthy donors will be partitioned into a bank of cryopreserved single-use doses of therapeutic product that can be available in real-time for therapy of COVID-19.

[498] Severe, post-intubation Stage 3 COVID-19 patients have no specific medical options other than supportive care and have a 30-day mortality rate of approximately 50%. Therefore, this specific patient population is suitable for the first- in-human evaluation of allogeneic RAPA-501 cells. The RAPA-501 treatment protocol focuses on rapid induction of an anti-inflammatory and tissue protective effect, thereby offering a novel therapeutic option for this patient population. Protocol investigators have substantial expertise in transplantation, infectious disease, and intensive care medicine; as such, protocol investigators will be highly qualified to diagnose and manage toxicities that may occur on this study. In addition, to help mitigate risk, the protocol will employ stopping rules and will be monitored by an independent DSMB.

[499] The initial clinical protocol of allogeneic RAPA-501 cells will be a phase I/phase II study. The primary objective of the phase I study component is to evaluate whether any dose limiting toxicity (DLT) occurs at dose level 1 (flat dose of RAPA-501 cells, 40 x 10⁶ cells) and at dose level 2 (flat dose of RAPA-501 cells, 160 x 10⁶ cells). DLT is defined as any grade 4 or 5 toxicity attributable to RAPA-501 therapy that occurs within 7 days of administration of RAPA-501 cell infusion. A standard 3+3 trial design will assess the phase I safety of Cohorts 1 and 2, using DLT rules for study implementation. Initiation of protocol therapy on the phase I component will be staggered by at least 7 days both within a treatment cohort and across cohorts. Initiation of therapy on Cohort 2 can proceed if each of the first 3 patients of the Cohort 1 do not experience a DLT. If there is a DLT in any of the first three patients on Cohort 1, then Cohort 1 must be expanded to n=6 patients; in such a case, advancement to Cohort 2 can only proceed if 1 out of 6 participants experience a DLT. The DLT rules also apply to the phase I aspect of Cohort 2. At the time that a cohort is deemed to be safe in the phase I study component, additional participants will be accrued such that a total of n=19 participants will receive RAPA-501 cells on any cohort eligible for phase II expansion.

[500] The primary objective of the phase II study component is to evaluate whether allogeneic RAPA-501 cells result in a mortality rate that is reduced relative to the anticipated historical control value. In the event that this phase II study component shows promise, subsequent definitive clinical trials can be envisioned (such as randomized trials). To help ensure patient safety, the phase II trial design will have three stages, as detailed below in Table 1. The first stage analysis will be after 6 patients. If 5 or more of these first 6 patients do not reach the primary study objective relating to 30-day survival, we will conclude that the therapy is not worth pursuing; in such a case, these results will be reported to the DSMB, who will provide guidance as to whether further accrual and patient treatment should proceed. On the other hand, if 0 out of 6 patients do not die in the first 30-days after RAPA-501 infusion, then early evidence for efficacy is established and accrual continues. The maximum discordance probability is 0.00091, which indicates that if 5 or more of the first 6 patients dies within the first 30-days after RAPA-501 therapy, then there is very slim (less than 0.091%) chance that the mortality rate would be less than 49% should the study continue to enroll all 19 patients. On the other hand, if 0 of the first 6 patients die, the trial will certainly meet its goal even if we enroll all 19 patients (which is allowed). On the other hand, if 0 of the first 6 patients die, the trial will certainly meet its goal even if we enroll all 19 patients (which is allowed). As indicated in Table 1, statistical analysis will again be performed after n=12 and n=19 RAPA-501 recipients are evaluable for the primary objective relating to 30-day survival. In the final analysis, if there are six or fewer deaths out of 19 patients at the 30-day time point, then the RAPA-501 therapy can be considered potentially promising to evaluate in definitive clinical trials. This statistical design would have 80% probability to accept the therapy for further trials if the true mortality rate is indeed 25%; and, there would be a 10% probability to reject the null hypothesis if the true mortality rate is indeed 49%.

Table 1. Three-stage Design for Phase II Evaluation of RAPA-501 Therapy of COVID-19

Stage Cumulative Not Promising if the Number of Deaths is Of Sample Greater Than or Equal To Promising if the

Number of Deaths is Less

Phase II Size Than or Equal To

1 6 5 0

2 12 7 1

3 19 7 6

[501] Important secondary study objectives, which will be monitored for 90-days post- allogeneic RAPA-501 cell therapy, are as follows: (1) Number of days requiring ventilation support; (2) Number of days of hospitalization among survivors; (3) Number of deaths due to any cause; (4) Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection; and (5) GVHD incidence and severity.

[502] Important exploratory study objectives, which will monitored for 6-months post- allogeneic RAPA-501 cell therapy, are as follows: (1) COVID-19 viral load, as determined by RT- PCR on nasopharyngeal and/or endotracheal tube swab samples; (2) Development of potentially protective host immunity to COVID-19, as determined by serologic studies; (3) Serum cytokine and chemokine levels, as determined by multiplex immunoassay; (4) Peripheral blood mononuclear cell secretion of cytokines and chemokines, as determined by supernatant generation and molecule detection by multiplex immunoassay; (5) Peripheral blood immune counts, including CD4+ and CD8+ T cells, NK cells, and B cells; (6) T cell expression of co- stimulation molecules (including CD28) and checkpoint receptor molecules (including PD-1); and (7) Peripheral blood micro-chimerism, as determined by PCR amplification of donor and host STR loci.

[503] Inclusion criteria for evaluation of allogeneic RAPA-501 cells for therapy of severe, post intubation Stage 3 COVID-19 disease are as follows: (1) Male or female patients > 18 years of age; (2) Patients with lab-confirmed SARS-CoV-2 infection; (3) Must have pulmonary infiltrate on radiologic examination; (4) Patient must be status-post intubation and mechanical ventilation (or, extracorporeal membrane oxygenation, ECMO) no more than 4 days from RAPA-501 infusion (surrogate for participant provides informed consent); (5) AST and ALT < 10 x upper limit of normal (ULN); and (6) Consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn at any time without prejudice to future medical care. Informed consent can be obtained from healthcare proxy if the subject is unable to provide consent due to medical status.

[504] Exclusion criteria for evaluation of allogeneic RAPA-501 cells for therapy of severe, post intubation Stage 3 COVID-19 disease are as follows: (1) Active uncontrolled infection with a non- COVID-19 agent; (2) Subjects with Severe ARDS (Riviello et al., 2016), as determined by institutional ICU staff and as defined by Berlin Criteria [Pa02/FI02 ratio <100 mmHg not eligible] or modified-Berlin Criteria (using Sp02/FI02 ratio); (3) Any irreversible disease or condition for which 6-month mortality is estimated to be greater than 50%; (4) End-stage liver disease with ascites unrelated to COVID-19 (Childs Pugh score > 12); (5) Uncontrolled or significant cardiovascular disease, including but not limited to: (a) myocardial infarction, stroke, or transient ischemic attack within the past 30 days; (b) uncontrolled angina within the past 30 days; (c) any history of clinically significant arrhythmias such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes; and (d) history of other clinically significant or uncontrolled heart disease, including: cardiomyopathy, congestive heart failure with New York Heart Association functional classification III or IV, myocarditis, pericarditis, or significant pericardial effusion; (6) Known chronic kidney disease of Stage 4 or 5 severity or requiring hemodialysis; (7) COVID-19- associated acute kidney injury requiring dialysis; (8) HIV, hepatitis B, or hepatitis C seropositive; (9) Pregnant or breastfeeding patients; (10) Patients with malignancy requiring active therapy (not including non-melanoma skin cancer); (11) Recipients of allogeneic hematopoietic cell transplant or solid organ transplant; (12) History of WHO Class III or IV pulmonary hypertension; (13) Documented deep vein thrombosis or pulmonary embolism within past 3 months; and (14) Subjects may be excluded at the discretion of the PI or if it is deemed that allowing participation would represent an unacceptable medical or psychiatric risk.

[505] The study treatment involves the intravenous infusion of a therapeutic dose of allogeneic RAPA-501 cells within 96 hours of the COVID-19 patients being mechanically ventilated.

[506] RAPA-501 cell products are cryopreserved in a solution containing Plasma- Fyte A, Human Albumin, and CryoStor® CS10 (final DMSO concentration, 5%) and stored in the vapor phase of liquid nitrogen at Rapa Therapeutics, EEC until testing results permit RAPA-501 product release to the clinical trial site. Cell manipulation procedures used to manufacture the RAPA-501 -Alio cell product will be performed in the GMP manufacturing suite at Rapa Therapeutics, LLC. Such manipulations will be performed in accordance with Current Good Manufacturing Practices using process- specific procedures and batch records. Infusion bags will contain approximately 50 ml of total volume and a RAPA-501-Allo cell dose of either 40 or 160 x 10⁶ cells per infusion. Infusion bags will be labeled with the product name, product identification number specific for that participant, study number, and the phrases “For Use by Intended Recipient Only”, “Unrelated Donor”, and “NOT TESTED FOR INFECTIOUS AGENTS.”

[507] The allogeneic RAPA-501 product must not be washed prior to infusion. The entire contents of the RAPA-501 cell bag will be infused, ideally within 30 minutes of thawing (must not be greater than 3 hours after thawing). Prior to administration of RAPA-501 cells, consideration can be given to provide premedication with diphenhydramine (25 to 50 mg IV) and acetaminophen (650 mg p.o. or by other gastro-intestinal route). RAPA-501 cells should be delivered to the patient care unit, thawed at the infusion site according to institutional SOPs, and infused immediately. Vital signs are to be monitored prior to RAPA-501 infusion, every 15 minutes during the infusion, and then every hour for two hours. If infusion reactions occur, they will be managed according to institutional practice.

[508] De-differentiation embodiments:

1. A method for de-differentiation of T cells, comprising: inoculating a culture input population of cells comprising T cells from a subject at a cell density in a culture medium comprising vitamin D, temsirolimus and an IL-2 signaling inhibitor; adding anti-CD3/anti-CD28 coated magnetic beads to said T cells and culture medium at a bead:T cell ratio of 1:1 to 1:12; incubating said culture input population of cells and culture medium for a period of time to yield de-differentiated T cells.

2. The method of embodiment 1, further comprising: harvesting said de-differentiated T cells.

3. The method of embodiment 2, further comprising, after harvesting said de-differentiated T cells: packaging at least a portion of said de-differentiated T cells in a package; and freezing said package containing said portion of said de-differentiated T cells.

4. The method of any one of embodiments 1-3, further comprising, before inoculating said culture input population of cells into said culture medium: harvesting said culture input population of cells from said subject.

5. The method of any one of embodiments 1-4, wherein said culture medium does not contain IL-2 and no IL-2 is added to said culture medium.

6. The method of any one of embodiments 1-5, wherein said cell density is at least 1.5 x 10⁶ T cells per mL.

7. The method of any one of embodiments 1-6, wherein said temsirolimus is present in said culture medium at a concentration of about 0.3 mM to about 1 mM.

8. The method of any one of embodiments 1-6, wherein said temsirolimus is present in said culture medium at a concentration of about 1 pM.

9. The method of any one of embodiments 1-8, wherein said IL-2 signaling inhibitor is an anti-IL-2 receptor antibody or fragment thereof.

10. The method of embodiment 9, wherein said IL-2 signaling inhibitor is basiliximab or daclizumab.

11. The method of any one of embodiments 1-10, wherein said IL-2 signaling inhibitor is present in said culture medium at a concentration of 5 to 50 pg/mL.

12. The method of any one of embodiments 1-11, wherein said period of time is about 3 days. 13. The method of any one of embodiments 1-12, wherein said bead:T cell ratio is 1:3.

14. The method of any one of embodiments 1-13, wherein said culture medium further comprises 5% human serum.

15. The method of any one of embodiments 1-14, wherein said culture medium comprises X- Vivo 20 medium.

16. The method of any one of embodiments 1-15, wherein said vitamin D is present in said culture medium at about 0.03 nM to about 1 nM.

17. The method of any one of embodiments 1-15, wherein said vitamin D is present in said culture medium at about 0.1 nM.

18. The method of any one of embodiments 1-11 and 13-17, further comprising: measuring an expression level of RAPTOR or RICTOR in said culture input population of cells, wherein said period of time lasts until the expression level of RAPTOR or RICTOR in the culture input population of cells is at least 50% and more preferably 90% reduced relative to a control population of T cells manufactured under the same conditions as the culture input population of cells without temsirolimus, IL-2 signaling inhibitor and Vitamin D.

19. The method of any one of embodiments 1-11 and 13-17, further comprising: measuring an expression level of RAPTOR or RICTOR and a housekeeping protein in said culture input population of cells, wherein said period of time lasts until the expression level of RAPTOR or RICTOR, respectively, in said culture input population of cells is reduced at least 50% relative to control population of T cells manufactured under the same conditions as the culture input population of cells without temsirolimus, IL-2 signaling inhibitor and Vitamin D, after normalizing for expression level of a housekeeping protein. 20. The method of embodiment 19, wherein said housekeeping protein is actin or GAPDH.

21. The method of any one of embodiments 18-20, wherein said step of measuring the expression level is performed by Western blot analysis.

22. The method of any one of embodiments 1-11 and 13-17, further comprising: measuring an expression level of RAPTOR or RICTOR in said culture input population of cells, wherein said period of time lasts until the expression level of RAPTOR or RICTOR in the culture input population of cells is reduced by at least 50% and more preferably by 90% relative to a control population of T cells manufactured under the same conditions as the culture input population of cells without temsirolimus, IL-2 signaling inhibitor and Vitamin D.

23. A de-differentiated T cell produced by the method of any one of embodiments 1-22.

24. A composition comprising a population of de-differentiated T cells, wherein at least a portion of said population of said de-differentiated T cells express less than 50% of both RAPTOR or RICTOR as compared to a control population of T cells, wherein the control population of T cells is manufactured under the same conditions as the culture input population of cells without temsirolimus, IL-2 signaling inhibitor and Vitamin D.

25. A method for de-differentiation of T cells, comprising: inoculating a culture input population of cells comprising T cells from a subject at a cell density in a culture medium comprising vitamin D and temsirolimus; adding anti-CD3/anti-CD28 coated magnetic beads to said T cells and culture medium at a bead:T cell ratio of 1:1 or less to stimulate said T cells; incubating said culture input population of cells and culture medium for a period of time to yield de-differentiated T cells.

26. The method of embodiment 25, further comprising: harvesting said de-differentiated T cells.

27. The method of embodiment 26, further comprising, after harvesting said de-differentiated T cells: packaging at least a portion of said de-differentiated T cells in a package; and freezing said package containing said portion of said de-differentiated T cells.

28. The method of any one of embodiments 25-27, further comprising, before inoculating said culture input population of cells into said culture medium: harvesting said culture input population of cells from said subject.

29. The method of any one of embodiments 25-28, wherein said culture medium does not contain IL-2 and no IL-2 is added to said culture medium.

30. The method of any one of embodiments 25-29, wherein said cell density is 1.5 x 10⁶ T cells per mL.

31. The method of any one of embodiments 25-30, wherein said temsirolimus is present in said culture medium at a concentration of about 0.3 mM to about 1 mM.

32. The method of any one of embodiments 25-30, wherein said temsirolimus is present in said culture medium at a concentration of about 1 pM.

33. The method of any one of embodiments 25-32, wherein said period of time is about 3 days.

34. The method of any one of embodiments 25-33, wherein said bead:T cell ratio is 1:3.

35. The method of any one of embodiments 25-34, wherein said culture medium further comprises 5% human serum.

36. The method of any one of embodiments 25-35, wherein said culture medium comprises X- Vivo 20 medium. 37. The method of any one of embodiments 25-36, wherein said vitamin D is present in said culture medium at about 0.03 nM to about 1 nM.

38. The method of any one of embodiments 25-37, wherein said vitamin D is present in said culture medium at about 0.1 nM.

39. The method of any one of embodiments 25-32 and 34-38, further comprising: measuring an expression level of RAPTOR or RICTOR in said culture input population of cells, wherein said period of time lasts until the expression level of RAPTOR or RICTOR in said culture input population of cells is reduced by at least 50% relative to a control population of T cells manufactured under the same conditions as the culture input population of cells without temsirolimus, IL-2 signaling inhibitor and Vitamin D.

40. The method of any one of embodiments 25-32 and 34-38, further comprising: measuring an expression level of RAPTOR, RICTOR and a housekeeping protein in said culture input population of cells, wherein said period of time lasts until the expression level of RAPTOR or RICTOR in the culture input population of cells is reduced by 50% or more preferably by 90% relative to a control population of T cells manufactured under the same conditions as the culture input population of cells without temsirolimus, IL-2 signaling inhibitor and Vitamin D after normalizing for housekeeping protein expression.

41. The method of embodiment 40, wherein said housekeeping protein is actin or GAPDH.

42. The method of any one of embodiments 39-41, wherein said step of measuring the expression level is performed by Western blot analysis.

43. The method of any one of embodiments 25-32 and 34-38, further comprising: measuring an expression level of RAPTOR or RICTOR in said culture input population of cells, wherein said period of time lasts until the expression level of RAPTOR or RICTOR in the culture input population of cells are reduced by at least 50% and more preferably by 90% relative to a control population of T cells manufactured under the same conditions as the culture input population of cells without temsirolimus, IL-2 signaling inhibitor and Vitamin D.

44. A de-differentiated T cell produced by the method of any one of embodiments 25-43.

45. A de-differentiated T cell population characterized by at least a 10% reduction and more preferably a 50% reduction in expression of RNA for the following T cell differentiation molecules relative to a control population of T cells cultured without the culture additives specified in these methods: cytolytic molecules, including but not limited to granzyme B; and cytokine molecules, including but not limited to IFN-g.

46. A de-differentiated T cell population characterized by at least a 10% increase and more preferably a 50% increase in expression of RNA for the following T cell differentiation molecules relative to a control population of T cells cultured without the culture additives specified in these methods: transcription factors associated with induced pluripotent stem cells, including but not limited to Nanog, KLF4, and KLF10; and molecules associated with naive T cells, including but not limited to the IL-7 receptor, CD 127.

47. A de-differentiated T cell population characterized by at least a 10% decrease and more preferably a 50% decrease in expression of RNA for the following T cell differentiation molecules relative to a control population of T cells cultured without the culture additives specified in these methods: transcription factors associated with Thl effector T cells, including but not limited to T-Bet and STAT1; however, concomitantly, the manufactured T cells will have equivalent expression of transcription factors associated with cell survival, including but not limited to HIF- 1 -alpha.

48. A de-differentiated T cell population characterized by at least a 10% increase and more preferably a 50% increase in expression of molecular markers of autophagy relative to a control population of T cells cultured without the culture additives specified in these methods, including but not limited to: an increase in protein level by Western Blot analysis of the autophagy-related molecule, p62.

49. The method of any one of embodiments 1-22, wherein said step of adding anti-CD3/anti- CD28 coated magnetic beads to said T cells and culture medium at a bead:T cell ratio of 1:1 to 1:12 is not performed.

50. The method of any one of embodiments 25-43, wherein said step of adding anti-CD3/anti- CD28 coated magnetic beads to said T cells and culture medium at a bead:T cell ratio of 1:1 or less to stimulate said T cells is not performed.

51. A population of de-differentiated T cells characterized by one or more of the following properties: at least a 10% decrease, and more preferably, a 50% decrease in mRNA expression of one or more of granzyme B, IL-10, and IFN-g relative to a control T cell population incubated under the same conditions without temsirolimus, vitamin D and the IL-2 signaling inhibitor; at least a 10% increase, and more preferably, a 50% increase in mRNA expression of one or more of Nanog, KLF4, KLF10 and CD127 relative to a control T cell population incubated under the same conditions without temsirolimus, vitamin D and the IL-2 signaling inhibitor; at least a 10% decrease, and more preferably a 50% decrease in mRNA expression of one or more of T-Bet and STAT1 relative to a control T cell population incubated under the same conditions without temsirolimus, vitamin D and the IL-2 signaling inhibitor;

HIF-1-a expression within about 20% of a control T cell population incubated under the same conditions without temsirolimus, vitamin D and the IL-2 signaling inhibitor; at least a 10% increase, and more preferably a 50% increase, in p62 expression relative to a control T cell population incubated under the same conditions without temsirolimus, vitamin D and the IL-2 signaling inhibitor; an expression level of RAPTOR or RICTOR reduced by at least 50% and more preferably by 90% relative to a control population of T cells manufactured under the same conditions as the culture input population of cells without temsirolimus, IL-2 signaling inhibitor and Vitamin D; an expression level of RAPTOR or RICTOR normalized by a housekeeping protein is reduced by at least 50% and more preferably by 90% relative to a control population of T cells manufactured under the same conditions as the culture input population of cells without temsirolimus, IL-2 signaling inhibitor and Vitamin D; and combinations thereof.

52. A de-differentiated T cell characterized by one or more of the following properties: at least a 10% decrease, and more preferably, a 50% decrease in mRNA expression of one or more of granzyme B, IL-10, and IFN-g relative to a control T cell incubated under the same conditions without temsirolimus, vitamin D and the IL-2 signaling inhibitor; at least a 10% increase, and more preferably, a 50% increase in mRNA expression of one or more of Nanog, KLF4, KLF10 and CD127 relative to relative to a control T cell incubated under the same conditions without temsirolimus, vitamin D and the IL-2 signaling inhibitor; at least a 10% decrease, and more preferably a 50% decrease in mRNA expression of one or more of T-Bet and STAT1 relative to a control T cell incubated under the same conditions without temsirolimus, vitamin D and the IL-2 signaling inhibitor;

HIF-1-a expression within about 20% of a control T cell incubated under the same conditions without temsirolimus, vitamin D and the IL-2 signaling inhibitor; at least a 10% increase, and more preferably a 50% increase, in p62 expression relative to a control T cell population incubated under the same conditions without temsirolimus, vitamin D and the IL-2 signaling inhibitor; an expression level of RAPTOR or RICTOR reduced by at least 50% and more preferably by 90% relative to a control T cell manufactured under the same conditions as the culture input population of cells without temsirolimus, IL-2 signaling inhibitor and Vitamin D; an expression level of RAPTOR or RICTOR normalized by a housekeeping protein is reduced by at least 50% and more preferably by 90% relative to a control T cell manufactured under the same conditions as the culture input population of cells without temsirolimus, IL-2 signaling inhibitor and Vitamin D; and combinations thereof.

[509] Re-differentiation embodiments:

1. A method for differentiating de-differentiated T cells to TREG/Th2 cells, comprising: culturing de-differentiated T cells in a culture medium comprising IL-2, IL-4 and TGF-b; adding anti-CD3/anti-CD28 coated magnetic beads at a ratio of 3:1 (bead:T cell ratio); incubating said de-differentiated T cells for a period of time to yield TREG/Th2 cells.

2. The method of embodiment 1, wherein said culture medium further comprises pemetrexed.

3. The method of any one of embodiments 1-2, wherein said IL-2 is present in said culture medium at a concentration of about 100 IU/mL.

4. The method of any one of embodiments 1-3, wherein said IL-4 is present in said culture medium at a concentration of about 1000 IU/mL.

5. The method of any one of embodiments 1-4, wherein said TGF-b is present in said culture medium at a concentration of about 10 ng/mL.

6. The method of embodiment 2, wherein said pemetrexed is present in said culture medium at a concentration of up to 100 nM. 7. The method of embodiment 2, wherein said pemetrexed is present in said culture medium at a concentration of about 10 nM.

8. The method of any one of embodiments 6-7, wherein said IL-2 is present in said culture medium at a concentration of about 100 IU/mL.

9. The method of any one of embodiments 6-8, wherein said IL-4 is present in said culture medium at a concentration of about 1000 IU/mL.

10. The method of any one of embodiments 6-9, wherein said TGF-b is present in said culture medium at a concentration of about 10 ng/mL.

11. A method for differentiating de-differentiated T cells to TREG/Th2 cells, comprising: culturing de-differentiated T cells, wherein said de-differentiated T cells express RAPTOR and RICTOR at a level that is at least 10% reduced relative to control T cells in a culture medium comprising IL-2, IL-4 and TGF-b; adding anti-CD3/anti-CD28 coated magnetic beads at a ratio of 3:1 (bead:T cell ratio); incubating said de-differentiated T cells for a period of time to yield TREG/Th2 cells.

12. The method of embodiment 11, wherein said culture medium further comprises pemetrexed.

13. The method of any one of embodiments 11-12, wherein said IL-2 is present in said culture medium at a concentration of about 100 IU/mL.

14. The method of any one of embodiments 11-13, wherein said IL-4 is present in said culture medium at a concentration of about 1000 IU/mL.

15. The method of any one of embodiments 11-14, wherein said TGF-b is present in said culture medium at a concentration of about 10 ng/mL.

16. The method of embodiment 12, wherein said pemetrexed is present in said culture medium at a concentration of up to 100 nM. 17. The method of embodiment 12, wherein said pemetrexed is present in said culture medium at a concentration of about 10 nM.

18. The method of any one of embodiments 16-17, wherein said IL-2 is present in said culture medium at a concentration of about 100 IU/mL.

19. The method of any one of embodiments 16-18, wherein said IL-4 is present in said culture medium at a concentration of about 1000 IU/mL.

20. The method of any one of embodiments 16-19, wherein said TGF-b is present in said culture medium at a concentration of about 10 ng/mL.

21. The method of any one of embodiments 1-20, wherein said culture medium is X-Vivo 20 supplemented with 5% human AB serum.

22. The method of any one of embodiments 1-21, wherein said period of time is between 3 days and 40 days.

23. A TREG/Th2 cell produced by the method of any one of embodiments 1-22.

24. A method for differentiating de-differentiated T cells to TREG cells, comprising: culturing de-differentiated T cells having reduced expression of RAPTOR and RICTOR relative to a control population of T cells in a culture medium comprising IL-2 and TGF-b; adding anti-CD3/anti-CD28 coated magnetic beads at a ratio of 3:1 (bead:T cell ratio); incubating said de-differentiated T cells for a period of time to yield TREG cells.

25. The method of embodiment 24, wherein said culture medium further comprises pemetrexed.

26. The method of any one of embodiments 24-25, wherein said IL-2 is present in said culture medium at a concentration of about 100 IU/mL. 27. The method of any one of embodiments 24-26, wherein said TGF-b is present in said culture medium at a concentration of about 10 ng/mL.

28. The method of embodiment 25, wherein said pemetrexed is present in said culture medium at a concentration of up to 100 nM.

29. The method of embodiment 25, wherein said pemetrexed is present in said culture medium at a concentration of about 10 nM.

30. The method of any one of embodiments 28-29, wherein said IL-2 is present in said culture medium at a concentration of about 100 IU/mL.

31. The method of any one of embodiments 28-30, wherein said TGF-b is present in said culture medium at a concentration of about 10 ng/mL.

32. A method for differentiating de-differentiated T cells to TREG cells, comprising: culturing de-differentiated T cells, wherein said de-differentiated T cells express RAPTOR and RICTOR at a level that is at least 10% reduced relative to control T cells in a culture medium comprising IL-2 and TGF-b; adding anti-CD3/anti-CD28 coated magnetic beads at a ratio of 3:1 (bead:T cell ratio); incubating said de-differentiated T cells for a period of time to yield TREG cells.

33. The method of embodiment 32, wherein said culture medium further comprises pemetrexed.

34. The method of any one of embodiments 32-33, wherein said IL-2 is present in said culture medium at a concentration of about 100 IU/mL.

35. The method of any one of embodiments 32-34, wherein said TGF-b is present in said culture medium at a concentration of about 10 ng/mL.

36. The method of embodiment 33, wherein said pemetrexed is present in said culture medium at a concentration of up to 100 nM. 37. The method of embodiment 33, wherein said pemetrexed is present in said culture medium at a concentration of about 10 nM.

38. The method of any one of embodiments 36-37, wherein said IL-2 is present in said culture medium at a concentration of about 100 IU/mL.

39. The method of any one of embodiments 36-38, wherein said TGF-b is present in said culture medium at a concentration of about 10 ng/mL.

40. The method of any one of embodiments 24-39, wherein said culture medium is X-Vivo 20 media supplemented with 5% AB serum.

41. The method of any one of embodiments 24-40, wherein said period of time is between 3 days and 40 days.

42. The method of any one of embodiments 1-41, wherein said de-differentiated T cells have a reduced expression of RAPTOR and RICTOR relative to a control population of T cells

43. A TREG cell produced by the method of any one of embodiments 1-22 and 24-42.

44. A TREG cell or hybrid TREG/Th2 cell produced by the method of any one of embodiments 1-22 and 24-42, wherein lymphocytes collected by apheresis for subsequent T cell culture are obtained in the steady-state or after subject treatment with an anti-TNF-oc therapeutic that is relatively selective in terms of neutralizing the serum, cell-free form of TNF-a, most notably the recombinant receptor molecule etanercept or the monoclonal antibody adalimumah.

45. A TREG cell or hybrid TREG/Th2 cell produced by the method of any one of embodiments 1-22 and 24-42, wherein the TREG cell or hybrid TREG/Th2 cell or a population therof has increased expression by flow cytometry of at least one the following molecules relative to control Thl/Tcl cells: CD25, CD27, 2B4, BTLA, CTLA4, TIGIT, TIM3, ICOS, LAIR1, 0X40, and combinations thereof.

46. A TREG cell or hybrid TREG/Th2 cell produced by the method of any one of embodiments 1-22 and 24-42, wherein the TREG cell or hybrid TREG/Th2 cell or a population thereof has reduced secretion of inflammatory cytokines relative to control Thl/Tcl cells, including IFN-g and TNF-a.

47. A TREG cell or hybrid TREG/Th2 cell produced by the method of any one of embodiments 1-22 and 24-42, wherein said TREG cell or hybrid TREG/Th2 cell or a population thereof has altered expression of T cell fate transcription factors relative to control Thl/Tcl cells, most notably a decrease in TBET and an increase in FOXP3.

48. A TREG cell or hybrid TREG/Th2 cell produced by the method of any one of embodiments 1-22 and 24-42, wherein said TREG cell or hybrid TREG/Th2 cell or a population thereof has additional phenotypic traits relative to control Thl/Tcl cells, including: increased secretion of the Th2 cytokine IL-4; and increased expression of the Th2 transcription factor GAT A3.

49. A population of TREG or TREG/Th2 cells having at least 5% of CD4+ or CD8+ T cells that express GATA3.

50. A population of TREG or TREG/Th2 cells having at least 5% of CD4+ or CD8+ T cells that express FoxP3

51. A population of TREG or TREG/Th2 cells having at least 10% of CD4+ or CD8+ T cells that express CD73.

52. A population of TREG or TREG/Th2 cells having at least 10% of CD4+ or CD8+ T cells that express CD 103.

53. A population of TREG or TREG/Th2 cells having at least 20% of CD4+ or CD8+ T cells that express CD150.

54. A population of TREG or TREG/Th2 cells that expresses at least 5 pg/mL/1 x 10⁶ cells/day of IL-4 after co- stimulation with anti-CD3/anti-CD28 beads at a bead:T cell ratio of 3 : 1.

55. A population of TREG or TREG/Th2 cells that expresses at least 100 pg/mL/1 x 10⁶ cells/day of IL-2 after co- stimulation with anti-CD3/anti-CD28 beads at a bead:T cell ratio of 3 : 1. 56. A population of TREG or TREG/Th2 cells that expresses less than 100 pg/mL/1 x 10⁶ cells/day of IFN-g or GM-CSF after co-stimulation with anti-CD3/anti-CD28 beads at a bead:T cell ratio of 3:1.

57. A population of TREG or TREG/Th2 cells that expresses less than 100 pg/mL/1 x 10⁶ cells/day of TNF-a or IL-17F after co- stimulation with anti-CD3/anti-CD28 beads at a bead:T cell ratio of 3:1.

58. A population of TREG or TREG/Th2 cells having one or more of the following properties: at least 10% increased expression of one or more of: CD25, CD27, 2B4, BTLA, CTLA4, TIGIT, TIM3, ICOS, LAIR1, 0X040, and combinations thereof, as measured by flow cytometry relative to control Thl/Tcl cells; at least 10% decreased secretion of IFN-g relative to control Thl/Tcl cells; at least 10% decreased secretion of TNF-a relative to control Thl/Tcl cells; at least 10% decreased expression of TBET relative to control Thl/Tcl cells; at least 10% increased expression of FOXP3 relative to control Thl/Tcl cells; at least 5% of CD4⁺ or CD8⁺ T cells that express GATA3 as measured by flow cytometry; at least 5% of CD4⁺ or CD8⁺ T cells that express FOXP3 as measured by flow cytometry; at least 5% of CD4⁺ or CD8⁺ T cells that express CD73 as measured by flow cytometry; at least 5% of CD4⁺ or CD8⁺ T cells that express CD103 as measured by flow cytometry; at least 5% of CD4⁺ or CD8⁺ cells that express both FOXP3 and GATA3 as measured by flow cytometry; at least 20% of CD4⁺ or CD8⁺ T cells that express CD150 as measured by flow cytometry; at least a 50% increase in expression of one or more of: GATA3, FoxP3, CD73, CD103, and CD 150 relative to a population of T cells characteristic of the T cells from which the population of TREG or TREG/T1I2 cells was produced; secretion of at least 5 pg/mL/1 x 10⁶ cells/day of IL-4 after co- stimulation with anti- CD3/anti-CD28 beads at a bead:T cell ratio of 3:1; secretion of at least 100 pg/mL/1 x 10⁶ cells/day of IL-2 after co- stimulation with anti- CD3/anti-CD28 beads at a bead:T cell ratio of 3:1; secretion of less than 100 pg/mL/1 x 10⁶ cells/day of IFN-g after co-stimulation with anti- CD3/anti-CD28 beads at a bead:T cell ratio of 3:1; secretion of less than 100 pg/mL/1 x 10⁶ cells/day of GM-CSF after co-stimulation with anti-CD3/anti-CD28 beads at a bead:T cell ratio of 3:1; secretion of less than 10 pg/mL/1 x 10⁶ cells/day of TNF-a after co-stimulation with anti- CD3/anti-CD28 beads at a bead:T cell ratio of 3:1; secretion of less than 10 pg/mL/1 x 10⁶ cells/day of IL-17 after co- stimulation with anti- CD3/anti-CD28 beads at a bead:T cell ratio of 3:1; and combinations thereof.

59. A TREG or TREG/Th2 cell having one or more of the following properties: at least 10% increased expression of one or more of: CD25, CD27, 2B4, BTLA, CTLA4, TIGIT, TIM3, ICOS, LAIR1, 0X040, and combinations thereof, as measured by flow cytometry relative to control Thl/Tcl cells; at least 10% decreased secretion of IFN-g relative to control Thl/Tcl cells; at least 10% decreased secretion of TNF-a relative to control Thl/Tcl cells; at least 10% decreased expression of TBET relative to control Thl/Tcl cells; at least 10% increased expression of FOXP3 relative to control Thl/Tcl cells; secretion of at least 5 pg/mL/1 x 10⁶ cells/day of IL-4 after co- stimulation with anti- CD3/anti-CD28 beads at a bead:T cell ratio of 3:1; secretion of at least 100 pg/mL/1 x 10⁶ cells/day of IL-2 after co- stimulation with anti- CD3/anti-CD28 beads at a bead:T cell ratio of 3:1; secretion of less than 100 pg/mL/1 x 10⁶ cells/day of IFN-g after co-stimulation with anti- CD3/anti-CD28 beads at a bead:T cell ratio of 3:1; secretion of less than 100 pg/mF/1 x 10⁶ cells/day of GM-CSF after co-stimulation with anti-CD3/anti-CD28 beads at a bead:T cell ratio of 3:1; secretion of less than 10 pg/mF/1 x 10⁶ cells/day of TNF-a after co-stimulation with anti- CD3/anti-CD28 beads at a bead:T cell ratio of 3:1; secretion of less than 10 pg/mF/1 x 10⁶ cells/day of IF- 17 after co- stimulation with anti- CD3/anti-CD28 beads at a bead:T cell ratio of 3:1; expression of GATA3, FOXP3, CD73 and CD103; and combinations thereof.

60. The method of any one of claims 1-41, wherein the de-differentiated T cells have one or more of the following properties: at least a 10% decrease, and more preferably, a 50% decrease in mRNA expression of one or more of granzyme B, IF- 10, and IFN-g relative to a control T cell population incubated under the same conditions without temsirolimus, vitamin D and the IF-2 signaling inhibitor; at least a 10% increase, and more preferably, a 50% increase in mRNA expression of one or more of Nanog, KFF4, KFF10 and CD 127 relative to a control T cell population incubated under the same conditions without temsirolimus, vitamin D and the IF-2 signaling inhibitor; at least a 10% decrease, and more preferably a 50% decrease in mRNA expression of one or more of T-Bet and STAT1 relative to a control T cell population incubated under the same conditions without temsirolimus, vitamin D and the IL-2 signaling inhibitor;

61. The method of any one of claims 1-41, wherein the de-differentiated T cells have one or more of the following properties: at least a 10% decrease, and more preferably, a 50% decrease in mRNA expression of one or more of granzyme B, IL-10, and IFN-g relative to a control T cell incubated under the same conditions without temsirolimus, vitamin D and the IL-2 signaling inhibitor; at least a 10% increase, and more preferably, a 50% increase in mRNA expression of one or more of Nanog, KLF4, KLF10 and CD 127 relative to relative to a control T cell incubated under the same conditions without temsirolimus, vitamin D and the IL-2 signaling inhibitor; at least a 10% decrease, and more preferably a 50% decrease in mRNA expression of one or more of T-Bet and STAT1 relative to a control T cell incubated under the same conditions without temsirolimus, vitamin D and the IL-2 signaling inhibitor;

Claims

What is claimed is:

1. A method for treating or preventing a pro -inflammatory disease or condition in a subject in need thereof, comprising: subjecting said subject to one or more primary treatment cycles, each of said one or more primary treatment cycles comprising: administering to said subject pentostatin; and/or administering to said subject cyclophosphamide; and subjecting said subject to one or more immune therapy treatment cycles comprising: administering to said subject a composition comprising a therapeutically effective amount of manufactured TREG cells.

2. The method of claim 1, wherein each of said one or more immune therapy treatment cycles further comprise administering to said subject a nucleoside reverse transcriptase inhibitor.

3. The method of claim 2, wherein said nucleoside reverse transcriptase inhibitor is an inhibitor of the NLRP3 inflammasome.

4. The method of claim 2, wherein said nucleoside reverse transcriptase inhibitor is lamivudine.

5. The method of claim 1, wherein each of said one or more primary treatment cycles is between 2 weeks and 5 weeks long.

6. The method of any one of claims 1-5, wherein each of said one or more immune therapy treatment cycles further comprise: administering to said subject pentostatin; and/or administering to said subject cyclophosphamide. 7. The method of claim 2, wherein each of said one or more immune therapy treatment cycles is 18 weeks long.

8. The method of claim 1, wherein pentostatin is administered to said subject at a dose of between 0.5 mg/m² and 4 mg/m².

9. The method of claim 1, wherein said pentostatin is administered on day 1 or days 1 and 4 of each of said one or more primary treatment cycles.

10. The method of claim 1, wherein a dose of said cyclophosphamide is between 50 mg and 400 mg.

11. The method of claim 1, wherein said cyclophosphamide is administered on days 1, 2 and 3 or days 1, 2, 3, 4, and 5 of each of said one or more primary treatment cycles.

12. The method of claim 1, wherein said method comprises two or more primary treatment cycles, wherein each of said two or more primary treatment cycles is separated by 0 to 2 weeks.

13. The method of claim 2, wherein a first of said one or more immune therapy treatment cycles and a last of said one or more primary treatment cycles are separated by 0 to 2 weeks.

14. The method of claim 4, wherein said lamivudine is administered to said subject at a dose between 150 mg daily and 150 mg twice daily.

15. The method of claim 1, wherein said pentostatin and cyclophosphamide are administered to said subject in a single composition.

16. The method of claim 1, wherein said steps of administering to said subject pentostatin and cyclophosphamide comprise: administering to said subject a first composition comprising pentostatin; and administering to said subject a second composition comprising cyclophosphamide.

17. The method of claim 14, wherein said single composition is administered to said subject intravenously. 18. The method of claim 6, wherein said step of administering to said subject pentostatin during each of said one or more immune therapy treatment cycles is performed on days 1 and 4 of each of said one or more immune therapy treatment cycles.

19. The method of claim 6 or claim 18, wherein said step of administering to said subject pentostatin during each of said one or more immune therapy treatment cycles is performed on days 1, 2, 3, 4 and 5 of each of said one or more immune therapy treatment cycles.

20. The method of any one of claims 6 and 18-19, wherein pentostatin is administered to said subject at a dose of between 1 mg/m² and 2 mg/m² during each of said one or more immune therapy treatment cycles.

21. The method of claim 20, wherein pentostatin is administered to said subject at a dose of 2 mg/m² during each of said one or more immune therapy treatment cycles.

22. The method of any one of claims 6 and 18-21, wherein cyclophosphamide is administered to said subject at a dose of between 100 mg and 200 mg during each of said one or more immune therapy treatment cycles.

23. The method of claim 22, wherein cyclophosphamide is administered to said subject at a dose of 100 mg.

24. The method of any one of claims 1-23, wherein said manufactured TREG cells are administered to said subject on day 8 of each of said one or more immune therapy treatment cycles.

25. The method of any one of claims 1-24, wherein said method comprises two or more immune therapy treatment cycles and each of said two or more immune therapy treatment cycles are separated by 0 to 4 weeks.

26. The method of any one of claims 1-24, wherein said method comprises two or more immune therapy treatment cycles and each of said two or more immune therapy treatment cycles are separated by at least 4 weeks. 27. The method of any one of claims 1-26, wherein said manufactured TREG cells are administered to said subject during each of said one or more immune therapy treatment cycles at a dose between 1 x 10⁶ cells per kg of the subject’s body weight and 5 x 10⁶ cells per kg of the subject’s body weight or at a flat dose of 40 x 10⁶ cells or 160 x 10⁶ cells.

28. The method of any one of claims 1-27, wherein said manufactured TREG cells comprise a ratio of central memory to effector memory cells selected from 1:1, 3:1, 10:1, 1:3 and 1:10.

29. The method of any one of claims 1-28, wherein said composition comprising manufactured TREG cells further comprises natural thymus -derived TREG cells.

30. The method of any one of claims 1-29, further comprising, prior to said one or more primary treatment cycles: harvesting peripheral lymphocytes from said subject.

31. The method of claim 30, further comprising, after harvesting peripheral lymphocytes from said subject: culturing said peripheral lymphocytes to yield said manufactured TREG cells.

32. The method of any one of claims 1-31, further comprising, after said one or more primary treatment cycles: harvesting peripheral lymphocytes from said subject.

33. The method of claim 32, further comprising, after harvesting peripheral lymphocytes from said subject after said one or more primary treatment cycles: culturing said peripheral lymphocytes to yield said manufactured TREG cells.

34. The method of any one of claims 1-33, further comprising, after each of said one or more primary treatment cycles: measuring absolute lymphocyte count (ALC) in said subject and, if ALC < 750 per pi proceeding to said one or more immune therapy treatment cycles. 35. A method for treating or preventing a pro -inflammatory disease or condition in a subject in need thereof, comprising: a first treatment cycle, a second treatment cycle, optionally, one or more additional treatment cycles, and one or more immune therapy treatment cycles, said first treatment cycle comprising: administering pentostatin to said subject, and/or administering cyclophosphamide to said subject; said second treatment cycle comprising: administering pentostatin to said subject, and/or administering cyclophosphamide to said subject; each of said one or more additional treatment cycles comprising: administering pentostatin to said subject, and/or administering cyclophosphamide to said subject each of said one or more immune therapy treatment cycles comprising: administering pentostatin to said subject, and/or administering cyclophosphamide to said subject, and administering manufactured TREG cells to said subject.

36. The method of claim 35, wherein said step of administering pentostatin to said subject is performed on day 1 of said first treatment cycle.

37. The method of claim 36, wherein pentostatin is administered to said subject at a dose of 1 mg/m² during said first treatment cycle. 38. The method of any one of claims 35-37, wherein said step of administering cyclophosphamide to said subject is repeated during said first treatment cycle.

39. The method of claim 38, wherein said step of administering cyclophosphamide to said subject is performed on days 1, 2, and 3 of said first treatment cycle.

40. The method of any one of claims 35-39, wherein cyclophosphamide is administered to said subject at a dose of 100 mg during said first treatment cycle.

41. The method of claim 35, wherein said first treatment cycle is 14 days long.

42. The method of claim 35, wherein said second treatment cycle is 14 days long.

43. The method of claim 35, wherein each of said one or more additional treatment cycles are each 14 days long.

44. The method of claim 35, wherein said first treatment cycle, said second treatment cycle and each of said one or more additional treatment cycles are separated by 0 to 2 weeks.

45. The method of claim 35, further comprising prior to administering pentostatin to said subject in said first treatment cycle: measuring the creatinine clearance (CrCl) of said subject and adjusting a dose of pentostatin to be administered to said subject based on the CrCl, wherein pentostatin is administered at 1 mg/m² when CrCl > 60 mL/min/1.73 m², wherein pentostatin is administered at 0.5 mg/m² when 60 mL/min/1.73 m² > CrCl > 30 mL/min/1.73 m², and wherein pentostatin is not administered when CrCl < 30 mL/min/1.73 m².

46. The method of claim 35, further comprising prior to administering cyclophosphamide to said subject in said first treatment cycle: measuring absolute neutrophil count (ANC) and adjusting a dose of cyclophosphamide to be administered to said subject based on the ALC and ANC, wherein cyclophosphamide is administered at a dose of 100 mg when ANC > 1000, wherein cyclophosphamide is administered at a dose of 50 mg when ANC is 500-999, and wherein cyclophosphamide is not administered when ANC < 500.

47. The method of any one of claims 35-46, wherein said step of administering pentostatin to said subject during said second treatment cycle is performed on day 1 of said second treatment cycle.

48. The method of claim 35, wherein pentostatin is administered to said subject at a dose of 2 mg/m² during said second treatment cycle.

49. The method of any one of claims 35-48, wherein said step of administering cyclophosphamide to said subject during said second treatment cycle is repeated during said second treatment cycle.

50. The method of claim 49, wherein said step of administering cyclophosphamide to said subject during said second treatment cycle is performed on days 1, 2, and/or 3 of said second treatment cycle.

51. The method of any one of claims 35-40, wherein cyclophosphamide is administered to said subject at a dose of 100 mg during said second treatment cycle.

52. The method of claim 35, further comprising prior to administering pentostatin to said subject during said second treatment cycle: measuring the creatinine clearance (CrCl) of said subject and adjusting a dose of pentostatin to be administered to said subject based on the CrCl, wherein pentostatin is administered at 2 mg/m² when CrCl > 60 mL/min/1.73 m², wherein pentostatin is administered at 1 mg/m² when 60 mL/min/1.73 m² > CrCl > 30 mL/min/1.73 m², and wherein pentostatin is not administered when CrCl < 30 mL/min/1.73 m².

53. The method of claim 35, further comprising prior to administering cyclophosphamide to said subject during said second treatment cycle: measuring absolute neutrophil count (ANC) and adjusting a dose of cyclophosphamide to be administered to said subject based on the ANC, wherein cyclophosphamide is administered at a dose of 100 mg when ANC > 1000, wherein cyclophosphamide is administered at a dose of 50 mg when ANC is 500-999, and wherein cyclophosphamide is not administered when ANC <

500.

54. The method of claim 35, further comprising, prior to each of said one or more additional treatment cycles: measuring absolute lymphocyte count (ALC) in said subject and adjusting the treatment of said subject based on the ALC, wherein if ALC < 750, administering to said subject a maintenance treatment cycle comprising subjecting said patient to said one or more immune therapy treatment cycles, and wherein if ALC > 750 subjecting patient to said one or more additional treatment cycles.

55. The method of claim 54, wherein each of said one or more immune therapy treatment cycles are 18 weeks long.

56. The method of claim 54, wherein ALC < 750, and wherein said manufactured TREG cells are administered to said subject a dose between 1 x 10⁶ cells per kg of the subject’s body weight and 5 x 10⁶ cells per kg of the subject’s body weight during each of said one or more immune therapy cycles or at a flat dose of 40 x 10⁶ cells or 160 x 10⁶ cells.

57. The method of claim 56, wherein said manufactured TREG cells are administered to said subject on day 8 of each of said one or more immune therapy treatment cycles.

58. The method of claim 35, wherein pentostatin is administered to said subject on days 1 and 4 of each of said one or more immune therapy treatment cycles at a dose of 2 mg/m².

59. The method of claim 35, wherein cyclophosphamide is administered to said subject on days 1, 2, 3, 4, and/or 5 of each of said one or more immune therapy treatment cycles at a dose of 100 mg. 60. The method of any one of claims 35-53, wherein each of said one or more immune therapy treatment cycles further comprises: administering to said subject a nucleoside reverse transcriptase inhibitor.

61. The method of claim 60, wherein said nucleoside reverse transcriptase inhibitor is lamivudine.

62. The method of claim 61, wherein said lamivudine is administered to said subject during each of said one or more immune therapy treatment cycles at a dose of 150 mg daily to 150 mg twice daily.

63. The method of any one of claims 35-62, wherein said subject is subjected to said one or more additional treatment cycles.

64. The method of claim 63, wherein said step of administering pentostatin to said subject during each of said one or more additional treatment cycles is performed on days 1 and/or 4 of said one or more additional treatment cycles.

65. The method of claim 64, wherein pentostatin is administered to said subject at a dose of 2 mg/m² during each of said one or more additional treatment cycles.

66. The method of any one of claims 63-65, wherein said step of administering cyclophosphamide to said subject is repeated during each of said one or more additional treatment cycles.

67. The method of claim 66, wherein said step of administering cyclophosphamide to said subject during each of said one or more additional treatment cycles is performed on days 1, 2, 3, 4 and/or 5 of each of said one or more additional treatment cycles.

68. The method of any one of claims 63-67, wherein cyclophosphamide is administered to said subject at a dose of 100 mg to 200 mg during each of said one or more additional treatment cycles. 69. The method of claim 63, further comprising prior to administering pentostatin to said subject during each of said one or more additional treatment cycles: measuring the creatinine clearance (CrCl) of said subject and adjusting a dose of pentostatin to be administered to said subject based on the CrCl, wherein pentostatin is administered at 2 mg/m² when CrCl > 60 mL/min/1.73 m², wherein pentostatin is administered at 1 mg/m² when 60 mL/min/1.73 m² > CrCl > 30 mL/min/1.73 m², and wherein pentostatin is not administered when CrCl < 30 mL/min/1.73 m².

70. The method of claim 63, further comprising prior to administering cyclophosphamide to said subject during each of said one or more additional treatment cycles: measuring absolute neutrophil count (ANC) and adjusting a dose of cyclophosphamide to be administered to said subject based on ANC, wherein cyclophosphamide is administered at a dose of 100 mg when ANC > 1000, wherein cyclophosphamide is administered at a dose of 50 mg when ANC is 500-999, and wherein cyclophosphamide is not administered when ALC < 50 or ANC < 500.

71. The method of claim 63, wherein said one or more additional treatment cycles comprise at least two additional treatment cycles, a final of said at least two additional treatment cycles comprising prior to administering cyclophosphamide to said subject during said final of said at least two treatment cycles: measuring absolute lymphocyte count (ALC) and absolute neutrophil count (ANC) and adjusting a dose of cyclophosphamide to be administered to said subject based on the ALC and ANC, wherein cyclophosphamide is administered at a dose of 200 mg when ALC > 1250, wherein cyclophosphamide is administered at a dose of 100 mg when ANC > 1000 and 750 < ALC < 1250, wherein cyclophosphamide is administered at a dose of 50 mg when ANC is 500- 999, and wherein cyclophosphamide is not administered when ANC < 500 and/or ALC < 750.

72. The method of claim 63, wherein each of said one or more additional treatment cycles are separated by 0 to 2 weeks. 73. The method of claim 63, further comprising, prior to each of said one or more additional treatment cycles: measuring absolute lymphocyte count (ALC) in said subject and adjusting the treatment of said subject based on the ALC, wherein if ALC <_750, administering to said subject a maintenance treatment cycle comprising administering to said subject a nucleoside reverse transcriptase inhibitor and no further of said one or more additional treatment cycles prior to said maintenance treatment cycle, and wherein if ALC > 750 continuing to subject patient to said one or more additional treatment cycles.

74. The method of claim 73, wherein each of said one or more immune therapy treatment cycles is 4 weeks long.

75. The method of any one of claims 60-61, further comprising during each of said one or more immune therapy treatment cycles: measuring the creatinine clearance (CrCl) of said subject and adjusting a dose of lamivudine to be administered to said subject based on the CrCl, wherein lamivudine is administered at 150 mg twice daily when CrCl > 50 mL/min/1.73 m², wherein lamivudine is administered at 150 mg daily when 50 mL/min > CrCl > 30 mL/min/1.73 m², and wherein lamivudine is not administered when CrCl < 30 mL/min/1.73 m².

76. A method for treating or preventing a pro -inflammatory disease or condition in a subject in need thereof, comprising: one or more treatment cycles comprising: administering to said subject a therapeutically effective amount of manufactured TREG cells.

77. The method of claim 76, wherein said manufactured TREG cells are administered at a dose of 1 x 10⁶ cells per kg of the subject’s body weight and 5 x 10⁶ cells per kg of the subject’s body weight or at a flat dose of 40 x 10⁶ cells or 160 x 10⁶ cells. 78. The method of claim 76, wherein said manufactured TREG cells comprise a ratio of central memory to effector memory cells selected from 1:1, 3:1, 10:1, 1:3 and 1:10.

79. The method of claim 76, wherein each of said one or more treatment cycles further comprise: administering to said subject pentostatin; and/or administering to said subject cyclophosphamide.

80. The method of claim 79, wherein pentostatin is administered to said subject at a dose of between 1 mg/m² and 2 mg/m².

81. The method of claim 79, wherein a dose of said cyclophosphamide is between 100 mg and 200 mg.

82. The method of claim 79, wherein said pentostatin is administered to said subject on days 1 and 4 of each of said one or more treatment cycles.

83. The method of claim 79, wherein said cyclophosphamide is administered to said subject on days 1, 2, 3, 4 and/or 5 of each of said one or more treatment cycles.

84. The method of claim 79, wherein said subject was previously treated with pentostatin and cyclopho sphamide .

85. The method of any one of claims 76-84, wherein each of said one or more treatment cycles further comprises administering to said subject a nucleoside reverse transcriptase inhibitor.

86. The method of claim 85, wherein said nucleoside reverse transcriptase inhibitor is an inhibitor of the NLRP3 inflammasome.

87. The method of claim 86, wherein said nucleoside reverse transcriptase inhibitor is lamivudine. 88. The method of claim 87, wherein said lamivudine is administered to said subject at a dose between 150 mg daily and 150 mg twice daily.

89. The method of any one of claims 76-88, further comprising administering to said subject normal TREG cells simultaneously with said manufactured TREG cells.

90. The method of any one of claims 76-89, wherein each of said one or more treatment cycles is 4 weeks apart.

91. The method of any one of claims 76-90, further comprising, prior to said one or more treatment cycles: harvesting peripheral lymphocytes from said subject.

92. The method of claim 91, further comprising, after harvesting peripheral lymphocytes from said subject: culturing said peripheral lymphocytes to yield said manufactured TREG cells.

93. A method for treating or preventing a pro -inflammatory disease or condition in a subject in need thereof, comprising: administering to said subject a therapeutically effective amount of manufactured TREG cells.

94. The method of claim 93, wherein said manufactured TREG cells are administered at a dose of 1 x 10⁶ cells per kg of the subject’s body weight and 5 x 10⁶ cells per kg of the subject’s body weight or at a flat dose of 40 x 10⁶ cells or 160 x 10⁶ cells.

95. The method of claim 93, wherein said manufactured TREG cells comprise a ratio of central memory to effector memory cells selected from 1: 1, 3:1, 10:1, 1:3 and 1:10.

96. The method of claim 93, further comprising, prior to administering said manufactured TREG cells to said subject: administering to said subject pentostatin; and/or administering to said subject cyclophosphamide.

97. The method of claim 96, wherein pentostatin is administered to said subject at a dose of between 0.5 mg/m² and 4 mg/m².

98. The method of claim 96, wherein a dose of said cyclophosphamide is between 50 mg and 400 mg.

99. The method of claim 93, wherein said subject was previously treated with pentostatin and cyclophosphamide.

100. The method of any one of claims 93-99, further comprising administering to said subject a nucleoside reverse transcriptase inhibitor.

101. The method of claim 100, wherein said nucleoside reverse transcriptase inhibitor is an inhibitor of the NLRP3 inflammasome.

102. The method of claim 101, wherein said nucleoside reverse transcriptase inhibitor is lamivudine.

103. The method of claim 102, wherein said lamivudine is administered to said subject at a dose between 150 mg daily and 150 mg twice daily.

104. The method of any one of claims 93-103, further comprising administering to said subject normal TREG cells simultaneously with said manufactured TREG cells.

105. The method of any one of claims 93-95, further comprising, prior to administering said manufactured TREG cells to said subject: harvesting peripheral lymphocytes from said subject; and culturing said peripheral lymphocytes to yield said manufactured TREG cells.

106. The method of any one of claims 1-105, further comprising administering to said subject an anti-TNF-a therapy. 107. A method for differentiating de-differentiated T cells to T_REG/T1L2 cells, comprising: culturing de-differentiated T cells in a culture medium comprising IL-2, IL-4 and TGF-b; adding anti-CD3/anti-CD28 coated magnetic beads at a ratio of 3:1 (bead:T cell ratio); incubating said de-differentiated T cells for a period of time to yield T_REG/T1L2 cells.

108. The method of claim 107, wherein said culture medium further comprises pemetrexed.

109. The method of any one of claims 107-108, wherein said IL-2 is present in said culture medium at a concentration of about 100 IU/mL.

110. The method of any one of claims 107-109, wherein said IL-4 is present in said culture medium at a concentration of about 1000 IU/mL.

111. The method of any one of claims 107-110, wherein said TGF-b is present in said culture medium at a concentration of about 10 ng/mL.

112. The method of claim 108, wherein said pemetrexed is present in said culture medium at a concentration of up to 100 nM.

113. The method of claim 108, wherein said pemetrexed is present in said culture medium at a concentration of about 10 nM.

114. The method of any one of claims 112-113, wherein said IL-2 is present in said culture medium at a concentration of about 100 IU/mL.

115. The method of any one of claims 112-114, wherein said IL-4 is present in said culture medium at a concentration of about 1000 IU/mL.

116. The method of any one of claims 112-115, wherein said TGF-b is present in said culture medium at a concentration of about 10 ng/mL.

117. A method for differentiating de-differentiated T cells to T_REG/T1L2 cells, comprising: culturing de-differentiated T cells, wherein said de-differentiated T cells express RAPTOR and RICTOR at a level that is at least 10% reduced relative to control T cells in a culture medium comprising IL-2, IL-4 and TGF-b; adding anti-CD3/anti-CD28 coated magnetic beads at a ratio of 3:1 (bead:T cell ratio); incubating said de-differentiated T cells for a period of time to yield T_REG/T1I2 cells.

118. The method of claim 117, wherein said culture medium further comprises pemetrexed.

119. The method of any one of claims 117-118, wherein said IL-2 is present in said culture medium at a concentration of about 100 IU/mL.

120. The method of any one of claims 117-119, wherein said IL-4 is present in said culture medium at a concentration of about 1000 IU/mL.

121. The method of any one of claims 117-120, wherein said TGF-b is present in said culture medium at a concentration of about 10 ng/mL.

122. The method of claim 118, wherein said pemetrexed is present in said culture medium at a concentration of up to 100 nM.

123. The method of claim 118, wherein said pemetrexed is present in said culture medium at a concentration of about 10 nM.

124. The method of any one of claims 122-123, wherein said IL-2 is present in said culture medium at a concentration of about 100 IU/mL.

125. The method of any one of claims 122-124, wherein said IL-4 is present in said culture medium at a concentration of about 1000 IU/mL.

126. The method of any one of claims 122-125, wherein said TGF-b is present in said culture medium at a concentration of about 10 ng/mL.

127. The method of any one of claims 107-126, wherein said culture medium is X-Vivo 20 supplemented with 5% human AB serum. 128. The method of any one of claims 107-127, wherein said period of time is between 3 days and 40 days.

129. A T_REG/T1L2 cell produced by the method of any one of claims 107-128.

130. A method for differentiating de-differentiated T cells to TREG cells, comprising: culturing de-differentiated T cells having reduced expression of RAPTOR and RICTOR relative to a control population of T cells in a culture medium comprising IL-2 and TGF-b; adding anti-CD3/anti-CD28 coated magnetic beads at a ratio of 3:1 (bead:T cell ratio); incubating said de-differentiated T cells for a period of time to yield TREG cells.

131. The method of claim 130, wherein said culture medium further comprises pemetrexed.

132. The method of any one of claims 130-131, wherein said IL-2 is present in said culture medium at a concentration of about 100 IU/mL.

133. The method of any one of claims 130-132, wherein said TGF-b is present in said culture medium at a concentration of about 10 ng/mL.

134. The method of claim 131, wherein said pemetrexed is present in said culture medium at a concentration of up to 100 nM.

135. The method of claim 131, wherein said pemetrexed is present in said culture medium at a concentration of about 10 nM.

136. The method of any one of claims 134-135, wherein said IL-2 is present in said culture medium at a concentration of about 100 IU/mL.

137. The method of any one of claims 134-136, wherein said TGF-b is present in said culture medium at a concentration of about 10 ng/mL.

138. A method for differentiating de-differentiated T cells to TREG cells, comprising: culturing de-differentiated T cells, wherein said de-differentiated T cells express RAPTOR and RICTOR at a level that is at least 10% reduced relative to control T cells in a culture medium comprising IL-2 and TGF-b; adding anti-CD3/anti-CD28 coated magnetic beads at a ratio of 3:1 (bead:T cell ratio); incubating said de-differentiated T cells for a period of time to yield TREG cells.

139. The method of claim 138, wherein said culture medium further comprises pemetrexed.

140. The method of any one of claims 138-139, wherein said IL-2 is present in said culture medium at a concentration of about 100 IU/mL.

141. The method of any one of claims 138-140, wherein said TGF-b is present in said culture medium at a concentration of about 10 ng/mL.

142. The method of claim 139, wherein said pemetrexed is present in said culture medium at a concentration of up to 100 nM.

143. The method of claim 139, wherein said pemetrexed is present in said culture medium at a concentration of about 10 nM.

144. The method of any one of claims 142-143, wherein said IL-2 is present in said culture medium at a concentration of about 100 IU/mL.

145. The method of any one of claims 142-144, wherein said TGF-b is present in said culture medium at a concentration of about 10 ng/mL.

146. The method of any one of claims 130-145, wherein said culture medium is X-Vivo 20 media supplemented with 5% AB serum.

147. The method of any one of claims 130-146, wherein said period of time is between 3 days and 40 days.

148. The method of any one of claims 107-147, wherein said de-differentiated T cells have a reduced expression of RAPTOR and RICTOR relative to a control population of T cells 149. A TREG cell produced by the method of any one of claims 107-128 and 130-148.

150. A T_REG cell or hybrid T_REG/T1L2 cell produced by the method of any one of claims 107- 128 and 130-148, wherein lymphocytes collected by apheresis for subsequent T cell culture are obtained in the steady-state or after subject treatment with an anti-TNF-oc therapeutic that is relatively selective in terms of neutralizing the serum, cell-free form of TNF-oc, most notably the recombinant receptor molecule etanercept or the monoclonal antibody adalimumab.

151. A T_REG cell or hybrid T_REG/T1L2 cell produced by the method of any one of claims 107- 128 and 130-148, wherein the T_REG cell or hybrid T_REG/T1L2 cell or a population therof has increased expression by flow cytometry of at least one the following molecules relative to control Thl/Tcl cells: CD25, CD27, 2B4, BTLA, CTLA4, TIGIT, TIM3, ICOS, LAIR1, 0X40, and combinations thereof.

152. A T_REG cell or hybrid T_REG/T1L2 cell produced by the method of any one of claims 107- 128 and 130-148, wherein the T_REG cell or hybrid T_REG/T1L2 cell or a population thereof has reduced secretion of inflammatory cytokines relative to control Thl/Tcl cells, including IFN-g and TNF-oc.

153. A T_REG cell or hybrid T_REG/T1L2 cell produced by the method of any one of claims 107- 128 and 130-148, wherein said T_REG cell or hybrid T_REG/T1L2 cell or a population thereof has altered expression of T cell fate transcription factors relative to control Thl/Tcl cells, most notably a decrease in TBET and an increase in FOXP3.

154. A T_REG cell or hybrid T_REG/T1L2 cell produced by the method of any one of claims 107- 128 and 130-148, wherein said T_REG cell or hybrid T_REG/T1L2 cell or a population thereof has additional phenotypic traits relative to control Thl/Tcl cells, including: increased secretion of the Th2 cytokine IL-4; and increased expression of the Th2 transcription factor GAT A3.

155. A population of T_REG or T_REG/T1L2 cells having at least 5% of CD4⁺ or CD8⁺ T cells that express GAT A3. 156. A population of TREG or TREG/T1I2 cells having at least 5% of CD4+ or CD8+ T cells that express FoxP3

157. A population of T_REG or T_REG/T1I2 cells having at least 10% of CD4+ or CD8+ T cells that express CD73.

158. A population of T_REG or T_REG/T1I2 cells having at least 10% of CD4+ or CD8+ T cells that express CD 103.

159. A population of T_REG or T_REG/T1I2 cells having at least 20% of CD4+ or CD8+ T cells that express CD 150.

160. A population of T_REG or T_REG/T1I2 cells that expresses at least 5 pg/mL of IL-4 after co stimulation with anti-CD3/anti-CD28 beads at a bead:T cell ratio of 3:1.

161. A population of T_REG or T_REG/T1I2 cells that expresses at least 100 pg/mL of IL-2 after co stimulation with anti-CD3/anti-CD28 beads at a bead:T cell ratio of 3:1.

162. A population of T_REG or T_REG/T1I2 cells that expresses less than 100 pg/mL of IFN-g or GM-CSF after co- stimulation with anti-CD3/anti-CD28 beads at a bead:T cell ratio of 3:1.

163. A population of T_REG or T_REG/T1I2 cells that expresses less than 100 pg/mL of TNF-a or IL-17F after co-stimulation with anti-CD3/anti-CD28 beads at a bead:T cell ratio of 3:1.

164. A population of TREG or TREG/Th2 cells having one or more of the following properties: at least 10% increased expression of one or more of: CD25, CD27, 2B4, BTLA, CTLA4, TIGIT, TIM3, ICOS, LAIR1, 0X040, and combinations thereof, as measured by flow cytometry relative to control Thl/Tcl cells; at least 10% decreased secretion of IFN-g relative to control Thl/Tcl cells; at least 10% decreased secretion of TNF-a relative to control Thl/Tcl cells; at least 10% decreased expression of TBET relative to control Thl/Tcl cells; at least 10% increased expression of FOXP3 relative to control Thl/Tcl cells; at least 5% of CD4⁺ or CD8⁺ T cells that express GATA3 as measured by flow cytometry; at least 5% of CD4⁺ or CD8⁺ T cells that express FOXP3 as measured by flow cytometry; at least 5% of CD4⁺ or CD8⁺ T cells that express CD73 as measured by flow cytometry; at least 5% of CD4⁺ or CD8⁺ T cells that express CD103 as measured by flow cytometry; at least 5% of CD4⁺ or CD8⁺ cells that express both FOXP3 and GATA3 as measured by flow cytometry; at least 20% of CD4⁺ or CD8⁺ T cells that express CD150 as measured by flow cytometry; at least a 50% increase in expression of one or more of: GATA3, FoxP3, CD73, CD103, and CD 150 relative to a population of T cells characteristic of the T cells from which the population of TREG or TREG/T1I2 cells was produced; secretion of at least 5 pg/mL/1 x 10⁶ cells/day of IL-4 after co- stimulation with anti- CD3/anti-CD28 beads at a bead:T cell ratio of 3:1; secretion of at least 100 pg/mL/1 x 10⁶ cells/day of IL-2 after co- stimulation with anti- CD3/anti-CD28 beads at a bead:T cell ratio of 3:1; secretion of less than 100 pg/mL/1 x 10⁶ cells/day of IFN-g after co-stimulation with anti- CD3/anti-CD28 beads at a bead:T cell ratio of 3:1; secretion of less than 100 pg/mL/1 x 10⁶ cells/day of GM-CSF after co-stimulation with anti-CD3/anti-CD28 beads at a bead:T cell ratio of 3:1; secretion of less than 10 pg/mL/1 x 10⁶ cells/day of TNF-a after co-stimulation with anti- CD3/anti-CD28 beads at a bead:T cell ratio of 3:1; secretion of less than 10 pg/mL/1 x 10⁶ cells/day of IL-17 after co- stimulation with anti- CD3/anti-CD28 beads at a bead:T cell ratio of 3:1; and combinations thereof.

165. A TREG or TREG/Th2 cell having one or more of the following properties: at least 10% increased expression of one or more of: CD25, CD27, 2B4, BTLA, CTLA4, TIGIT, TIM3, ICOS, LAIR1, 0X040, and combinations thereof, as measured by flow cytometry relative to control Thl/Tcl cells; at least 10% decreased secretion of IFN-g relative to control Thl/Tcl cells; at least 10% decreased secretion of TNF-a relative to control Thl/Tcl cells; at least 10% decreased expression of TBET relative to control Thl/Tcl cells; at least 10% increased expression of FOXP3 relative to control Thl/Tcl cells; at least 5% of CD4⁺ or CD8⁺ T cells that express GATA3 as measured by flow cytometry; at least 5% of CD4⁺ or CD8⁺ T cells that express FOXP3 as measured by flow cytometry; at least 5% of CD4⁺ or CD8⁺ T cells that express CD73 as measured by flow cytometry; at least 5% of CD4⁺ or CD8⁺ T cells that express CD103 as measured by flow cytometry; at least 5% of CD4⁺ or CD8⁺ cells that express both FOXP3 and GATA3 as measured by flow cytometry; at least 20% of CD4⁺ or CD8⁺ T cells that express CD150 as measured by flow cytometry; expression of at least 5 pg/mL/1 x 10⁶ cells/day of IL-4 after co-stimulation with anti- CD3/anti-CD28 beads at a bead:T cell ratio of 3:1; expression of at least 100 pg/mL/1 x 10⁶ cells/day of IL-2 after co- stimulation with anti- CD3/anti-CD28 beads at a bead:T cell ratio of 3:1; expression of less than 100 pg/mL/1 x 10⁶ cells/day of IFN-g after co- stimulation with anti-CD3/anti-CD28 beads at a bead:T cell ratio of 3:1; expression of less than 100 pg/mL/1 x 10⁶ cells/day of GM-CSF after co- stimulation with anti-CD3/anti-CD28 beads at a bead:T cell ratio of 3:1; expression of less than 10 pg/mL/1 x 10⁶ cells/day of TNF-a after co- stimulation with anti-CD3/anti-CD28 beads at a bead:T cell ratio of 3:1; expression of less than 10 pg/mL/1 x 10⁶ cells/day of IL-17 after co-stimulation with anti- CD3/anti-CD28 beads at a bead:T cell ratio of 3:1; and combinations thereof.

166. The method of any one of claims 107-148, wherein the de-differentiated T cells have one or more of the following properties: at least a 10% decrease, and more preferably, a 50% decrease in mRNA expression of one or more of granzyme B, IL-10, and IFN-g relative to a control T cell population incubated under the same conditions without temsirolimus, vitamin D and the IL-2 signaling inhibitor; at least a 10% increase, and more preferably, a 50% increase in mRNA expression of one or more of Nanog, KLF4, KLF10 and CD 127 relative to a control T cell population incubated under the same conditions without temsirolimus, vitamin D and the IL-2 signaling inhibitor; at least a 10% decrease, and more preferably a 50% decrease in mRNA expression of one or more of T-Bet and STAT1 relative to a control T cell population incubated under the same conditions without temsirolimus, vitamin D and the IL-2 signaling inhibitor; HIF-1-a expression within about 20% of a control T cell population incubated under the same conditions without temsirolimus, vitamin D and the IL-2 signaling inhibitor; at least a 10% increase, and more preferably a 50% increase, in p62 expression relative to a control T cell population incubated under the same conditions without temsirolimus, vitamin D and the IL-2 signaling inhibitor; an expression level of RAPTOR or RICTOR reduced by at least 50% and more preferably by 90% relative to a control population of T cells manufactured under the same conditions as the culture input population of cells without temsirolimus, IL-2 signaling inhibitor and Vitamin D; an expression level of RAPTOR or RICTOR normalized by a housekeeping protein is reduced by at least 50% and more preferably by 90% relative to a control population of T cells manufactured under the same conditions as the culture input population of cells without temsirolimus, IL-2 signaling inhibitor and Vitamin D; and combinations thereof.

167. The method of any one of claims 107-148, wherein the de-differentiated T cells have one or more of the following properties: at least a 10% decrease, and more preferably, a 50% decrease in mRNA expression of one or more of granzyme B, IL-10, and IFN-g relative to a control T cell incubated under the same conditions without temsirolimus, vitamin D and the IL-2 signaling inhibitor; at least a 10% increase, and more preferably, a 50% increase in mRNA expression of one or more of Nanog, KLF4, KLF10 and CD 127 relative to relative to a control T cell incubated under the same conditions without temsirolimus, vitamin D and the IL-2 signaling inhibitor; at least a 10% decrease, and more preferably a 50% decrease in mRNA expression of one or more of T-Bet and STAT1 relative to a control T cell incubated under the same conditions without temsirolimus, vitamin D and the IL-2 signaling inhibitor; HIF-1-a expression within about 20% of a control T cell incubated under the same conditions without temsirolimus, vitamin D and the IL-2 signaling inhibitor; at least a 10% increase, and more preferably a 50% increase, in p62 expression relative to a control T cell population incubated under the same conditions without temsirolimus, vitamin D and the IL-2 signaling inhibitor; an expression level of RAPTOR or RICTOR reduced by at least 50% and more preferably by 90% relative to a control T cell manufactured under the same conditions as the culture input population of cells without temsirolimus, IL-2 signaling inhibitor and Vitamin D; an expression level of RAPTOR or RICTOR normalized by a housekeeping protein is reduced by at least 50% and more preferably by 90% relative to a control T cell manufactured under the same conditions as the culture input population of cells without temsirolimus, IL-2 signaling inhibitor and Vitamin D; and combinations thereof.

168. A T_REG or T_REG/T1I2 cell produced by the method of any one of claims 166-167.

169. The method of any one of claims 1-106, wherein the pro-inflammatory disease or condition is chosen from infection, graft-versus-host disease, an autoimmune disease, a nervous system pathology, end-organ failure, graft rejection, acute respiratory distress syndrome (ARDS), pneumonia, tissue damage, cardiovascular disease, and elevated inflammatory markers.

170. The method of claim 169, wherein the infection is due to a coronavims.

171. The method of claim 169, the infection is COVID-19.

172. The method of claim 171, wherein the subject is suffering from Stage 3 COVID-19.

173. The method of any one of claims 1-106 and 169-172, wherein the manufactured TREG cells are the manufactured T cells or population thereof of any one of claims 129, 149-165 and 174. The method of any one of claims 1-106 and 169-173, further comprising administering to the subject an anti-viral agent, wherein the pro-inflammatory conditions is a viral infection.

175. The method of claim 174, wherein the viral infection is due to a coronavims.

176. The method of claim 174, wherein the viral infection is COVID-19.

177. The method of claim 176, wherein the subject is suffering from Stage 3 COVID-19.

178. The method of any one of claims 174-177, wherein the anti- viral agent is selected from the group consisting of remdesivir, hydroxychloroquine and a plasma transfusion.

179. The method of any one of claims 1-106 and 169-178, further comprising administering to the subject a therapeutically effective amount of an immune modulation agent.

180. The method of claim 179, wherein the immune modulation agent is selected from the group consisting of an IL-6 inhibitor, a mTOR inhibitor, and a Janus Kinase inhibitor.

181. The method of any one of claims 1-106 and 169-180, wherein the manufactured TREG cells are autologous to said subject.

182. The method of any one of claims 1-106 and 169-180, wherein the manufactured TREG cells are allogenic to said subject.

183. The method of any of claims 1-106, wherein the pro-inflammatory disease or condition is selected from the group consisting of atherosclerosis, myocardial injury, myocarditis, acute myocardial infarction, heart failure, autoimmune vasculitis, a dysrhythmia, a venous thromboembolic event, acute pancreatitis, chronic pancreatitis, trypsinogen gene mutation, alcoholism, bacterial hepatitis, viral hepatitis, alcoholic or nonalcoholic steatohepatitis, drug- induced liver injury, ischemia/reperfusion injury of the liver, lung inflammation, acute respiratory distress syndrome (ARDS), cystic fibrosis, chronic obstructive pulmonary disease (COPD), asthma, glomerulonephritis, end-stage renal disease, acute kidney disease, chronic kidney disease, infection-related kidney damage, ischemia/repefusion injury of the kidney, immune complex formation/depositon in the kidney, complement pathway dysregulation, inflammatory bowel disease, Chron’s disease ulcerative colitis, idiopathic inflammatory bowel disease, endometriosis, pelvic inflammatory disease, multiple sclerosis, Guillan-Barre syndrome, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, traumatic brain injury, stroke, conjunctivitis, uveitis, scleritis, ocular mucuous membrane pemphigoid, diabetic retinopathy, macular degeneration, muscular dystrophy, inflammatory myopathy, system metabolic disease, type I diabetes, type II diabetes, system lupus erythematous, rheumatoid arthritis, psoriasis, graft- versus-host disease, graft rejection, system inflammatory disease, COVID-19, and systemic inflammatory response syndrome.